Ultrasound-assisted transthoracic diagnostic techniques by Koegelenberg, Coenraad Frederik Nicolaas
 
 
Ultrasound – Assisted 
Transthoracic Diagnostic Techniques  
 
Dissertation presented for a PhD degree in Internal Medicine 
at the University of Stellenbosch 
Promoter: Prof Chris T Bolliger 
Co-Promoters: Prof Andreas H Diacon & Prof Colleen A Wright 
Faculty of Health Sciences 
Department of Medicine  
by  
Coenraad Frederik Nicolaas Koegelenberg 
December 2011 
 
 
ii 
DECLARATION 
 
By submitting this dissertation electronically, I declare that the entirety of the 
work contained therein is my own, original work, that I am the sole author thereof 
(save to the extent explicitly otherwise stated), that reproduction and publication 
thereof by Stellenbosch University will not infringe any third party rights and that I 
have not previously in its entirety or in part submitted it for obtaining any 
qualification. 
     
1 April 2011 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © 2011 University of Stellenbosch 
 
All rights reserved 
University of Stellenbosch: http://scholar.sun.ac.za
 
 
iii 
SUMMARY 
 
Although transthoracic ultrasonography is a well established modality, it is still 
underutilised by chest physicians. The aim of this research project was to 
investigate the feasibility, diagnostic yield and safety of ultrasound(US)-assisted 
transthoracic biopsies performed by clinicians in various settings relevant to daily 
practice of respiratory medicine. We conducted four clinical trials which are 
summarised below:  
 
1. In a prospective study on the feasibility of US-assisted transthoracic fine 
needle aspiration (TTFNA) of drowned lung secondary to a proximal mass 
lesion, a novel indication for US-assisted TTFNA was described. TTFNA 
passes >20mm from the visceral pleura had a sensitivity of 74.2% and 
were also more likely to contain malignant cells than more superficial 
passes. The surprisingly high yield and the fact that no serious 
complications were observed validated this approach, which may be an 
alternative to bronchoscopy.  
 
2. In the largest single-centre study on US-assisted TTFNA with rapid on-site 
evaluation (ROSE) and cutting needle biopsy (CNB) in the setting of 
superior vena cava (SVC) syndrome ever reported, we were able to 
accurately diagnose 96% of all patients who presented with an associated 
mass lesion that abutted or infiltrated the chest wall. No pneumothoraces 
or major haemorrhage was caused. We also validated the single-session 
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approach, and were able to conclude that US-assisted TTFNA (with 
ROSE) is the initial investigation of choice in suspected bronchogenic 
carcinoma, whereas both TTFNA and CNB need to be performed in all 
other cases.  
 
3. We continued to validate the novel single-session sequential approach in 
a study on anterosuperior mediastinal masses. US-assisted TTFNA with 
ROSE was performed on 45 consecutive patients, immediately followed 
by CNB where a provisional diagnosis of epithelial carcinoma or probable 
tuberculosis (TB) could not be established. An accurate cytological 
diagnosis was made in 73.3%, and was more likely to be diagnostic in 
epithelial carcinoma and TB than all other pathology (p<0.001). CNB 
yielded a diagnosis in 88.2%. Overall 93.3% of patients were diagnosed 
by the single-session approach. No pneumothorax or major haemorrhage 
was observed.  
 
4. In a prospective study, we compared US-assisted Abrams and Tru-Cut 
needle biopsies with regard to their yield for pleural TB. Pleural biopsy 
specimens obtained with Abrams needles contained pleural tissue in 
91.0% of cases and were diagnostic in 81.8%, whereas Tru-Cut needle 
biopsy specimens only contained pleural tissue in 78.7% (p=0.015) and 
were diagnostic in 65.2% (p=0.022).  
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In conclusion, we investigated the feasibility of US-assisted biopsies performed 
by respiratory physicians in various settings, and consistently found acceptable 
to very high diagnostic yields with minimal complications. Furthermore, we were 
able to validate a novel indication for US-assisted TTFNA (US-assisted TTFNA of 
drowned lung), validate the use of a single-session sequential approach (US-
assisted TTFNA with ROSE followed by CNB where indicated) in at least two 
clinical settings (SVC syndrome and anterosuperior mediastinal masses) and we 
were able to show that US-assisted Abrams needle biopsy is superior to Tru-Cut 
needles biopsy when histological confirmation of TB pleuritis is required.  
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OPSOMMING 
 
Alhoewel transtorakale ultrasonografie ‘n gevestigde modaliteit is, word dit 
onderbenut deur pulmonoloë. Die doel van hierdie navorsingsprojek was om die 
praktiese uitvoerbaarheid, diagnostiese opbrengs en veiligheid van sonargerigte 
transtorakale biopsies uitgevoer deur klinici in verskeie situasies relevant tot die 
alledaagse praktyk te ontleed. Ons het vier kliniese proewe uitgevoer wat 
hieronder opgesom word: 
 
1. In ‘n prospektiewe studie oor die praktiese uitvoerbaarheid van 
sonargerigte transtorakale fyn naald aspirasie (TTFNA) van areas van 
obstruktiewe pneumonitis sekondêr tot proksimale massa letsels, is ‘n 
nuwe indikasie vir sonargerigte TTFNA beskryf. TTFNA aspirasies wat 
>20mm van die visserale pleura geneem is, het ‘n sensitiwiteit van 74.2% 
gehad en was meer geneig om maligne selle op te lewer as meer 
oppervlakkige aspirasies. Die verbasende hoë diagnostiese sensitiwiteit 
en afwesigheid van ernstige komplikasies het die praktiese waarde van 
hierdie benadering bevestig.  
 
2. In die grootste studie nog oor sonargerigte TTFNA met spoedige in-teater 
evalusies (SITE) en sny-naald biopsie (SNB) in die teenwoordigheid van 
superior vena cava (SVC) sindroom, kon ons 96% van pasiënte wat 
presenteer het met ‘n geassosieerde massa letsel wat die borskaswand 
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betrek, akkuraat diagnoseer. Geen pneumotoraks of major bloeding is 
waargeneem nie. Ons kon ook die praktiese uitvoerbaarheid van ‘n enkel-
sessie benadering bevestig en kon tot die gevolgtrekking kom dat 
sonargerigte TTFNA (met SITE) die aanvanklike ondersoek van keuse is 
waar bronguskarsinoom vermoed word, maar dat beide TTFNA en SNB 
noodsaaklik is in ander gevalle.  
 
3. Ons het voortgegaan om die waarde van die nuwe enkel-sessie 
benadering te bevestig in ‘n studie oor antero-superior mediastinale 
massas. Sonargerigte TTFNA met SITE is uitgevoer op 45 pasiënte en in 
gevalle waar ‘n voorlopige diagnose van epiteliale karsinoom of 
waarskynlike tuberkulose (TB) nie bevestig kon word nie, is dit onmiddelik 
gevolg deur SNB. ‘n Akkurate sitologiese diagnose is gemaak in 73.3% 
van gevalle en meer algemeen in epiteliale karsinoom en TB as ander 
patologie (p<001). SNB was diagnosties in 88.2%. In 93.3% kon ‘n 
diagnose verkry word met die enkel-sessie benadering. Geen 
pneumotoraks of major bloeding is waargeneem nie.  
 
4. In ‘n prospektiewe studie is sonargerigte Abrams naald en Tru-Cut naald 
biopsies se opbrengs vir pleurale TB met mekaar vergelyk. Pleurale 
biopsie monsters wat met ‘n Abrams naalde geneem is, het pleurale 
weefsel in 91.0% gevalle getoon en was diagnosties in 81.8%, vergeleke 
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met Tru-Cut naalde wat slegs in 87.7% pleurale weefsel opgelewer het 
(p=0.015) en wat net in in 65.2% diagnosties was (p=0.022).  
 
Opsommend het ons die praktiese uitvoerbaarheid van sonargerigte biopsies 
uitgevoer deur pulmonoloë in veskeie kliniese situasies nagevors, en het 
deurlopend aanvaarbare tot hoë diagnostiese opbrengste gevind met minimale 
komplikasies. Verder kon ons ‘n nuwe indikasie vir sonargerigte TTFNA beskryf 
en evalueer (sonargerigte TTFNA van obstruktiewe pneumonitis); ‘n enkel-sessie 
sekwensiële benadering se waarde bevestig (sonargerigte TTFNA met SITE, 
gevolg deur SNB waar aangedui) in ten minste twee kliniese situasies (SVC 
sindroom en anterosuperior mediastinale massas); en was dit moontlik om te 
bewys dat UK-geleide Abrams naald biopsies superior tot Tru-cut naald biopsies 
is in die histologiese bevestiging van TB pleuritis.   
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Chapter 1 
 
INTRODUCTION 
 
 
Transthoracic ultrasonography (US) is a well established modality in the 
evaluation of respiratory disorders, but is still not utilised to its full potential by 
chest physicians, both in the developed and developing world [1-7]. 
Transthoracic US has many advantages that make it an ideal investigation in a 
health care system with limited resources, the most significant being its cost in 
terms of acquisition, maintenance and consumables. Furthermore it is mobile, 
utilises no radiation and has a short examination time [1-5]. Moreover, US-
assisted biopsy can be performed by a single clinician with no sedation and 
minimal monitoring, even potentially outside of theatre [1-3].  
 
Transthoracic Ultrasound: Technical Aspects  
Basic transthoracic US can be performed by means of the most basic entry-level 
two-dimensional ultrasound equipment [1,2]. A low frequency curvilinear probe 
(range: 2–5 MHz) is essential, whereas a high frequency linear probe (range: 5–
10 MHz) is a useful addition [1,2]. Higher frequency gives better resolution closer 
to the probe, but at the cost of lower depth penetration. A lower frequency probe 
with its curvilinear shape is ideal for covering a large area and is therefore 
suitable for initial screening of superficial and deeper structures, while the high 
frequency probe with a linear shape is used for refined assessment of an 
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abnormal chest wall or pleural area [1,2]. A comprehensive review of the 
technical aspects of transthoracic ultrasonography is presented in Chapter 2.   
 
Diagnostic Transthoracic Ultrasonography   
Transthoracic US is frequently utilised for the qualitative and quantitative 
description of pleural effusions and the assessment of pleural thickening, pleural 
tumours and chest wall abnormalities [1-8]. Furthermore, US can visualise 
parenchymal pathology (tumours, consolidations and other processes) provided 
they abut the pleura [1-7]. More advanced applications include the detection of 
pneumothoraces and pulmonary emboli [1,2]. A comprehensive review of the 
practical application of diagnostic transthoracic US is presented in Chapter 2.   
 
Ultrasound-Assisted Interventions  
Principles and Basis Applications  
As a guide to diagnostic procedures, US not only potentially increases the 
diagnostic yield, but also minimises risk compared to blind procedures [1-8]. It is 
therefore ideal for image-guided chest wall, pleural, peripheral pulmonary and 
mediastinal interventions, including diagnostic thoracentesis and biopsy [1-8]. 
Real-time US guidance of needle aspiration and/or needle biopsy may be 
performed with the aid of commercially available reusable probes. Most 
experienced physicians, however, prefer and utilise the “freehand” technique. 
After appropriate patient positioning, the intended site of needle insertion is 
sonographically identified and marked, while the direction, depth of interest and 
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safety range for the procedure are determined [1,2]. The procedure is then 
performed (not under real-time guidance), while the patient is requested not to 
change position in order to avoid a positional shift of the area of interest relative 
to the skin mark.  
 
Transthoracic US assistance improves the success rate of pleural aspirations [9-
11]. The success rate of US-guided thoracentesis can be as high as 97% [11]. 
US detects pleural fluid septations with greater sensitivity than computed 
tomography (CT) and also minimises the risk of visceral puncture [10]. Moreover, 
the risk of pneumothorax following aspirations is reduced, independent of the 
size of the effusion [12]. 
 
US is also ideal for identifying the optimal site for safe and effective intercostal 
drainage (ICD). The current British Thoracic Society pleural disease guideline 
states that US-guidance is strongly recommended for all drainage of pleural fluid 
[11]. This is particularly relevant in patients with loculated parapneumonic 
effusions, where thickened parietal pleura, adhesions or loculations often 
complicate insertion. Depending on operator experience, US may also guide 
further decisions regarding the need for intrapleural fibrinolytics, thoracoscopy or 
for surgical intervention in addition to tube drainage and antibiotics [13]. 
 
A recent survey carried out in the United Kingdom highlighted the dangers of 
blind pleural procedures: 67 of 101 trusts reported at least one serious 
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complication from ICD. In all, 47 cases of serious lung or chest wall injuries with 
8 deaths and 6 cases of ICD placement on the wrong side were described [14]. 
 
Closed Pleural Biopsies  
Closed pleural biopsy needles were introduced forty years after Jacobaeus 
established thoracoscopy. Within a decade various needles were described, 
including the Abrams (guillotine), Cope (hook) and Vim-Silverman (puncture) 
needles [15-18]. Of these devices, the Abrams needle was consistently shown to 
have a superior yield and became the most widely used instrument [15,19]. 
Cutting needle biopsy (CNB) was a relatively recent addition: In 1989 Macleod 
described the use of blind Tru-cut needle biopsy as an alternative to Abrams 
needles in patients who present with large pleural effusions [20].  
 
A significant fall in the incidence of tuberculosis (TB) in most of the developed 
world over the last 50 years led to an equally significant reduction in operator 
experience amongst respiratory physicians, to the point where even relatively 
experienced pulmonologists have become reluctant to utilise blind closed pleural 
biopsy even in settings where reported diagnostic yields are relatively high [11].  
Unaided (blind) closed pleural biopsy has a relatively modest diagnostic yield, 
particularly for pleural malignancy. The diagnostic yield of blind Abrams needle 
biopsies is less than 60% for pleural malignancy [21]. Tuberculous pleuritis leads 
to more homogenous pleural involvement, and unaided closed biopsies are 
therefore more likely to be diagnostic for pleural tuberculosis. Published results 
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vary, but the reported diagnostic yields are generally in the order of 80% [22-26]. 
Kirsch and co-workers even reported a yield of 87%, provided at least six 
specimens are harvested [27].  
 
Recent studies have suggested that image-guidance may significantly increase 
the yield while also decreasing the risk for complications [28-30]. In fact, Qureshi 
et al. were able to identify 73% of malignant effusions on appearance alone [28]. 
They found that pleural thickening >10mm, pleural nodularity and diaphragmatic 
thickening >7mm were highly suggestive of malignant disease. Chang previously 
found that the diagnostic yield of US-guided Tru-cut pleural biopsy to be as high 
as 87% for all pleural pathologies (77% for malignancies) [29]. For malignant 
mesothelioma, Diacon showed that this figure may be as high as 100% [30].  
 
Transthoracic Fine Needle Aspiration and Needle Biopsy of Solid Tumours 
Peripheral lung, pleural based and mediastinal masses are detectable by US 
provided that chest wall contact is present [1,2]. These tumours most frequently 
appear hypoechoic with posterior acoustic enhancement and are ideally suited 
for transthoracic US-assisted biopsy, as no aerated lung needs to be transversed 
with the biopsy device [1-4]. US-assisted transthoracic fine needle aspiration 
(TTFNA) has the added advantage that it may be performed outside of theatre, 
which may be an important practical consideration in patients with advanced 
disease. TTFNA is generally performed under local anaesthesia with a 22-gauge 
injection-type or spinal needle [1,2]. CNB follow the same principles as TTFNA, 
5University of Stellenbosch: http://scholar.sun.ac.za
but the devices are more invasive and carry the higher risk of vascular or visceral 
trauma [2]. US has the added advantage that it may be used to screen for a 
pneumothorax following transthoracic biopsy, albeit a rare complication [1,2]. In 
fact, one study found US to be superior to chest radiographs in diagnosing 
pneumothoraces [31].   
 
Diacon and co-workers found that US-assisted CNB had a sensitivity of 85.5% 
for lung tumours abutting the chest wall and a 100% for mesothelioma [30]. They 
observed a pneumothorax rate of 4%, and concluded that US-assisted CNB was 
safe in the hands of pulmonologists. In a subsequent study the same 
investigators found that US-assisted TTFNA with rapid on-site evaluation (ROSE) 
by a cytopathologist of tumours abutting the chest wall had a diagnostic yield of 
82%. CNB was shown to be diagnostic in 76%, whereas CNB and TTFNA had a 
combined yield of 89% [32]. Both US-guided CNB and FNA had a low 
complication rate, with pneumothoraces observed in 4 and 1.3% respectively 
[32]. Subanalyses of their data showed that US-guided TTFNA was significantly 
superior to CNB in confirming a diagnosis of bronchogenic carcinoma (95% vs. 
81%, p = 0.006), whereas CNB was superior in cases of non-carcinomatous 
tumours and non-malignant lesions.  Schubert et al. reported similar findings [33]. 
Both investigators concluded that CNB may be reserved for cases where 
cytology is non-contributory and a diagnosis other than lung cancer is suspected.  
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In a landmark study from the late 1980s, Saito and co-workers were able to 
diagnose 31 of 45 mediastinal masses by means of US-guided needle biopsies 
[34]. In total, 13 of 15 patients with malignancies had diagnostic biopsies. Yang 
et al. subsequently found Tru-Cut needles to have a diagnostic yield of 88.9% for 
mediastinal tumours [35]. Yang also pioneered the supraclavicular approach for 
US-guided biopsies of superior mediastinal tumours [36], when they obtained 
diagnostic biopsies from 12 of 15 patients. Sawhney et al. reported the highest 
sensitivity: they were able to diagnose all 25 patients with mediastinal masses by 
means of US-guided Tru-cut needle biopsy [37]. Samad and co-workers reported 
a more modest yield of 80.5% [38]. Comparable findings were subsequently 
reported by Anderson, Ikezoe and Tikkakoshi [39-41]. Studies that included more 
than 40 patients reported a 1-6% complication rate from CNB, with 
pneumothoraces, haemothoraces and haemoptysis the most common serious 
complications [34-36,38-40].   
 
Other Ultrasound-Assisted Interventions 
The indications for US-assisted transthoracic TTFNA and CNB are not limited to 
solid tumours. Yang and co-workers, for example, reported a diagnostic yield as 
high as 93% with US-assisted biopsies of pulmonary consolidation of unknown 
aetiology [42]. This procedure is potentially useful in the immunocompromised 
patient, given the extensive differential diagnosis. Yang was also able to 
sonographically demonstrate abscess cavities in 94% of 35 patients with 
radiologically confirmed lung abscesses, and was able to obtain pathogens by 
means of aspirates in 90% [43]. 
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 Central Theme and Aims of Research Project 
The central theme of this PhD research project was to investigate the feasibility, 
diagnostic yield and safety of US-assisted transthoracic biopsies performed by 
clinicians in various settings relevant to the daily practice of respiratory 
physicians. The ultimate aim was not only to broaden the potential indications for 
US-assisted transthoracic biopsies by investigating novel indications, but also to 
compare various biopsy devices and to validate a novel, single-session 
sequential approach of US-assisted transthoracic fine needle aspiration (TTFNA) 
with rapid on-site evaluation (ROSE) followed by cutting needle biopsy (CNB) in 
various settings. The central hypothesis was that US-assisted transthoracic 
diagnostic techniques in the hands of chest physicians would be safe and have a 
diagnostic yield comparable to more invasive investigations (generally perceived 
to be the gold standards). Four separate studies were conceptualised and 
designed in order to address the aims and central hypothesis of this research 
project.  
 
Study Specific Aims & Objectives 
Study 1 – US-assisted biopsy in a novel clinical setting: US-assisted TTFNA of 
drowned lung  
The parenchyma of normal aerated lungs is not discernable by means of US [1-
5]. Proximal lung tumours are therefore not considered amenable to US-assisted 
transthoracic FNA or CNB. Proximal lung tumours may, however, cause varying 
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degrees of pulmonary collapse (resorptive atelectasis) and postobstructive 
pneumonitis. “Drowned lung” is a radiological term often used to describe these 
areas which are considered to represent accumulated secretions, and typified on 
chest CT by enhanced pulmonary vasculature contrasted against surrounding 
pulmonary consolidation [44,45]. Provided the consolidation extends to the chest 
wall, fluid filled airways are detectable on US as fluid bronchograms, which are 
dynamic anechoic tubular structures within consolidated lung that fluctuate with 
respiration [1,2,46]. 
 
The diagnostic yield for malignancy of US-assisted TTFNA harvested from areas 
of areas of drowned lung secondary to proximal tumours is not known. Moreover, 
endobronchial inspection and sampling by means of flexible bronchoscopy is 
generally considered the standard diagnostic approach in this scenario [47,48]. 
We therefore aimed to explore the feasibility of US-assisted TTFNA as an 
alternative to bronchoscopy in this setting by prospectively investigating its 
diagnostic yield and safety. This aim is addressed in Chapter 3.  
 
Studies 2 and 3 – The single-session approach: US-assisted TTFNA with ROSE 
followed by CNB (where indicated) in two novel clinical settings   
US-assisted TTFNA and CNB in the setting of chest wall, pleural and pulmonary 
malignancies abutting the chest wall have a very high diagnostic yield and are 
safe, even in the hands of non-radiologists [30,32,48]. TTFNA with ROSE and 
CNB have been shown to be complementary techniques for intrathoracic mass 
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lesions [30,32,33]. The former has a significantly higher sensitivity for 
bronchogenic carcinoma, but the latter remains superior in non-carcinomatous 
tumours and in benign lesions [30,32,33]. Ultrasound and the addition of ROSE 
therefore potentially allow for a single-session approach, with US-assisted 
TTFNA followed by CNB limited to those cases where diagnostically useful 
material cannot be confirmed [30,32,33]. Although this single-session approach 
has been validated in pulmonary and pleural mass lesions [30,32,33], its 
applicability to other clinical settings remains unknown. We therefore aimed to 
assess the diagnostic yield and safety of the single-session sequential approach 
in two novel settings: superior vena cava syndrome and anterosuperior 
mediastinal masses. These aims are addressed in Chapter 4.  
 
Study 4 – US-assisted pleural biopsy: A direct comparison of the diagnostic yield 
of Abrams and Tru-cut needle biopsies for pleural tuberculosis 
Although a presumptive diagnosis of pleural tuberculosis (TB) can be made 
based on elevated levels of adenosine deaminase (ADA) and interferon-gamma 
in pleural fluid, actual histological and/or microbiological confirmation of TB 
pleuritis remains the gold standard [22,49]. Pleural tissue can be harvested either 
by means of closed biopsy, thoracoscopy or open surgical biopsy [22,49]. Access 
to thoracoscopy and open surgical biopsy is limited in many parts of the world 
where closed biopsies remain the preferred initial investigation [22].  
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In a small prospective study, Chang and co-workers found a superior diagnostic 
yield for pleural TB with US-assisted Tru-cut compared to traditional Abrams 
needle biopsies [29]. In that study, which was performed in an area with 
moderate TB prevalence, only two of ten Abrams needle biopsies in cases of 
pleural TB were diagnostic. As most authors have reported diagnostic 
sensitivities in the order of 50-85% for Abrams needle biopsies [22,49,50], 
uncertainty remained as to which closed pleural biopsy techniques was superior 
for the confirmation of pleural TB. 
 
The aim of this prospective study was to compare US-assisted Abrams needle 
biopsies to US-assisted Tru-cut needle biopsies with regards to their diagnostic 
yield for pleural TB. This aim is addressed in Chapter 5.  
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Radiology: pleural ultrasound
COENRAAD FN KOEGELENBERG, CHRIS T BOLLIGER, ANDREAS DIACON
INTRODUCTION
Although the introduction of diagnostic sonography of the
abdomen dates back to the late 1940s, ultrasonography of
the thorax lagged behind by many decades. The inability of
ultrasound (US) to penetrate aerated tissue has diverted
chest physicians from recognizing its excellent ability to
visualize the chest wall, pleura and pathology of lung abut-
ting the pleura. The major advantages of thoracic US
include its dynamic properties, low cost, lack of radiation,
mobility and short examination time.1–6 It is also well
suited for use in intensive care units, where suboptimal
conditions for radiography make the diagnosis of clinically
significant thoracic abnormalities difficult.3 Furthermore,
US of the chest is increasingly being used to guide inter-
ventional procedures, such as thoracentesis, biopsies of the
chest wall, pleura or abutting lung and the placement of
intercostal drains. The indications for pleural and chest
wall US are summarized in Table 21.1. The main aim of
this chapter is to demystify ultrasonography for the chest
physician by reviewing the basic principles and techniques
from the perspective of the non-radiologist.
AN APPROACH TO THORACIC
ULTRASONOGRAPHY
Technical principles
‘Ultrasounds’ are acoustic waves with a frequency above
human hearing. Most US scanners operate in the fre-
quency range of 2–15 megahertz (MHz). A very basic
understanding of how the US scanner employs these ultra-
sounds to generate an image is paramount in order to
comprehend its uses and limitations.
The US unit produces sound by means of a piezoelec-
tric transducer encased in a handheld probe that is
attached to the processing unit with an electric cable. This
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Table 21.1 The indications for pleural and chest wall
ultrasounda
Indications
1 To detect a pleural effusion and guide
thoracentesis and drainage, especially in small or
loculated effusions
2 To differentiate a subpulmonary effusion from a
subphrenic fluid accumulation and diaphragm
paralysis in radiographically elevated
hemidiaphragms
3 To localize pleural tumors, pleural thickening and
lung tumors that abut the pleural surface and to
guide needle aspiration and/or biopsies thereof
4 To assist the evaluation of patients with pleuritic
chest pain
5 To clarify the nature of unknown pleural densities
6 To recognize pneumothorax, especially for
emergency situations, or when radiographic
equipment is unavailable
7 To localize pleural fluid prior to a thoracoscopy
8 To evaluate empyema and a parapneumonic pleural
effusion in order to detect loculations and septae,
and to guide aspiration with or without tube drainage
aAdapted with permission from: Tsai TH, Yang PC. Ultrasound in the
diagnosis and management of pleural disease. Curr Opin Pulm Med 2003;
9: 282–90.
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sound is focused in the transducer and is efficiently trans-
mitted into the thorax. Ultrasound waves are propagated
in liquid media (e.g. pleural effusions) or in tissues with a
high water content (e.g. muscle, liver, consolidated lung or
tumors), but are reflected off interfaces between dissimilar
densities (e.g. gas or bone). If the US encounters gas (e.g.
normal aerated lungs or a pneumo thorax) or solids (e.g.
ribs), the density difference is so great that most of the
acoustic energy is reflected. This phenomenon is known as
acoustical impedance and explains why structures deeper
than the visceral pleura are invisible by means of ultra-
sonography in the non-diseased state.
The reflected part of the sound waves is detected as an
echo. The time delay between emitted US and the received
echo is used to calculate the depth of the structure causing
the reflection. Furthermore, the greater the difference
between acoustic impedances, the larger the echo will be.
The transducer captures sound waves returning to the
probe and converts these echoes into electrical pulses,
which are ultimately processed and transformed into a
digital image. The intensity and distribution of the pixels
appearing on the screen is determined by three character-
istics of the echo, namely (1) its direction, (2) its intensity
and (3) the time elapsed from emission to capture. Images
may contain ‘hyperechoic’ or white areas caused by high-
amplitude echoes and ‘hypoechoic’ or dark areas from
low-amplitude echoes.
The ultrasound unit
Adequate pleural and chest wall ultrasonography can be per-
formed by means of the most basic, entry-level,
two-dimensional black-and-white US equipment. Doppler
and color flow echo are not required for routine pleural exam-
ination. For documentation of still images, a basic thermal
printer is sufficient. Most modern scanners also allow for the
transferral of images to data storage devices and can capture
dynamic information in video format, which is preferable.
The US scanner is adorned by a confusing array of con-
trols and options. It is imperative that the occasional sono-
grapher familiarizes themself with the scanner and its most
important function keys. It is helpful to differentiate
between settings to optimize the machine for thoracic US
in general, and controls for fine tuning the scanning for the
individual case. For occasional thoracic scanning, basic
settings programmed for abdominal sonography will
suffice. However, if a machine is to be used mainly for tho-
racic US, we recommend calling upon an expert to assist
with the basic setting up of the machine, which includes
contrast and brightness of the monitor as well as default
settings of depth and gain when using different probes.
Thoracic US is best performed with two transducers. A
3.7 MHz (range: 2–5 MHz) curvilinear probe is compul-
sory, and an 8 MHz (range: 5–10 MHz) linear probe is a
very helpful addition. As a rule, higher frequency gives
better resolution closer to the probe, but at the cost of
lower penetration. A lower frequency probe (e.g. 3.5 MHz)
with curvilinear shape for covering a large area is therefore
suitable for initial screening of superficial and deeper
structures, while the high frequency probe (e.g. 8 MHz)
with a linear shape is used for refined assessment of an
abnormal chest wall or pleural area.
The three most important controls on a standard key-
board are ‘depth’, ‘gain’ and ‘freeze’. The depth function is
a digital zoom that defines what portion of the scanned
image is displayed on the monitor at what magnification.
The scale is displayed on a vertical axis. Obese subjects or
patients with a large effusion or intrathoracic tumors may
require a depth setting of up to 12 cm. High frequency
scanning is performed at a maximum depth of around
3–4 cm. The gain is, in essence, a measure for the amplifi-
cation of the echoes and determines the brightness of the
image. The freeze function allows for the capturing of still
images, and to perform measurements with the appropri-
ate keys and the trackball. Only experienced users should
change advanced parameters, such as the frequency of a
particular probe.
Patient positioning
The optimal patient position for scanning is a paramount
but under-appreciated aspect. Sonographic access to the
chest can be achieved via the abdomen, intercostal spaces
or the upper thoracic aperture (supraclavicular fossa). It is
important to review a patient’s chest radiograph and com-
puted tomography (CT) scan prior to performing a chest
US examination. This will not only identify the area of
interest, but will also guide the positioning of the patient.
The posterior chest is best scanned with the patient in the
sitting position using a bedside table as an armrest (Figure
21.1a,b), whereas the lateral and anterior chest wall can be
examined with the patient in either the lateral decubitus or
even supine position (Figure 21.1c). Maximum visualiza-
tion of the lung and pleura is achieved by examining along
the intercostal spaces. Raising the arm above the patient’s
head increases the intercostal space distance and facilitates
scanning in erect or recumbent positions. A patient can
fold the arms across the chest in order to displace the
scapulae when surveying the upper posterior thorax.
Superior sulcus pathology can be visualized apically with
the patient in the supine or sitting position.
Scanning
Once the patient is adequately positioned and the area of
interest is identified, liberal application of gel is the final
step before scanning. It is advisable to hold the probe like
a pen for writing on paper, and not like chalk for writing
on a blackboard (Figure 21.1b). Experienced sonographers
keep their eyes on the screen while their hand moves the
probe across the area of interest and provides the posi-
21-Pleural Disease-ch21-cpp:21-Pleural Disease-ch21-ppp  18/3/08  08:11  Page 272
20
University of Stellenbosch: http://scholar.sun.ac.za
Diagnostic thoracic ultrasonography  273
tional information. The probe is moved slowly, preferably
along intercostal spaces, which are oblique and not hori-
zontal. Frequent pauses are needed for observing the spon-
taneous movement of structures with respiration. Unclear
findings can be compared with the contralateral side.
DIAGNOSTIC THORACIC ULTRASONOGRAPHY
Normal chest wall and pleura
The initial surveillance of a normal chest with the low fre-
quency probe will yield a series of echogenic layers of
muscles and fascia planes (Figure 21.2a). The ribs appear
as curvilinear structures on transverse scans, associated
with posterior acoustic shadowing (Figure 21.2b). When
the ribs are scanned along the longitudinal, the anterior
cortex appears as a continuous echogenic line.
The visceral and parietal pleura can normally not be
differentiated by means of a low-frequency probe, which
instead displays one highly echogenic line representing 
the pleura and pleuropulmonary surface. With a high-
resolution linear probe (e.g. 8 MHz), the visceral and pari-
etal portions of the pleura can be seen as two distinct
echogenic lines, with the latter seemingly thinner in
appearance. The two layers can be seen to slide over each
other with respiratory motion. The respiratory movement
of the lung relative to the chest wall is visible with both
probes and is called the ‘lung sliding’ sign. Its presence on
real-time US is strong evidence against a pneumothorax.7
(a) (b)
(c)
Figure 21.1 Scanning positions for chest ultrasound. (a) The
posterior chest is best scanned with the patient in the sitting
position using a bedside table as an armrest. (b) Note the way in
which the probe is held. It is important to ask the patient to fold
their arms across the chest when surveying the superior posterior
chest. (c) The lateral chest wall can be examined with the patient
in the lateral decubitus position with the arm raised, and the
anterior chest wall with the patient supine (not shown).
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Figure 21.2 The typical appearance of a normal chest on
ultrasound. (a) Transverse image through the intercostal space.
The chest wall is visualized as multiple layers of echogenicity
representing muscles and fascia. The visceral and parietal pleura
appear as echogenic bright lines that slide during respiration
(sliding sign). Reverberation artifacts beneath the pleural lines
imply an underlying air-filled lung. S, skin; CW chest wall; P,
pleura; Pp, parietal pleura; Pv, visceral pleura; L, lung; R,
reverberation artifact. (b) Longitudinal image across the ribs.
Normal ribs are seen as hyperechoic chambered surfaces
(arrowheads) with prominent acoustic shadows beneath the ribs.
Pp, parietal pleura; Pv, visceral pleura. (c) An example of a comet
tail artifact observed in an otherwise normal subject. C, comet-
tail artifact. Reproduced with permission from: Tsai TH, Yang PC.
Ultrasound in the diagnosis and management of pleural disease.
Curr Opin Pulm Med 2003; 9: 282–90.
(a) (b)
(c)
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The ‘curtain-sign’ describes the variable obscuring of
underlying structures by air containing tissue. In normal
subjects, the curtain-sign is seen in the costophrenic angle.
The upper abdominal organs are easily visible on expira-
tion, but during inspiration the normal air-filled lung is
moved downwards in front of the probe and temporarily
obscures the sonographic window.
The parenchyma of normal aerated lungs is invisible by
means of US. The large change in acoustic impedance at
the pleura–lung interface causes horizontal artifacts that
are seen as a series of echogenic parallel lines equidistant
from one another below the pleura. These bright but form-
less lines are known as reverberation artifacts and dimin-
ish in intensity with increasing distance from the pleura
(Figure 21.2a). Vertical ‘comet-tail’ artifacts (Figure
21.2c), caused by fluid-filled subpleural interlobular
septae, can also be seen originating at the pleura–lung
interface. The normal diaphragm is best seen through the
lower intercostal spaces or via the liver or spleen. It is seen
as an echogenic 1 mm thick line which contracts with
inspiration.
Pleural effusions
SONOGRAPHIC DIAGNOSIS
The value of ultrasonography for detection and quantifica-
tion of pleural effusions is uncontested. Ultrasound is par-
ticularly helpful in determining the nature of localized or
diffuse pleural opacities, and is more sensitive than decu-
bitus expiratory films in identifying minimal or loculated
effusions.8 Sonographically, a pleural effusion appears as
an anechoic, homogeneous space between parietal and vis-
ceral pleura (Figure 21.3). This space may change in shape
with respiration, and the atelectatic lung inside a large
effusion may appear as a tongue-like structure within the
effusion. In inflammatory effusions, adhesions between
the two pleural surfaces may result in the absence of lung
motion above the effusion. If an abnormal elevation of a
hemidiaphragm is noted on the chest radiograph, subpul-
monary effusion can be differentiated from a subphrenic
fluid collection or diaphragm paralysis.9
DETERMINING THE NATURE OF A PLEURAL EFFUSION
The sonographic appearance of a pleural effusion depends
on its nature, cause and chronicity. Four appearances are
recognized based on the internal echogenicity: anechoic;
complex but non-septated; complex and septated; and
homogenously echogenic. Transudates are invariably
 anechoic, unseptated and free flowing, whereas complex,
septated or echogenic effusions are usually exudates.10,11
Malignant effusions are often anechoic. Nodular pleural
thickening is apparent in the minority of malignant effu-
sions, and echogenic swirling patterns have recently been
linked to these effusions.12 Inflammatory effusions are
often associated with strands of echogenic material and
septations which show more or less mobility with respira-
tion and the cardiac cycle. The presence of septae has
several implications. Chen et al.13 demonstrated that
patients with septated effusions needed longer chest tube
drainage, longer hospital care and were more likely to
require fibrinolytic therapy or surgery compared with
those with unseptated effusions. Tu et al.14 recently con-
firmed some of these findings in medical intensive care
unit patients. Empyema may cause a strongly echogenic
effusion that may be mistaken for a solid pleural lesion.
ESTIMATING THE VOLUME OF A PLEURAL EFFUSION BY
ULTRASOUND
Several studies have shown reasonable correlation between
the volume of an effusion estimated with planimetric
measurements and its square dimensions.15–17 Such geo-
metric calculations are hampered by the uneven distribu-
tion of fluid in the presence of pleuropulmonary
adhesions. We suggest the following practical way to clas-
sify the volume of an effusion: minimal, if the echo-free
space is confined to the costophrenic angle; small, if the
space is greater than the costophrenic angle but still within
the range of the area covered with a 3.5 MHz curvilinear
probe; moderate, if the space is greater than a one-probe
range but within a two-probe range; and large, if the space
is bigger than a two-probe range.
DIFFERENTIATION OF EFFUSION FROM PLEURAL 
THICKENING
To distinguish small effusions from anechoic pleural thick-
ening can be challenging. Both may appear as anechoic on
US. Nearly 20 percent of echo-free pleural lesions will not
yield free fluid, whereas a significant percentage of
complex-appearing lesions will do so. Mobility is a good
sign for effusion. Marks et al.18 found that if a lesion
changed shape with respiratory excursion and if it con-
tained movable strands or echo densities, the lesion was an
effusion. If a color Doppler is available, the fluid color sign
is the most sensitive and specific ultrasonographic evidence
of a small effusion. The sign refers to the presence of a color
signal within the fluid collection that is believed to arise
from transmitted motion during respiratory or cardiac
cycles. This sign has a sensitivity of 89.2 percent and speci-
ficity of 100 percent in detecting minimal fluid collections.19
Pleural thickening
Pleural thickening is defined as focal lesions arising from
the visceral or parietal pleura that is greater than 3 mm in
width with or without an irregular margin (Figure 21.4). It
appears as broadening of the pleura and does not exhibit a
fluid color sign or display movement relative to the chest
wall. Pleural thickening most often appears hypoechoic,
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(a) (b)
(c)
(e)
(d)
(f)
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but increased echogenicity with focal shadowing is some-
times observed and is indicative of  calcification.
Pneumothorax and hydropneumothorax
Pneumothorax detection requires more skill and experi-
ence than the investigation of pleural fluid. A pneumo -
thorax (Figure 21.5) can be diagnosed by means of the
absence of normal lung sliding, exaggerated horizontal
reverberation artifacts and the loss of comet-tail artifacts,
provided that no diaphragmatic paralysis, prior pleurode-
sis, pleural adhesions or adult respiratory distress syn-
drome are present.20–22 Chronic obstructive pulmonary
disease (COPD) can mimic the sonographic sings of pneu-
mothorax. This allows the exclusion, but not the confir-
mation of pneumothorax in such patients with US.23
Despite these limitations, ultrasonography is particularly
useful in intensive care units and in other situ ations where
radiographic equipment is unavailable. Herth et al.24 have
recently shown that a pneumothorax following trans-
bronchial biopsy can be reliably excluded with US (sensi-
tivity 100 percent; specificity 83 percent). This is likely to
reduce costs for chest radiographs, increase patient
comfort and offers an excellent opportunity to acquire and
practice pneumothorax detection.
Hydropneumothorax can also be identified with US by
means of the visualization of air–fluid boundary.25 The
sliding sign above the air–fluid level will be absent. A
mobile air–fluid level will generate a ‘curtain sign’ with
respiration, because the air within the pleura obscures the
underlying effusion during inspiration.
Figure 21.3 (opposite) (a) Pleural effusion is presented as an echo-free space between the visceral and parietal pleura. Compressive
atelectasis of the lung may be seen in a large effusion. The effusion can be subclassified as anechoic (b), complex non-septated (c),
complex septated (d), or homogenously echogenic (e). Note the movable echogenic spots within the complex non-septated effusion, and
the floating strands and septa within the complex septated effusion (arrowheads). (f) Pleural effusion associated with pleural nodules or
nodular thickenings is characteristic of malignant effusion. PE, pleural effusion; D, diaphragm; RLL, right lower lobe; L, lung; T, pleural
tumor. Reproduced with permission from: Tsai TH, Yang PC. Ultrasound in the diagnosis and management of pleural disease. Curr Opin
Pulm Med 2003; 9: 282–90.
Figure 21.4 Pleural thickening: The arrows indicate sheetlike
pleural thickening. Pp, parietal pleura; PE, pleural effusion.
Reproduced with permission from: Tsai TH, Yang PC. Ultrasound in
the diagnosis and management of pleural disease. Curr Opin Pulm
Med 2003; 9: 282–90.
Figure 21.5 A pneumothorax. It should be appreciated that the
most specific sign, namely the absence of the sliding sign (see
text), can only observed in real time. Note the broadened pleural
line, reverberation artifact and absence of comet-tail artifacts.
Ppl, parietal pleura; Pn, pneumothorax; R, reverberation artifact.
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Pleural tumors
Benign pleural tumors appear on US as well-defined
rounded masses of variable echogenicity on either the
parietal or visceral pleura. Both metastatic pleural tumors
and malignant mesothelioma appear as polypoid pleural
nodules or irregular sheetlike pleural thickening,26 often
with large pleural effusions (Figure 21.6).Tumors with low
echogenicity can exhibit posterior echo enhancement.
Lung tumors abutting or invading the pleura
and chest wall
A peripheral lung tumor will be detectable by US provided
that pleural contact is present (Figure 21.7). Visceral
pleura or chest wall invasion has important implications
for lung tumor staging (T2 or T3 staging, respectively).
Although CT is routinely used for determining the extent
of invasion, high-resolution real-time US scanning has
been found to be superior to routine chest CT in evaluat-
ing tumor invasion of the pleura and chest wall.27,28 When
a tumor abutted to the chest wall is visualized with US, all
layers of the chest wall, i.e. muscle, fascia, parietal pleura
and visceral pleura, can be examined and the extent of
tumor invasion can be accurately determined (Figure
21.8).
(b)
(a)
Figure 21.6 Pleural tumors: Two examples of the ultrasound
appearance of pleural tumors, one with a large pleural effusion
(a) and one without (b). Note the posterior echo enhancement.
PE, pleural effusion; T, pleural tumor; Pp, parietal pleura; L, lung.
Reproduced with permission from: Tsai TH, Yang PC. Ultrasound in
the diagnosis and management of pleural disease. Curr Opin Pulm
Med 2003; 9: 282–90.
Figure 21.7 A peripheral lung lesion is shown schematically on
the left without (top) and with (bottom) pleural contact. The
corresponding sonar images recorded with a sector scanner are
shown on the right. Only the lesion with pleural contact is visible
on ultrasound. Note that the acoustic window is too narrow to
demonstrate the whole circumference of the lesion, but it allows
determination of its full depth. Reproduced with permission from:
Diacon AH, Theron J, Bolliger CT. Transthoracic ultrasound for the
pulmonologist. Curr Opin Pulm Med 2005; 11: 307–12.
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Chest wall pathology
Soft-tissue masses such as lipomas can readily be detected
by high-frequency US. Supraclavicular and axillary lymph
nodes with malignant infiltration appear bulky, rounded
and hypoechoic.29 Extracapsular spread is suggested by
irregular borders. Sonography can detect bony metastases
to the ribs, which appear as hypoechoic masses in place of
the normal echogenicity of the rib with disruption of the
cortical line. US is also reported to be more sensitive than
radiography in the detection of rib fracture, which appears
as a breach or displacement of the cortex of the rib with or
without localized swelling or haematoma.
Diaphragmatic paralysis
The diaphragm is best visualized at the costophrenic angle
or through the liver or spleen. Sonographic examination of
a paralyzed diaphragm will yield paradoxical movement of
the diaphragm with respiration.30 This can be accentuated
with forced inspiration (‘sniff ’ test). Long-term paralysis
causes muscle atrophy.30
Diverse pulmonary pathology
Apart from solid tumors, numerous pathological processes
can replace the air within lung tissue and thereby become
detectable with US, provided that the pleura is abutted.
PNEUMONIA AND LUNG ABSCESSES
Pleural based pneumonic consolidation is detectable by
means of US, although the extent of disease appears
smaller on US than on chest radiographs. In the early
phase of consolidation the lung appears diffusely
echogenic, resembling the sonographic texture of the liver.
Air bronchograms appear as echogenic branches. Fluid
bronchograms are sometimes observed. They appear as
anechoic tubular structures, representing fluid-filled
airways, and are typically seen in bronchial obstruction.
Their presence should alert the clinician to the possibility
of a post-obstructive pneumonitis, secondary to a proxi-
mal tumor. Sonographically observed consolidation is not
indicative of an infective etiology. Pulmonary infarction,
hemorrhage and bronchoalveolar carcinoma are three
examples of non-infective consolidation that is similar in
appearance on US. US may guide transthoracic needle
aspirations or biopsies of peripheral pulmonary infiltrates
in cases with diagnostic uncertainty regarding the
 aetiology.31
A lung abscess abutting the pleura appears sonographi-
cally as a hypoechoic lesion with a well-defined or irregu-
lar wall (Figure 21.9). The centre of the abscess is most
often anechoic, but may reveal internal echoes and septa-
tions. Abscesses with air fluid levels on chest radiograph
are more inhomogeneous and will display the curtain sign.
PULMONARY EMBOLISM
Ultrasound can serve for the acute bedside assessment of
patients presenting with possible pulmonary embolism.32
Pulmonary infarction is recognized as a peripheral wedge-
(a) (b)
Figure 21.8 (a) An ultrasound (US) image showing a lung tumor with posterior echo enhancement. Note that both of the visceral and
parietal pleural lines are intact. (b) This US shows tumor extension beyond the pleura. The visceral pleural line is interrupted, and the
respiratory movement of the tumor is disturbed in real-time US. Invasion of the pleural cavity by the tumor is evident. L, lung; T, tumor; Pv,
visceral pleural; Pp, parietal pleura. Reproduced with permission from: Diacon AH, Theron J, Bolliger CT. Transthoracic ultrasound for the
pulmonologist. Curr Opin Pulm Med 2005; 11: 307–12.
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shaped consolidation, often accompanied by a pleural
effusion. US is also useful to diagnose venous thrombosis
as well as the sequelae of thromboembolic disease such as
right ventricular overload and dilated hepatic veins. This
indication of US is currently still reserved for experienced
physicians with a keen interest in US, as pulmonary spiral
CT angiography remains the investigation of choice.
PULMONARY EDEMA
In the setting of patients with acute dyspnea it has been
reported that the presence of bilateral, widespread comet-
tail artifacts is a reliable sign to differentiate patients with
pulmonary edema from those with chronic obstructive
airway disease in the intensive care unit (ICU).33 Comet-
tail artifacts were absent in 92 percent of patients with
chronic obstructive airway disease.
ULTRASOUND-GUIDED INTERVENTIONS
Principles
Ultrasound is particularly well suited for assisting pleural
and chest wall interventions, including diagnostic thora-
centesis, closed tube drainage, chest wall and pleural biop-
sies and biopsies of lung tumors abutting or invading the
pleura. The use of US for these procedures increases the
success rate and minimizes risk compared with procedures
carried out blindly.
With regard to needle biopsies, specific reusable probes
for real-time US guidance of needle biopsies are commer-
cially available. Many prefer the so-called ‘freehand’ tech-
nique for its simplicity. Following adequate patient posi-
tioning, the intended site of needle insertion is sonograph-
ically identified and marked, while the direction, the depth
of interest and the safety range for the procedure are mem-
orized. The patient must not change position in order to
prevent a positional shift of the area of interest relative to
the skin mark. It is occasionally even necessary to ask the
patient to hold their breath for the duration of the aspira-
tion. The practice of identifying a puncture site at a radiol-
ogy department prior to transporting a patient elsewhere
for thoracentesis should be discouraged, particularly in the
case of small effusions, as both the fluid collection and the
skin mark might shift considerably with minor changes in
body position.
Thoracentesis
Sonography is superior to chest radiographs in detecting
pleural effusions and identifying the optimal site for diag-
nostic thoracentesis.34 The largest and most accessible area
of fluid accumulation can be identified, and an aspiration
can easily be performed by means of the ‘freehand’ tech-
nique. The success rate of US-guided thoracentesis can be
as high as 97 percent.35 US guided thoracentesis improves
the diagnostic yield and decreases the risk of complications
in all patients, but is particularly helpful when a safe pro-
cedure is mandatory, e.g. in patients with bleeding diathe-
sis or the critically ill patient.
Closed tube drainage
Ultrasound is ideal for identifying the optimal site for
effective and safe pleural drainage. This is particularly rel-
evant in an ICU setting and in patients with loculated
parapneumonic effusions and empyemas with septations.
Depending on operator experience, US may also guide
further decisions regarding the need for subsequent
intrapleural fibrinolytics or for surgical intervention in
addition to drainage and antibiotics.36
Effusions can also be accessed by means of an 18- or 
16-gauge needle under direct (real-time) US visualization.
This allows direct thoracentesis followed by an insertion of
a guide wire, which is used to guide serial incremental
dilatation of a tract and deployment of a pigtail small-bore
catheter (8–14 F). These tubes are better tolerated than
large bore (20–24 F) intercostal drains.37
Closed pleural biopsy in the presence of a
pleural effusion
Sonography is an extremely useful guide for biopsies of the
pleura. Focal pleural abnormalities (thickening or tumors)
can be identified with US, and biopsy can be aimed at these
areas of interest. The ability to estimate the size of an asso-
Figure 21.9 A peripheral lung abscess. Note the hypoechoic
centre and irregular wall. A, abscess cavity; L, lung.
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ciated effusion decreases the risk of visceral pleural lacera-
tions, which is particularly relevant in cases with minimal
pleural effusion.
Conventionally, closed pleural biopsies (e.g. with the
Abrams needle) could only safely be performed in the
presence of a sizeable pleural effusion or pneumothorax
determined clinically or on chest radiography. However,
US can demonstrate small fluid collections and facilitate
the use of devices that were not primarily designed for
fluid aspiration (e.g. Tru-cut needles). Numerous studies
have concluded that US-guided Tru-cut needle biopsies
have higher sensitivity and specificity in the diagnosis of
pleural malignancy and tuberculosis than unaided Abrams
needle biopsies.38–41
Transthoracic fine needle aspirations and
needle biopsies of solid tumors
Ultrasound-guided fine needle aspiration or cutting
biopsy performed under local anesthesia is safe and has a
high diagnostic yield.42 Chest wall and anterior mediastinal
masses, pleural tumors or thickening, as well as peripheral
lung tumors that either abut or invade the pleura or chest
wall, are ideally suited for US-guided biopsy procedures.
The risk of pneumothorax is low as no air-containing
tissue needs to be transversed with the biopsy device. US-
guided biopsies can be performed at the bedside, which
offers advantages in distressed patients with advanced
disease. The shortened procedure time is also particularly
helpful in less cooperative patients.
Transthoracic fine needle aspirations (TTFNA) are per-
formed under local anaesthesia, preferably with a 22-gauge
injection-type or spinal needle. A recent prospective study
found that TTFNA and closed needle biopsies corre-
sponded well in the diagnosis of epithelial lung carcinoma
and in the distinction of small cell and non-small cell lung
cancer. TTFNA alone seems sufficient for the diagnosis of
epithelial lung carcinoma, while closed needle biopsies
have a higher yield in non-carcinomatous lesions and
pleural tumors.43
Cutting needle biopsies follow the same principles as
TTFNA, but such devices are more invasive and carry the
risk of vascular trauma if the anatomical locations of sub-
clavian, brachial, intercostal and mammarian arteries are
not respected. Chang et al.38 found that US-guided Tru-
cut had a sensitivity of 61.5 percent and specificity of 100
percent. Tru-Cut biopsy is particularly helpful for diag-
nosing malignant mesothelioma without open surgical
biopsy. A recent study of cutting needle biopsies under
CT-guidance in diffuse pleural thickening showed a sensi-
tivity and specificity for mesothelioma of 88 and 100
percent, respectively.44 In a study employing US for
tumors greater than 3 cm in diameter, the sensitivity and
specificity for mesothelioma was 100 percent.42
Cytopathological support for rapid on-site evaluation
(ROSE) of TTFNA smears is extremely helpful in deciding
whether a histological specimen obtained via cutting
needle biopsy is needed or not.43 In the absence of ROSE,
cutting biopsies should be performed in all cases where
cytology is non-contributory and in cases where a diagno-
sis other than lung cancer is suspected. Conveniently,
US is a good tool for exclusion of a pneumothorax post-
aspiration or biopsy. If the lesion remains visible on US
and is unchanged in location, shape and size, it implies
that no free air is present between the sampled lesion and
the visceral pleura, and that a clinically relevant pneu-
mothorax is unlikely. US-guided biopsies are safe proce-
dures, with an overall complication rate of only 1–2
percent.42,43
Aspiration and biopsy of diffuse pulmonary
infiltrates, consolidations and lung abscesses
The indications for US-assisted TTFNA and biopsies are
by no means limited to solid tumors. Yang et al.31 found
US-guided biopsy of pulmonary consolidation helpful in
determining its cause, and reported a diagnostic yield of as
high as 93 percent. This procedure is particularly useful in
the immunocompromised patient, given the extensive dif-
ferential diagnosis. The same author was able to sono-
graphically demonstrate abscess cavities in 94 percent of 35
patients with radiologically confirmed lung abscesses.45 By
US, lung abscesses were depicted as hypoechoic lesions
with irregular outer margins and an abscess cavity that was
manifested as a hyperechoic ring. More than 90 percent of
all aspirates of these abscesses yielded pathogens, whereas
less than 10 percent of patients had positive blood cultures.
CONCLUSION
The usefulness of US for chest physicians is firmly estab-
lished. Basic thoracic ultrasonography is an elegant and
low-cost investigation that extends the physicians’ diag-
nostic and interventional potential at the bedside in
peripheral lung, pleural and chest wall disease. It has the
potential to replace CT-guided fine needle aspirations or
biopsies of all lesions involving the pleura and chest wall,
as well as lung masses or consolidations abutting the
pleura. Basic thoracic sonography is fairly simple and easy
to learn. Academic institutions should strive to have a
basic formal training program in ultrasonography in place
in order to ensure that all aspiring chest physicians are
familiar with chest ultrasonography.
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KEY POINTS
● Thoracic ultrasonography can be performed by
means of the most basic ultrasound equipment.
● In healthy individuals, ultrasound can visualize
the chest wall, the diaphragm and the pleura, but
not the lung parenchyma.
● The main domain of thoracic ultrasound is the
investigation of chest wall abnormalities, pleural
thickening and pleural tumors, and the qualita-
tive and quantitative description of pleural effu-
sions.
● Ultrasound can visualize lung tumors and other
parenchymal pulmonary processes provided that
they abut the pleura.
● Ultrasound is the ideal tool to assist with thora-
centesis and drainage of effusions.
● Ultrasound-assisted fine needle aspiration and
cutting needle biopsy of lesions arising from the
chest wall, pleura and lung are safe and have a
high yield in the hands of chest physicians.
● New applications of ultrasound include the diag-
nosis of pneumothorax and pulmonary
embolism.
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Abstract
Thoracic ultrasonography can be performed by means of the most
basic ultrasound (US) equipment. In healthy individuals, US can visu-
alize the chest wall, the diaphragm and the pleura but not the lung
parenchyma. The main domain of thoracic US is the investigation of
chest wall abnormalities, pleural thickening and pleural tumours,
and the qualitative and quantitative description of pleural effusions.
US can visualize lung tumours, pulmonary consolidations and other
parenchymal pulmonary processes provided they abut the pleura.
US is the ideal tool to assist with thoracentesis and drainage of effu-
sions. US-assisted fine needle aspiration and cutting needle biopsy
of lesions arising from the chest wall, pleura and peripheral lung are
safe and have a high yield in the hands of chest physicians. US may
also guide aspiration and biopsy of diffuse pulmonary infiltrates,
consolidations and lung abscesses, provided the pleura is abutted.
Advanced applications of transthoracic US include the diagnosis of a
pneumothorax and pulmonary embolism.
Copyright © 2008 S. Karger AG, Basel
Ultrasonography of the thorax remains an underutilized
investigation. Although diagnostic sonography of the
abdomen has been around for more than 60 years, its tho-
racic counterpart has lagged behind for many decades. The
inability of ultrasound (US) to penetrate aerated tissue
diverted clinicians from appreciating its excellent ability to
visualize the chest wall, pleura and pathology of lung abut-
ting the pleura [1]. The major advantages of thoracic US
include its mobility, dynamic properties, low cost, lack of
radiation, and short examination time [1–6]. Thoracic US is
also increasingly being used to assist interventional proce-
dures. The main aim of this chapter is to demystify ultra-
sonography for the clinician by reviewing the basic
principles and recent advances from the perspective of the
non-radiologist.
General Technical Aspects
Adequate thoracic ultrasonography can be performed by
means of the most basic, entry-level, two-dimensional
black-and-white US equipment. A low frequency probe
(e.g. 3.5 MHz) with curvilinear shape for covering a large
area is suitable for initial screening of superficial and deeper
structures, while a high frequency probe (e.g. 8 MHz) with
a linear shape is used for refined assessment of an abnormal
chest wall or pleural area. Doppler and colour flow echo are
not required for routine thoracic examination.
Optimal patient position for scanning is an underappre-
ciated aspect. It is important to review a patient’s chest radi-
o graph and computed tomography (CT) scan prior to
per forming a thoracic US examination. This will not only
identify the area of interest, but will also guide the position-
ing of the patient. The posterior chest is best scanned with
the patient in the sitting position using a bedside table as an
armrest (fig. 1), whereas the lateral and anterior chest wall
can be examined with the patient in either the lateral decu-
bitus or even supine position. Maximum visualization of
the lung and pleura is achieved by examining along the
intercostal spaces. Raising the arm above the patient’s head
increases the intercostal space distance and facilitates scan-
ning in erect or recumbent positions. A patient can fold the
arms across the chest in order to displace the scapulae when
Bolliger CT, Herth FJF, Mayo PH, Miyazawa T, Beamis JF (eds): Clinical Chest Ultrasound: From the ICU to the Bronchoscopy Suite.
Prog Respir Res. Basel, Karger, 2009, vol 37, pp 22–33
Transthoracic Ultrasound for Chest Wall,
Pleura, and the Peripheral Lung
Coenraad F.N. Koegelenberg  Andreas H. Diacon 
Chris T. Bolliger
Division of Pulmonology, Department of Medicine, University of Stellenbosch and 
Tygerberg Academic Hospital, Tygerberg, Cape Town, South Africa
33
University of Stellenbosch: http://scholar.sun.ac.za
Transthoracic Ultrasound 23
surveying the upper posterior thorax. Superior sulcus
pathology can be visualized apically with the patient in the
supine or sitting position.
Diagnostic Thoracic Ultrasonography
The Normal Thorax
A series of echogenic layers of muscles and fascia planes are
seen during the initial surveillance of a normal chest with the
low frequency probe (fig. 2a). Ribs appear as curvilinear stru -
ctures on transverse scans, associated with posterior acoustic
shadowing. When the ribs are scanned longitudinally, the
anterior cortex appears as a continuous echogenic line.
The visceral and parietal pleura are normally displayed
by a low-frequency probe as one highly echogenic line rep-
resenting the pleura and pleuropulmonary surface. With a
high-resolution linear probe, the visceral and parietal pleura
can be seen as two distinct echogenic lines, with the  latter
seemingly thinner in appearance (online suppl. video 1).
The two layers can be seen to slide over each other during
in- and expiration. The respiratory movement of the lung
relative to the chest wall is visible with both probes and  is
called the ‘lung sliding’ sign (online suppl. video 2). Its pres-
ence on real-time US is strong evidence against the presence
of a pneumothorax [7].
The normal diaphragm is best seen through the lower
intercostal spaces or via the liver or the spleen. It is seen as
an echogenic 1- to 2-mm-thick line which contracts with
inspiration.
The ‘curtain sign’ describes the variable obscuring of
underlying structures by air-containing tissue. In normal
subjects, the curtain sign is seen in the costophrenic angle.
The upper abdominal organs are easily visible on expira-
tion, but during inspiration the normal air-filled lung is
moved downwards in front of the probe and temporarily
obscures the sonographic window.
The parenchyma of normal aerated lungs is invisible by
means of US. The large change in acoustic impedance at the
pleura-lung interface causes horizontal artefacts that are
seen as a series of echogenic parallel lines equidistant from
one another below the pleura. These bright but formless
lines are known as reverberation artefacts and diminish in
intensity with increasing distance from the pleura. Vertical
‘comet-tail’ artefacts, caused by fluid-filled subpleural inter-
lobular septa, can also be seen originating at the pleura-
lung interface (fig. 2b).
Chest Wall Pathology
Soft-Tissue Masses and Lymph Nodes
Soft-tissue masses arising from the chest wall can readily be
detected by high-frequency US. These include abscesses,
lipomas and a plethora of other (mostly benign) lesions.
Masses generally have variable echogenicity and US find-
ings are too non-specific to differentiate between various
aetiologies [1, 4].
Supraclavicular and axillary lymph nodes are accessible
by means of US, and US may even aid in distinguishing
reactive from malignant lymph nodes [4]. An echogenic
fatty hilum and oval or triangular shapes are indicative of
inflammatory lymph nodes, whereas lymph nodes with
malignant infiltration usually show loss of the fatty hilum
leading to a hypoechoic appearance [4, 8]. Malignant nodes
also appear bulky, and extracapsular spread is suggested by
irregular borders [9].
Skeletal Pathology
Sonography may sometimes detect bony metastases to the
ribs, which appear as hypoechoic masses replacing the
 normal echogenicity of a rib and leading to the disruption of
the cortical line [9]. US is also reported to be more sensitive
than radiography in the detection of rib fracture [10], which
appears as a breach or displacement of the cortex of the rib
with or without a localized swelling or haematoma.
Fig. 1. Scanning position for thoracic US. The posterior chest is best
scanned with the patient in the sitting position using a bedside table
as an armrest. Note the way in which the probe is held. It is important
to ask the patient to fold his arms across his chest when surveying
the superior posterior chest. The lateral chest wall can be examined
with the patient in the lateral decubitus position with the arm raised,
and the anterior chest wall with the patient supine (not shown).
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Diaphragmatic Abnormalities
Diaphragmatic movements are best assessed through solid
upper abdominal viscera, i.e. the liver or the spleen [1]. A
degree of asymmetry in the movement of the hemidi-
aphragms is considered normal [4]. Sonographic examina-
tion of a paralyzed diaphragm will yield paradoxical
movement of the diaphragm with respiration [11]. This can
be accentuated with forced inspiration (‘sniff ’ test). Long-
term paralysis causes muscle atrophy [11].
Pleural Pathology
Pleural Effusions
The value of sonography for the detection and quantifica-
tion of pleural effusions remains uncontested. US is partic-
ularly useful in assessing the nature of localized or diffuse
pleural opacities, and is more sensitive than decubitus expi-
ratory films in identifying minimal or loculated effusions
[12]. Sonographically, a pleural effusion appears as an ane-
choic, homogeneous space between parietal and visceral
pleura (fig. 3). This space may change in shape with respira-
tion, and the atelectatic lung inside a large effusion may
appear as a tongue-like structure within the effusion. In
inflammatory effusions, adhesions between the two pleural
surfaces may result in the absence of lung motion above the
effusion. If an abnormal elevation of a hemidiaphragm is
noted on a chest radiograph, subpulmonary effusion can be
differentiated from a subphrenic fluid collection and
diaphragm paralysis [13].
The US appearance of a pleural effusion depends on its
nature, cause and chronicity. Four appearances are recognized
a b
Fig. 2. a The typical appearance of a normal
chest on US (transverse image through the
intercostal space with high frequency probe).
The chest wall is visualized as multiple layers
of echogenicity representing muscles and fas-
cia. The visceral and parietal pleura appear as
echogenic bright lines that slide during respi-
ration. Reverberation artefacts beneath the
pleural lines imply an underlying air-filled
lung. S Skin; CW chest wall; P pleura;
Pp parietal pleura; Pv visceral pleura;
L lung; R reverberation artefact. b An
example of a comet-tail artefact observed in
an otherwise normal subject. C Comet-tail
artefact.
Fig. 3. A pleural effusion is presented as an echo-free space between
the visceral and parietal pleura. Compressive atelectasis of the lung is
seen on this high-frequency US. This is an example of an anechoic  eff -
usion. CWChest wall; PEpleural effusion; L lung; D diaphragm.
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based on the internal echogenicity: anechoic (fig. 3), complex
but non-septated (fig. 4a), complex and septated (fig. 4b), and
homogenously echogenic. Transudates are invariably anechoic,
unseptated, and free flowing, whereas complex, septated or
echogenic effusions are usually exudates [14, 15]. Malignant
effusions are often anechoic. Nodular pleural thickening is
apparent in the minority of malignant effusions, and echogenic
swirling patterns have been linked to these effusions [16].
Inflammatory effusions are often associated with strands of
echogenic material and septations (online suppl. video 3) which
show more or less mobility with respiration and the cardiac
cycle. The presence of septa has several implications. Chen et al.
[17] demonstrated that patients with septated effusions needed
longer chest tube drainage, longer hospital care, and were more
likely to require fibrinolytic therapy or surgery compared with
those with unseptated effusions. Tu et al. [18] confirmed some
of these findings in medical intensive care unit patients.
Several studies have shown reasonable correlation bet -
ween the volume of an effusion estimated with planimetric
measurements and its square dimensions [19–21]. Such geo-
metric calculations are hampered by the uneven distribution
of fluid in the presence of pleuropulmonary adhesions.
Although not prospectively tested, we suggest the following
practical way to classify the volume of an effusion: minimal,
if the echo-free space is confined to the costophrenic angle;
small, if the space is greater than the costophrenic angle but
still within the range of the area  covered with a 3.5-MHz
curvilinear probe; moderate, if the space is greater than a
one-probe range but within a two-probe range, and large, if
the space is bigger than a two-probe range [1].
Distinguishing small effusions from pleural thickening can
be challenging. Both may appear as hypoechoic on US.
Furthermore, empyema may also cause a strongly echo genic
effusion that may be mistaken for a solid pleural lesion.
Mobility is an important sign for effusion. Marks et al. [22]
found that if a lesion changed shape with respiratory excur-
sion and if it contained movable strands or echo densities, the
lesion was an effusion. If a colour Doppler is available, the
fluid colour sign is the most sensitive and specific ultrasono-
graphic evidence of a small effusion. The sign refers to the
presence of a colour signal within the fluid collection that is
believed to arise from transmitted motion during respiratory
or cardiac cycles. This sign has a sensitivity of 89.2% and
specificity of 100% in detecting minimal fluid collections [23].
Pleural Thickening
Pleural thickening can be defined as a focal lesion arising
from the visceral or parietal pleura that is greater than 3 mm
in width with or without an irregular margin (fig. 5). It
appears as broadening of the pleura and does not exhibit a
fluid colour sign or display movement relative to the chest
wall (online suppl. video 4). Pleural thickening most often
appears hypoechoic, but increased echogenicity with focal
shadowing is sometimes observed and is indicative of calcifi-
cation and chronicity.
a b
Fig. 4. More examples of pleural effusions. a A low-frequency US of a complex non-septated effusion showing movable echogenic shadows
(E) within the effusion. b A low-frequency US of a complex septated effusion with thick septa (S) and loculations (L) (also see online suppl.
video 3). 
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Pneumothorax and Hydropneumothorax
The detection of a pneumothorax requires a higher level of
skill and experience than the detection of pleural fluid. A
pneumothorax (online suppl. video 5) can be diagnosed by
means of the absence of normal lung sliding, exaggerated
horizontal reverberation artefacts and the loss of comet-tail
artefacts, provided that no diaphragmatic paralysis, prior
pleurodesis, pleural adhesions or adult respiratory distress
syndrome are present [24–27]. Ultrasonography is particu-
larly useful in intensive care units and in other situations
where radiographic equipment is unavailable. Herth et al.
[26] showed that a pneumothorax following transbronchial
biopsy can be reliably excluded with US (sensitivity 100%;
specificity 83%). Soldati et al. [27] very recently found US
to be superior to chest radiographs in diagnosing pneu-
mothoraces in patients following blunt chest trauma. In
their prospective study they were able to show that a rapid
US performed by an experienced operator had a sensitivity
of 92% (spiral CT was used as the gold standard). Only 52%
of pneumothoraces in their study population were visible
on routine chest radiographs.
Hydropneumothorax can also be identified with US by
means of the visualization of air-fluid boundary [28], which
can move with respiration. The sliding sign above the air-
fluid level will be absent. The ‘curtain sign’ describes rever-
beration artefacts originating from the air within the pleura
that obscures the underlying effusion during inspiration,
allowing a confident diagnosis to be made.
Pleural Tumours
Benign pleural tumours are rare and appear on US as well-
defined rounded masses of variable echogenicity (depend-
ing on their fat content) on either the parietal or visceral
pleura. Both metastatic pleural tumours and malignant
mesothelioma give rise to polypoid pleural nodules or
irregular sheet-like pleural thickening [29], often with large
pleural effusions (fig. 6).
Pulmonary Pathology
Neoplasms
A peripheral lung tumour will be detectable by US provided
that pleural contact is present. These tumours most often
appear hypoechoic with posterior acoustic enhancement
[3] (fig. 7). Associated pulmonary collapse may cause fluid
bronchograms. Visceral pleura or chest wall invasion has
important implications for lung tumour staging (T2 or T3
staging, respectively). Although computer tomography is
routinely used for determining the extent of invasion, high-
resolution real-time US scanning has been found to be
Fig. 5. Pleural thickening (PT). Note the hypoechoic appearance
with distal enhancement (suggestive of chronicity). This patient was
previously treated for tuberculous pleuritis (also see online suppl.
video 4).
a b
Fig. 6. Two examples of the sonographic appearance of pleural
tumours, one with a large pleural effusion (a) and one without (b). Note
the posterior echo enhancement (E). PE Pleural effusion; Tpleural
tumour; Ppparietal pleura; L lung [from 2, with permission].
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superior to routine chest CT in evaluating tumour invasion
of the pleura and chest wall [30, 31]. When a tumour
abutted to the chest wall is visualized with US, all layers of
the chest wall, i.e. muscle, fascia, parietal pleura and visceral
pleura, can be examined and the extent of tumour invasion
can be accurately determined (fig. 8). Loss of movement of
a visualized tumour with respiration suggests extension
beyond the parietal pleura.
Colour Doppler US may aid in distinguishing malignant
from benign pulmonary masses [32–34]. Almost two thirds
of peripheral malignant masses will demonstrate a colour
Doppler signal (low-impedance flow) due to neovascular-
ity. A constant flow pattern correlates with malignancy,
whereas a pulsatile or triphasic flow pattern is often
observed in either malignant or benign masses [31]. At least
one study has found that residual peripheral metastases
showed diminished vascularity at colour Doppler imaging
following chemotherapy [35].
Pneumonia and Lung Abscess
Apart from solid tumours, numerous pathological
processes can replace the air within lung tissue and
thereby become detectable with US, provided that the
pleural contact is present. Pleural-based pneumonic con-
solidation is detectable by means of US, although the
extent of disease appears smaller at US than on chest radi-
ographs. In the early phase of consolidation, the lung
appears diffusely echogenic, similar to the ultrasono-
graphic texture of the liver. Air and fluid bronchograms
appear as echogenic branches that vary with respiration.
Fluid bronchograms appear as anechoic tubular struc-
tures, representing fluid-filled airways, and are typically
seen in bronchial obstruction [9]. Fluid bronchograms
should alert the clinician to the possibility of a postob-
structive pneumonitis, secondary to a proximal tumour.
US may also aid in distinguishing a central obstructive
tumour (usually hypoechoic) from distal consolidation
(more echogenic) [36]. Sonographically observed consoli-
dation is not synonymous with infective pneumonia.
Pulmonary infarction, haemorrhage and bronchoalveolar
carcinoma are examples of noninfective causes of consoli-
dations that are similar in appearance on US. US may
guide transthoracic needle aspirations or biopsies of
peripheral pulmonary infiltrates in cases with diagnostic
uncertainty regarding the aetiology [37, 38].
A lung abscess abutting the pleura appears as a hypoe-
choic lesion with a well-defined or irregular wall (fig. 9)
[38]. The centre of the abscess is most often anechoic, but
may reveal septations and internal echoes. Abscesses con-
taining air fluid levels are more inhomogeneous.
Pulmonary Oedema and other Alveolar-Interstitial
Syndromes
In the setting of patients with acute dyspnoea it has been
reported that the presence of bilateral, widespread comet-
tail artefacts (fig. 10) is a reliable sign to differentiate
patients with pulmonary oedema from those with chronic
obstructive airway disease [39]. Lichtenstein et al. [40]
reported that comet-tail artefacts were absent in 92% of
patients with chronic obstructive airway disease, but
detectable in 93% of patients with alveolar-interstitial
 syndromes.
Pulmonary Embolism
US can aid in the acute bedside assessment of patients pre-
senting with possible pulmonary embolism [41].
Pulmonary infarction is recognized as a peripheral wedge-
shaped hypoechoic region, often accompanied by a
pleural effusion [42–44]. A central hyperechoic bronchi-
ole and a congested pulmonary vessel can sometimes be
Fig. 7. A peripheral lung lesion is shown schematically without (top)
and with (bottom) pleural contact. The corresponding sonar images
recorded with a sector scanner are shown on the right. Only the
lesion with pleural contact is visible on US. Note that the acoustic
window is too narrow to demonstrate the whole circumference of
the lesion, but it allows determining its full depth [from 3, with per-
mission].
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observed [4]. The extent of pulmonary infarction is
invariably underappreciated at US, as is the case for pneu-
monic consolidation. US is also useful in detecting the
sequelae of thromboembolic disease such as right ventric-
ular overload and dilated hepatic veins. In experienced
hands, thoracic US has a sensitivity of 77–89% and speci-
ficity of 66–83% for pulmonary embolism [42–44].
However, sonographic detection of pulmonary emboli is
currently still reserved for physicians with an interest in
US, as pulmonary spiral CT angiography remains the
investigation of choice.
a b
Fig. 8. a An US image showing a lung tumour with posterior echo enhancement. Note that both the visceral as well as the parietal pleural
lines are intact. b This US shows tumour extension beyond the pleura. The visceral pleural line is interrupted, and the respiratory movement of
the tumour is disturbed in real-time US. Invasion of the pleural cavity by the tumour is evident. L Lung; T tumour; Pv visceral pleura;
Pp parietal pleura [from 2, with permission].
Fig. 9. A peripheral lung abscess. Note the hypoechoic centre and
irregular wall. A Abscess cavity; L lung.
Fig. 10. A high-frequency US of a patient with pulmonary oedema
showing widespread pronounced comet-tail artefacts (a reliable
signs of interstitial pulmonary oedema). C Comet-tail artefacts;
E pleural effusion.
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Other Pulmonary Pathology
Pleural-based cysts (e.g. echinococcus cysts) can be visual-
ized as large anechoic (round) lesions (fig. 11). Pulmonary
arteriovenous malformations may also be seen at US as these
congenital abnormalities are often peripheral. Arterio venous
malformations appear as distinct hypoechoic lesions with
posterior acoustic enhancement [45]. Lesions show high vas-
cularity on Doppler with low-impedance flow.
Rounded atelectasis may give rise to a pleural-based
mass with associated pleural thickening and extrapleural
fat. The invaginated pleura may be seen as an echogenic line
running from the pleura into the mass [46].
US-Guided Interventions 
Principles
US is ideal for guiding chest wall, pleural and peripheral
pulmonary interventions, including diagnostic thoracente-
sis, closed tube drainage, chest wall and pleural biopsies and
biopsies of lung tumours abutting or invading the pleura.
The use of US increases the success rate and minimises risk
compared to blind procedures [1].
Specific reusable probes for real-time US guidance of
needle biopsies are commercially available. Many experi-
enced physicians, however, prefer the so-called ‘freehand’
technique. Following adequate patient positioning, the
intended site of needle insertion is sonographically identi-
fied and marked, while the direction, the depth of interest
and the safety range for the procedure are determined and
memorized [1] (online suppl. video 6). It is essential that
the subject must not change position in order to prevent a
shift of the area of interest relative to the skin mark. It is
occasionally even necessary to ask the patient to hold his
breath for the duration of the aspiration. The practice of
identifying a puncture site at a radiology department prior
to transporting a patient elsewhere for thoracentesis should
be discouraged, particularly in the case of small effusions,
as both the fluid collection and the skin mark might shift
considerably with minor changes in body position.
Chest Wall Biopsy
Soft-tissue masses of indeterminate aetiology may be sam-
pled by means of US-assisted fine needle aspirations (FNA)
or biopsies [4]. US-guided procedures may also be used to
detect chest wall invasion by pulmonary tumours. High-
resolution US is superior to routine chest CT in evaluating
tumour invasion of the pleura and chest wall [30, 31], and
Nakano et al. [47] have even suggested US-assisted cutting
needle biopsy (CNB) of the chest wall for the preoperative
assessment of chest wall invasion by pulmonary neoplasms
(specificity: 100%, diagnostic accuracy: 83%).
Pleural Fluid Aspiration
US is superior to chest radiographs for the documentation
of the optimal site for diagnostic thoracentesis [48]. The
most accessible area of fluid accumulation can be identified,
and an aspiration can easily be performed by means of the
‘freehand’ technique (online suppl. video 7). The success rate
of US-guided thoracentesis can be as high as 97% [49]. US-
guided thoracocentesis improves the diagnostic yield and
decreases the risk of complications in all patients, but is
particularly helpful when a safe procedure is mandatory,
e.g. in patients with bleeding diathesis.
Intercostal Tube Drainage
Ultrasonography is ideal for identifying the optimal site for
safe and effective pleural drainage (fig. 12). This is particu-
a b
Fig. 11. This patient presented with a sus-
pected hydatid cyst. Her CT chest showed
cystic mass (pleural based) (a), and a FNA
was safely performed with the assistance of
low-frequency US (b). C Cyst.
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larly relevant in patients in an ICU setting and with locu-
lated parapneumonic effusions, where thickened parietal
pleura, adhesions or loculations often complicate insertion.
Depending on operator experience, US may also guide fur-
ther decisions regarding the need for subsequent intraple -
ural fibrinolytics, thoracoscopy or for surgical intervention
in addition to tube drainage and antibiotics [50].
US-guided drains are most frequently inserted by means
of the ‘freehand’ technique. As an alternative, effusions may
also be accessed by means of an 18- or 16-gauge needle
under direct (real-time) US visualization. This allows direct
fluid aspiration followed by an insertion of a guide wire,
which is used to guide dilatation of a tract and deployment
of a small-bore catheter (8–14 french). These tubes are bet-
ter tolerated than large bore (20–24 french) intercostal
drains [51], although common sense suggests that smaller
bore drains are more likely to fail in the presence of pus
with a high viscosity. Some prospective studies have found
that 8- to 12-french pigtail catheters or 10- to 14-french
catheters inserted with the Seldinger technique under US or
CT guidance were at least as effective as larger catheters
inserted without imaging [51–53]. However, the position-
ing of the catheter tips with guidance is likely to be superior
compared to a blind insertion, irrespective of drain size.
Most of these studies also employed a strict rinsing sched-
ule (often several times a day), which might be difficult to
sustain in everyday clinical practice. Moreover, a recent
study found a failure rate of 19% with small-bore catheters
and concluded that the threshold for using fibrinolytics and
large-bore catheters should be low in empyema [54].
Closed Pleural Biopsies
US is an extremely helpful guide for biopsies of the pleura.
Focal pleural abnormalities can be identified with US, and
biopsy can be aimed at areas of interest. Measuring the size
of an associated effusion decreases the risk of visceral lacer-
ations, which is particularly relevant in cases with small
pleural effusion [1].
Closed pleural biopsies (e.g. with the Abrams needle)
could conventionally only be performed in the presence of a
sizeable pleural effusion or pneumothorax visible on chest
radiography. Ultrasonography, however, can demonstrate
small fluid collections and facilitate the use of devices that
were not primarily designed for pleural biopsies in the
absence of an effusion. Numerous studies have shown that
US-assisted Tru-Cut needle biopsies have higher sensitivity
and specificity in the diagnosis of pleural malignancy than
unaided Abrams needle biopsies [55–59]. Chang et al. [55]
found a sensitivity of up to 86% for pleural malignancies or
tuberculosis, whereas Helio et al. [56] showed that US-
assisted biopsies had a sensitivity of 77% and a positive pre-
dictive value of 100% for malignant mesothelioma. Diacon
a b
Fig. 12. A low-frequency US was used to guide a diagnostic aspiration and the insertion of an intercostal drain in this
patient with empyema. a His chest radiograph was suggestive of a large loculated right-sided effusion. b US con-
firmed this, but also revealed a raised right hemidiaphragm. An optimal site for the aspiration and drain insertion was
subsequently identified. E Effusion; D diaphragm; L liver.
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et al. [59] found that US-assisted biopsies had a sensitivity
and specificity of 100% for mesothelioma provided the
tumours were greater than 3 cm in diameter.
Transthoracic FNA and Needle Biopsies of Solid Tumours
Transthoracic FNA (TTFNA) and needle biopsies of solid
tumours by means of US-assisted FNA or cutting biopsy
performed under local anaesthesia and by non-radiologists
are safe procedures and have high diagnostic yields [59].
Peripheral lung tumours that either abut or invade the
pleura or chest wall and anterior mediastinal masses are
ideally suited for these procedures (fig. 13). No aerated lung
needs to be transversed with the biopsy device, and the risk
of pneumothorax is therefore low. Furthermore, US-
assisted biopsies can be readily performed outside a theatre,
which offers advantages in immobile patients with
advanced disease. TTFNA are performed under local
anaesthesia, preferably with a 22-gauge injection-type or
spinal needle (online suppl. video 8). CNB follow the same
principles as TTFNA, but such devices are more invasive
and carry the risk of vascular trauma if the anatomical loca-
tions of subclavian, brachial, intercostal and mammarian
arteries are not respected.
A prospective study by Diacon et al. [59] found that
TTFNA and closed needle biopsies performed by pulmo-
nologists corresponded well in the diagnosis of epithelial
lung carcinoma and in the distinction of small cell and non-
small cell bronchogenic carcinoma. They were able to show
that US-guided ‘free-hand’ CNB of lung tumours abutting
the chest wall had a diagnostic sensitivity of 85.5%. The
same investigators also found that US-assisted TTFNA with
rapid on-site evaluation by a cytopathologist of tumours
abutting the chest wall were diagnostic in 82% [60].
Subanalyses of their data proved that US-guided TTFNA,
compared to CNB, had a superior yield for bronchial carci-
noma whereas CNB was superior in the minority of cases
with non-carcinomatous tumours and non-malignant
lesions [60]. CNB should therefore be performed in all
cases where cytology is non-contributory and in cases
where a diagnosis other than lung cancer is suspected. Both
US-guided CNB and FNA had a low complication rate, with
pneumothoraces observed in 4 and 1.3%, respectively [60].
US is not only used to assist transthoracic procedures,
but also to exclude a pneumothorax post-TTFNA or biopsy.
If the lesion remains visible and unchanged in location,
shape and size, it implies that no free air is present between
the sampled lesion and the visceral pleura, and that a clini-
cally relevant pneumothorax is unlikely [1, 3].
TTFNA and/or Needle Biopsies of Diffuse Parenchymal
Infiltrates, Consolidations and Lung Abscesses
The indications for US-assisted TTFNA and biopsies are
not limited to solid tumours but can be helpful in other
aetiologies of lung consolidation. Yang et al. [37] reported a
diagnostic yield of as high as 93% with US-assisted biopsies
of pulmonary consolidation of unknown aetiology. This
procedure is particularly useful in the immunocompro-
mised patient, given the extensive differential diagnosis.
The same author was able to sonographically demonstrate
abscess cavities in 94% of 35 patients with radiologically
confirmed lung abscesses [61]. At US, lung abscesses were
depicted as hypoechoic lesions with irregular outer margins
and an abscess cavity that was manifested as a hyperechoic
ring. More than 90% of all aspirates of these abscesses
yielded pathogens, whereas less than 10% of patients had
positive blood cultures.
a b
Fig. 13. An example of a case suitable for
US-guided fine-needle aspiration and/or
biopsy. a The chest radiograph showed a
lesion in the peripheral right mid lung field.
b The corresponding sonar image shows
that good transthoracic access to the
tumour is provided. An US-guided FNA and
biopsy confirmed small cell lung cancer
[from 3, with permission].
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patients (35.5%), whereas deeper FNA was diagnostic in 23 
patients (74.2%, p = 0.002). Deeper FNA confirmed malig-
nancy in all cases with diagnostic superficial FNA. We ob-
served no pneumothoraces or major hemorrhage. All pa-
tients were ultimately diagnosed with malignancy (bron-
chogenic carcinoma, n = 30; lymphoma, n = 1).  Conclusions: 
US-assisted FNA of drowned lung has an acceptable diag-
nostic yield and is safe.  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Transthoracic ultrasound (US) has become a valuable 
diagnostic aid for respiratory physicians  [1–6] and is in-
creasingly being used to guide interventional procedures 
such as thoracentesis and biopsies of the pleura and lung 
tumors that abut the chest wall  [1, 2, 7–9] . Studies have 
shown that US-assisted transthoracic fine-needle aspira-
tion (FNA) in the setting of intrathoracic malignancies 
that extend to the chest wall is safe and has a high diag-
nostic yield, particularly in the setting of bronchogenic 
carcinoma where the diagnostic sensitivity is greater than 
90%  [7–9] .
 Key Words 
 Drowned lung   Lung cancer   Transthoracic fine-needle 
aspiration   Ultrasound 
 Abstract 
 Background: Proximal lung tumors, though not discernable 
by means of transthoracic ultrasound (US), may cause vary-
ing degrees of pulmonary collapse and postobstructive 
pneumonitis which may give rise to a ‘drowned lung’ ap-
pearance on chest computed tomography (CT) and US. The 
diagnostic yield for malignancy of US-assisted transthoracic 
fine-needle aspiration (FNA) of these areas of drowned lung 
is unknown.  Objectives: We aimed to explore the feasibility 
of US-assisted FNA in this setting by prospectively investigat-
ing its diagnostic yield and safety.  Methods: We enrolled 31 
patients (aged 59.4  8 9.7 years, 17 males) with central tu-
mors and secondary drowned lung on CT scan. A respiratory 
physician performed transthoracic US to identify the target 
drowned lung tissue. Three US-assisted superficial FNA pass-
es ( ^  20 mm from the pleura) were followed by 3 deeper FNA 
passes ( 1 20 mm) aimed in the direction of a visible or ap-
proximated central mass. Rapid on-site evaluation of speci-
mens was used.  Results: Superficial FNA was diagnostic in 11 
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 The parenchyma of normal aerated lungs is not dis-
cernable by means of US. Proximal lung tumors are 
therefore not considered amenable to US-assisted trans-
thoracic FNA or cutting-needle biopsies. Proximal lung 
tumors may, however, cause varying degrees of pulmo-
nary collapse (resorptive atelectasis) and postobstructive 
pneumonitis. ‘Drowned lung’ is a radiological term often 
used to describe these areas which are considered to rep-
resent accumulated secretions and are typified on chest 
computed tomography (CT) by enhanced pulmonary 
vasculature contrasted against the surrounding pulmo-
nary consolidation ( fig.  1 )  [10, 11] . The fluid-filled air-
ways are detectable on US as fluid bronchograms, which 
are dynamic anechoic tubular structures within consoli-
dated lung that fluctuate with respiration, provided the 
consolidation extends to the chest wall ( fig. 2 )  [2, 12] .
 The diagnostic yield for malignancy of US-assisted 
FNA of areas of drowned lung secondary to proximal tu-
mors is not known. Moreover, endobronchial inspection 
and sampling by means of flexible bronchoscopy is gener-
ally considered the standard diagnostic approach in this 
scenario  [10, 13, 14] . We therefore aimed to explore the 
feasibility of US-assisted transthoracic FNA in this set-
ting by prospectively investigating its diagnostic yield 
and safety. Furthermore, we tested the hypothesis that 
aspirations performed close to the primary tumor would 
have a greater chance of yielding diagnostic material than 
more superficial passes.
 Materials and Methods 
 Study Population 
 Our institution is a 1,200-bed academic hospital in Cape 
Town, South Africa. It is 1 of 2 referral centers and renders a ter-
tiary service to a population of approximately 1.5 million people. 
Over a 3-year period (from May 2007 to April 2010) we screened 
the CT scans of all adult patients ( 1 18 years) with suspected bron-
chogenic carcinoma reviewed at the Division of Pulmonology’s 
daily radiology meeting, which acts as a forum where all internal 
and external referrals of patients with potential bronchogenic car-
cinoma are routinely presented (from January 2007 to December 
2009, 906 cases of confirmed primary lung cancer were presented 
at this meeting according to our divisional cancer registry). All 
patients with an unequivocal central mass lesion with secondary 
drowned lung (on CT scan) were subsequently invited to partici-
pate in this prospective observational study, provided that the 
suspected carcinoma did not extend to the visceral pleura, at least 
1 lobe was involved, at least 40 mm of drowned lung (minimal 
distance measured from visceral pleura) was present, and a tissue 
diagnosis was not known. For the purposes of this study, drowned 
lung was defined on contrasted CT scan as consolidated lung pa-
renchyma with enhanced pulmonary vasculature distinct from 
and distal to a central mass lesion. The Health Research Ethics 
 Fig. 1. This CT scan of one of the study subjects shows a distinct 
central mass lesion (primary tumor) with secondary drowned 
lung. Note the enhanced pulmonary vasculature. In this particu-
lar patient, aspirates were taken in the supine position anterolater-
ally in order to transect at least 40 mm of drowned lung (as mea-
sured from the visceral pleural to the drowned lung-tumor inter-
face). PT = Primary tumor; DL = drowned lung. 
 Fig. 2. An example of the US appearance of drowned lung. The 
arrow depicts the preserved bronchovascular bundle appearing as 
fluid-filled tubular structures. Note that the fluid bronchograms 
are best appreciated on real-time US. No clear plane between the 
drowned lung and tumor mass could be identified in this particu-
lar case. 
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Committee of Stellenbosch University approved the study (proj-
ect No. N08/01/010). Written informed consent was obtained 
from all subjects upon enrolment and also prior to any invasive 
procedures.
 Transthoracic US 
 A consultant respiratory physician performed the sonography 
(Toshiba JustVision 200 SSA-320A; Toshiba Medical Systems 
Corporation, Utsunomiya, Japan). A standard 3.75-MHz sector 
probe was used and the patients’ positions for US scanning were 
determined by the corresponding CT scan, e.g. patients with low-
er-lobe involvement were generally examined in the sitting posi-
tion using a bedside table as an armrest, whereas patients with 
upper-lobe involvement were scanned in the supine position. All 
procedures were performed in a bronchoscopy suite without the 
support of a specialist radiologist. The physician was asked to spe-
cifically comment on the presence of drowned lung and whether 
a distinct border between the apparent proximal mass and distal 
drowned lung could be observed. An associated effusion, if pres-
ent, was documented as follows: minimal (if the echo-free space 
was confined to the costophrenic angle), small (if the space was 
greater than the costophrenic angle but still within the range of 
the area covered with a 3.75-MHz curvilinear probe), moderate 
(if the space was greater than a 1-probe range but within a 2-probe 
range, and large (if the space was larger than a 2-probe range)  [1] . 
The intended puncture site was subsequently identified and 
marked, and the direction and the depth of interest for the proce-
dure were documented. The site of aspirations was the epicenter 
of pleural contact, and the intended direction was towards the 
observed or anticipated location of the central mass lesion while 
care was taken to avoid any major blood vessels or viscera. All 
procedures were subsequently performed ‘freehand’ (not under 
direct real-time US guidance).
 Transthoracic FNA 
 Aspirations were performed with 22-gauge spinal needles of 
40- or 90-mm length as needed (Tae-Chang, Kong Ju City, Korea) 
connected to a 10-ml syringe under sterile conditions with local 
anesthesia (lignocaine 1%) and no sedation. Three superficial 
passes at a depth not greater than 20 mm from the visceral pleura 
were performed, followed by 3 deeper passes ranging from 20 to 
60 mm. For the purposes of the study, care was taken not to aspi-
rate pleural fluid or to contaminate the needles with pleural effu-
sion. The inner stylet of the spinal needle was only removed once 
the target area had been reached, and no suction was applied while 
the needle was withdrawn. Aspirates (all from slightly different 
directions and depths) were directly expressed onto slides, 
smeared, and submitted for rapid on-site evaluation (ROSE) using 
both Diff-Quik (Rapidiff; Clinical Sciences Diagnostics, Johan-
nesburg, South Africa) and rapid Papanicolaou staining methods 
 [15] .
 ROSE of Cytology Specimens 
 The cytopathologist present in theater was experienced in 
ROSE and was asked to comment on the presence or absence of 
diagnostically useful material obtained during each individual 
pass. Material that was considered not diagnostically useful in-
cluded exclusively blood, necrotic tissue, or the total absence of 
cellular material. The cytopathologist was subsequently asked to 
comment on cytological evidence of drowned lung, which for the 
purposes of this study was defined as an aspirate that contained a 
paucity of bronchial cells with a predominance of alveolar mac-
rophages or pneumocytes (75% or more). Finally, he or she was 
asked to comment on the presence of malignant cells and, if pres-
ent, whether they could be provisionally categorized as non-small 
cell lung carcinoma, small cell lung carcinoma, epithelial carci-
noma not otherwise specified, or malignant cells of unknown or-
igin.
 Immediate Postprocedure Care 
 The FNA site was reexamined by means of US immediately 
after the procedures, and a chest radiograph was obtained if the 
pre- and postprocedure US findings differed and at the discretion 
of the attending physician. All patients were observed for at least 
2 h prior to discharge and complications were noted. The presence 
or absence of chest wall hemorrhage and a pneumothorax was 
specifically documented.
 Further Assessment and Statistical Analysis 
 All cytology slides were reviewed in the laboratory by a second 
experienced cytopathologist who had an array of special stains 
(including immunohistochemistry) at his or her disposal and had 
to concur with the original cytopathologist prior to issuing a final 
cytological diagnosis. In case of disagreement, a third cytopathol-
ogist was consulted to resolve the case.
 Further investigations for patients who remained undiag-
nosed or who required additional staging were guided by the pa-
tient’s attending respiratory physician. These investigations po-
tentially included bronchoscopy with direct forceps and/or trans-
bronchial needle aspiration biopsies (TBNA), CT-guided FNA, or 
even surgical biopsies. All patients were followed up until a tissue 
diagnosis could be confirmed. All cases of bronchogenic carci-
noma were staged according to the 2002 Union Internationale 
Contre le Cancer staging system for lung cancer  [16] .
 Descriptive statistics and McNemar’s test (performed to assess 
whether the proportion of positive diagnoses was the same be-
tween deep and superficial passes) were utilized. p  ^  0.05 in a 
2-tailed test was considered statistically significant. Unless stated 
otherwise, data are displayed as means  8 standard deviation 
(SD). We used standard methods to calculate the sensitivity  [17] . 
We had no firm data to base the sample size estimation of this 
proof-of-concept study on; therefore, we only used approxima-
tions. We considered a difference of 50% between superficial and 
deeper passes worth detecting, and posited a yield of 25 and 75%, 
respectively. A study population of 30 subjects was therefore con-
sidered sufficient (with a 5% confidence level allowing for 25% 
nondiagnostic aspirations).
 Results 
 Patients  
 Over the 3-year period we screened  1 1,000 CT scans 
and identified 39 patients with drowned lung. We en-
rolled all 31 patients (aged 59.4  8 9.7 years, 17 males) who 
fulfilled the inclusion criteria. Of these, 30 patients were 
ultimately diagnosed with bronchogenic carcinoma and 
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1 with a lymphoma ( tables 1 ,  2 ). Eight patients were not 
included as they had an established tissue diagnosis (all 
bronchogenic carcinoma) at the time of screening. Only 
1 of the 31 patients enrolled had undergone a preceding 
bronchoscopy, which was nondiagnostic (the single case 
of Hodgkin’s lymphoma).
 Imaging 
 On CT scan the central mass lesions’ maximum diam-
eter in any plane ranged from 12 to 60 mm. The extent of 
pulmonary involvement with regard to drowned lung 
ranged from 40 to 61 mm (52.6  8 5.8 mm) expressed as 
the shortest distance between the pleura and the central 
mass. Anatomically the areas of drowned lung varied 
from total lung (n = 8, 25.8%) to bilobar lung (n = 1, 3.2%) 
to unilobar right lung (n = 22, 71.0%) ( table 3 ).
 Drowned lung was confirmed in all cases on US and 
measured from 40 to 62 mm (54.3  8 8.9 mm) from the 
visceral pleura. A clear plain of separation between areas 
of distal drowned lung and the proximal mass lesion was 
only observed in 10 cases (32.3%). Twelve patients (38.7%) 
had evidence of an associated effusion ranging from min-
imal (n = 5, 16.1%) to small (n = 7, 22.6%).
 Fine-Needle Aspirations 
 A total of 93 superficial FNA passes (range 9–20 mm 
from the pleura) and 94 deep FNA passes (range 25–60 
mm) were performed. Laboratory confirmation of bron-
chogenic carcinoma was possible in 11 of the 31 patients 
based on specimens obtained by means of superficial 
passes (sensitivity 35.5%) and in 23 patients based on 
specimens obtained with deep FNA passes (sensitivity 
74.2%, p = 0.002). Deep passes confirmed malignancy 
in all cases in which superficial passes were diagnostic 
(in no case was a diagnosis made based solely on a su-
perficial FNA). Cytological evidence of drowned lung 
was present in 28 patients based on superficial passes 
(90.3%) and in 24 patients based on deep passes (77.4%, 
p = 0.343).
 At least 1 of the 3 deep FNA passes was performed to 
a depth greater than that of the measured (on US) or es-
timated (on CT scan) tumor-drowned lung interface in 8 
patients. These passes yielded the only positive speci-
mens in 3 patients, whereas both sets (including passes 
that did not cross this interface) were positive in 3 more 
cases. Both were negative in 2 cases.
 Further Investigations 
 Of the 23 patients with a firm cytological diagnosis of 
bronchogenic carcinoma, most had either advanced non-
small cell lung cancer ( table 2 ) or small cell lung cancer. 
Only 3 patients required a subsequent bronchoscopy with 
TBNA to clarify the staging. Of the 8 cases in which a di-
agnosis could not be established by means of US-assisted 
transthoracic FNA, 7 were diagnosed by bronchoscopy 
with TBNA and 1 by mediastinoscopy (the solitary case 
of lymphoma). In total, 11 patients (35.5%) required fur-
ther investigation, which in no case was deemed high 
risk.
Table 1. F inal established diagnoses of all study subjects (n = 31)
Diagnoses n %
Non-small cell lung cancer
Adenocarcinoma 10 32.3
Squamous cell carcinoma 12 38.7
Undifferentiated/large cell 3 9.7
Small cell lung cancer 5 16.1
Hodgkin’s lymphoma (nodular sclerosing type) 1 3.2
Table 2. F inal TNM staging1 of all cases of non-small cell lung 
cancer (n = 25)
Stage n %
I 0 0
II 2 8
IIIA 2 8
IIIB 10 40
IV 11 44
1 According to the 2002 Union Internationale Contre le Cancer 
staging system [16].
Table 3. A natomical extent of drowned lungs (n = 31)
Lobes involved n %
Complete right lung 5 16.1
Isolated right upper lobe 11 35.5
Isolated right middle lobe 1 3.2
Isolated right lower lobe 1 3.2
Right lower and middle lobes 1 3.2
Complete left lung 3 9.7
Isolated left upper lobe 9 29.0
Isolated left lower lobe 0 0.0
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 Complications 
 The procedures were well tolerated and no pneumo-
thoraces were noted. Only 1 case of minor hemorrhage 
which subsided upon compression alone and did not re-
quire surgical sutures was documented.
 Discussion 
 This prospective study is, to the best of our knowledge, 
the first to investigate US-assisted transthoracic FNA of 
drowned lung to determine the diagnostic yield for ma-
lignancy. We found that FNA passes at a depth greater 
than 20 mm from the visceral pleura had a diagnostic 
sensitivity of 74.2% and that they were more likely to con-
tain malignant cells than more superficial passes (74.2 vs. 
35.5%, p = 0.002). Furthermore, we observed no serious 
complications.
 We previously showed that transthoracic US-assisted 
FNA with ROSE and cutting-needle biopsies had a com-
bined sensitivity of 81% for a spectrum of benign and ma-
lignant lesions that abutted the pleura  [8] . More impor-
tantly, this technique had a sensitivity of 95% for bron-
chogenic carcinoma and a pneumothorax rate of only 
1.3%  [8] . In another study we found that this modality 
had a diagnostic sensitivity of 96% in patients who pre-
sented with superior vena cava syndrome with an associ-
ated mass lesion abutting the chest wall  [9] . Yang et al.  [18] 
previously found that US-guided cutting-needle biopsies 
have a diagnostic yield of 94.6% for subpleural pulmo-
nary tumors. Although the diagnostic yield in the present 
study is certainly not on par with these figures, our data 
provides novel evidence that transthoracic US-assisted 
FNA may even be useful in cases where the primary tu-
mor does not extend to the chest wall.
 Approximately 35% of patients had cytological evi-
dence of bronchogenic carcinoma on superficial FNA 
passes. Although this figure was significantly less than 
on deeper passes, it remained an important observation 
as these aspirates were obtained at a distance from the as-
sociated pulmonary mass. Interestingly this yield is very 
similar to that of sputum cytology  [13, 19, 20] , suggesting 
that endobronchial shedding and pooling of tumor cells 
may be the source of the diagnostic material obtained by 
means of superficial sampling from the drowned lung. 
We specifically aimed to avoid the potential contamina-
tion of specimens with malignant cells inadvertently ob-
tained from pleural fluid, making it a much less likely 
source.
 Bronchoscopy has an overall sensitivity of 88–95% for 
malignancy in patients with centrally located lung lesions 
 [13, 21] , which is superior to the sensitivity of US-assisted 
transthoracic FNA. It allows for the inspection of central 
airways, evaluation for therapeutic airway management, 
and the acquisition of histological samples that may allow 
for superior subtyping and immunohistochemistry  [13] . 
Furthermore, mediastinal nodal staging by means of 
TBNA has important implications for the staging and 
management of lung cancer  [16, 22] . Ten patients under-
went bronchoscopy in our study, which in 3 patients only 
indicated the need for endobronchial mediastinal stag-
ing. In fact, the vast majority of our study population had 
advanced lung cancer.
 As this study was purely a proof-of-concept study de-
signed to explore the feasibility of US-assisted transtho-
racic FNA in a novel setting, it was not designed to com-
pare US-assisted transthoracic FNA with bronchoscopy 
(or CT-guided FNA) or to define which patient may be 
best suited for a particular procedure. Notwithstanding 
these important considerations, our findings suggest that 
transthoracic US-assisted FNA of drowned lung may be 
utilized in specific circumstances, which may include pa-
tients who are considered high risk for bronchoscopy, 
those who refuse to undergo bronchoscopy, and those in 
whom a preceding bronchoscopy had been nondiagnos-
tic. Moreover, it may be viewed as an acceptable alterna-
tive when endoscopic mediastinal staging is irrelevant  [1] 
or when bronchoscopy is unavailable. Only future ran-
domized studies will, however, be able to specifically de-
lineate the subgroup of patients with drowned lung in 
whom a bronchoscopy may be considered superfluous.
 Some practical considerations need to be emphasized. 
US-assisted FNA can be performed by a single clinician 
with no sedation and minimal monitoring, even poten-
tially outside of theater  [1] . The disposables (especially the 
needles) are cheap, and we once again showed that the 
procedure is safe even without the assistance of specialist 
radiologists. We observed no pneumothoraces or major 
hemorrhage, a finding that was not unexpected as no aer-
ated lung was transversed and only 22-gauge needles 
were utilized.
 We specifically only included cases with at least 40 
mm of drowned lung (as measured from the visceral 
pleura) in order to have ample drowned lung to sample 
and to avoid direct sampling of the primary tumor by 
means of superficial FNA passes. A clear plane between 
the drowned lung and tumor mass could, however, only 
be identified in a minority of subjects with the aid of US, 
and in the majority this plane was purely an estimation 
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based on CT scan findings. The relative contribution of 
FNA passes from the actual tumor mass and from sur-
rounding drowned lung to the reported diagnostic yield 
for deep passes is therefore uncertain. Although this may 
be viewed as a limitation of the study, this distinction 
seems irrelevant, as in practice knowing which specimen 
confirmed a cytological diagnosis of bronchogenic carci-
noma would seem immaterial.
 Our study was not designed to establish the true inci-
dence of drowned lung secondary to lung cancer in our 
population, but our data suggest it to be a relatively rare 
presentation. Over a 3-year period we identified only 39 
patients with central tumors and drowned lung, 38 of 
whom were diagnosed with lung cancer. We recorded 906 
cases of primary lung cancer during that period, suggest-
ing that approximately 4% of all patients with lung cancer 
had drowned lung at the time of initial presentation.
 In conclusion, US-assisted FNA of drowned lung is 
safe and has an acceptable diagnostic yield, particularly 
when deep passes are performed. It may be a feasible al-
ternative to bronchoscopy where endoscopy is considered 
high risk, where bronchoscopy has failed to yield a diag-
nosis, or where mediastinal staging is considered unnec-
essary. Future studies aimed at specifically delineating 
the subgroup of patients in whom a bronchoscopy may be 
considered superfluous are therefore indicated.
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Diagnostic yield and safety of ultrasound-
assisted biopsies in superior vena cava
syndrome
C.F.N. Koegelenberg*, C.T. Bolliger*, D. Plekker*, C.A. Wright#, K. Brundyn#,
M. Louw#, P. Schubert#, M.M. van den Heuvel* and A.H. Diacon*,"
ABSTRACT: The yield and safety of ultrasound (US)-assisted transthoracic fine needle
aspirations (TTFNA) and cutting needle biopsies (CNB) in the setting of superior vena cava
(SVC) syndrome are unknown. The aims of the present prospective study were to asses the
diagnostic yield and safety of US-assisted TTFNA and CNB in SVC syndrome with an associated
mass lesion abutting the chest wall.
Over a 3-yr period, the present authors screened 59 patients with SVC syndrome, and enrolled
25 patients who had an associated mass lesion that extended to the chest wall. US-assisted
TTFNA with rapid on-site evaluation (ROSE) was performed in all cases. CNBs were performed
where a provisional diagnosis of bronchogenic carcinoma could not be established, and in 57.1%
of patients with bronchogenic carcinoma (limited due to safety constraints).
ROSE of US-assisted TTFNA confirmed diagnostically useful material in 24 patients, and
cytological diagnoses were ultimately made in all of these cases (diagnostic yield 96%). US-
assisted CNB had a diagnostic yield of 87.5%. Minor haemorrhage occurred in one out of 25
TTFNA and three out of 16 CNB. Neither procedure resulted in major haemorrhage nor
pneumothoraces.
US-assisted TTFNA and CNB have a high diagnostic yield and are safe in the setting of SVC
syndrome with an associated mass lesion abutting the chest wall.
KEYWORDS: Bronchogenic carcinoma, cutting needle biopsy, superior vena cava syndrome,
transthoracic fine needle aspiration, ultrasound
T
he superior vena cava (SVC) syndrome is a
clinical entity caused by obstruction of the
superior vena cava by infiltration, com-
pression or thrombosis [1]. Intrathoracic neo-
plasms, mainly bronchogenic carcinomas and
lymphomas, are by far the most common causes
[1–3]. An SVC syndrome secondary to an
intrathoracic neoplasm is generally considered
an oncological emergency that requires an expe-
dient diagnostic evaluation and initiation of
treatment [1, 4]. Bronchoscopy and associated
procedures have a reported diagnostic yield of
.70% in this setting, whereas mediastinoscopy
or mediastinotomy have a diagnostic yield of
.90% [5, 6]. The latter procedures are associated
with a high anaesthetic risk and a relatively high
complication rate, and major haemorrhage is seen
in a significant percentage of cases due to high
venous pressure [5, 6]. Moreover, associated
brain oedema may complicate mediastinoscopy
or mediastinotomy, as patients may experience
significant discomfort in the supine position [1].
Thoracic ultrasound (US) is a well-established
diagnostic aid to the clinician [7–10]. The major
advantages of this modality include its dynamic
properties, low cost, lack of radiation, mobility
and short examination time [7–12]. US of the
chest is increasingly being used to guide inter-
ventional procedures, such as thoracentesis, and
biopsies of tumours of the chest wall, pleura or
peripheral lung [7]. Intrathoracic mass lesions
abutting or invading the chest wall are visible at
US [7–9]. Recent studies on US-guided transthor-
acic fine needle aspirations (TTFNA) utilising
rapid on-site evaluation (ROSE) and US-assisted
cutting needle biopsies (CNB) of mass lesions
involving or abutting the pleura have shown that
these procedures are not only safe but also have a
high diagnostic sensitivity [13, 14].
There is, however, a paucity of data on the
diagnostic yield and safety of US-assisted TTFNA
with ROSE and CNB in the setting of SVC
syndrome caused by mass lesions that either
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abut or invade the chest wall. The aims of the present
prospective study were to assess the feasibility, diagnostic
yield and safety of these investigations in the setting of SVC
syndrome and, specifically, in the hands of nonradiologists.
METHODS
Study population
All adult patients (o18 yrs of age) with a clinical diagnosis of
SVC syndrome referred to the Division of Pulmonology of
Tygerberg Academic Hospital, Cape Town, South Africa, were
potential candidates for the present 3-yr prospective analytical
observational study. Tygerberg Academic Hospital is a 1,200-
bed university hospital. It is one of two referral centres and
renders a tertiary service to a population of ,1.5 million
people. The Committee for Human Research of the University
of Stellenbosch, Cape Town, South Africa, ethically approved
the study. Written informed consent was obtained from all
subjects on enrolment and also prior to any invasive
procedures.
A contrasted computed tomography (CT) scan of the chest and
upper abdomen was performed on all patients, according to
standard operating procedure at the Tygerberg Academic
Hospital. Studies routinely included the supraclavicular fossae
and lesions were classified on radiological appearance as to the
most likely origin: ‘‘mediastinal’’ (lesions predominantly
located in the anterior mediastinum with extension to the
pleura), ‘‘pulmonary’’ (lesion with centre in the lung, acute
angle to the pleura), ‘‘pleural’’ (pleural based, blunt angle to
the lung) or ‘‘chest wall’’ (lesions centred in the chest wall with
pleural involvement). All CT scans were scored by an
independent radiologist with regards to the maximum length
of the interface between the particular lesion and the thoracic
wall (in the longest plane). The depth of lesions relative to the
pleural surface and the presence of chest wall invasion were
also documented.
The initial evaluation of all patients included, where applic-
able, fine needle aspiration (FNA) of palpable and/or
radiologically detectable supraclavicular lymph nodes or
diagnostic pleural aspirations. Only cases with confirmed
partial or complete SVC obstruction that remained undiag-
nosed following these investigations and where an intrathor-
acic mass lesion abutted the chest wall to an extent that it made
a FNA feasible were enrolled onto the present prospective
observational study.
Thoracic US
A consultant respiratory physician or a senior registrar under
supervision performed the sonography (Toshiba Just Vision
200 SSA-320A; Toshiba Medical Systems Corporation, Tochigi-
ken, Japan). All procedures were performed in a bronchoscopy
suite without the support of a specialist radiologist. Although
the preferred patient position for the procedure was supine,
with a parasternal approach, the clinician could employ a more
lateral or apical approach if this was deemed feasible and safe.
The operator reviewed the thoracic CT scan prior to perform-
ing the transthoracic US. The interface between the intrathor-
acic mass lesion and chest wall was then identified by means of
a standard 3.75-MHz sector probe. An interface of o1 cm2
visible throughout inspiration and expiration in an area not
covered by bony elements was considered the minimal
requirement for an US-assisted procedure. Procedures were
performed ‘‘freehand’’ (i.e. not under direct US guidance). The
intended site was marked, and the direction, the depth of
interest and the safety range for the procedure documented.
The patient was instructed not to change position in order to
prevent a positional shift of the area of interest relative to the
skin mark. Care was taken to avoid the major intrathoracic
blood vessels, and the intercostal and mammarian arteries, as
well as any major collateral veins that may have formed
secondary to the SVC obstruction.
TTFNA
Under sterile technique and local anaesthesia with lignocaine
1%, aspirations were performed with a 22-G spinal needle (40
or 90 mm; Becton Dickinson, Madrid, Spain) connected to a
10-mL syringe. Aspirates from at least four slightly different
directions and depths were directly expressed onto slides,
smeared and submitted for ROSE using Diff-Quik (Rapidiff;
Clinical Sciences Diagnostics, Southdale, South Africa) and
rapid Papanicolaou staining methods.
ROSE of cytology specimens
The cytopathologist present in theatre was experienced in
ROSE and was asked to comment on the presence or absence of
diagnostically useful material obtained during each individual
pass. Material that was considered not diagnostically useful
included blood, necrotic tissue or the total absence of cellular
material. Where diagnostically useful material was present, the
cytopathologist was asked to make a provisional diagnosis of
malignant or nonmalignant pathology. Where malignant cells
were present, the pathologist provisionally typed the speci-
mens into one of two main categories: 1) epithelial carcinomas
of the lung, or 2) other malignancies. Furthermore, epithelial
carcinomas were subtyped into nonsmall cell lung cancer
(NSCLC), small cell lung cancer (SCLC) or epithelial carcinoma
of unsure type. Finally, the cytopathologist was asked to
further provisionally subtype NSCLC into one of the follow-
ing: 1) adenocarcinoma, 2) squamous cell carcinoma, 3)
undifferentiated carcinoma, or 4) NSCLC, unsure subtype.
In the case of nonmalignant pathology or malignancies other
than epithelial carcinoma, the cytopathologist was asked to
give an opinion on the representative nature of the specimen
and, if considered representative, which further investigations
were appropriate (e.g. performing a cutting needle biopsy or
collecting further aspirates for cultures for mycobacteria
or fungi).
Cutting needle biopsies
Cutting needle biopsies were obtained following TTFNA in all
cases where the provisional on-site diagnosis was not an
epithelial carcinoma of the lung. In cases where the on-site
diagnosis was epithelial carcinoma, biopsies were only
performed if o2 cm of safe range could be assured (i.e. no
major mediastinal organs, blood vessels and collateral veins
were within 2 cm of the intended CNB path). Superficial veins
were avoided. Manually operated 14-gauge Tru-cut biopsy
needles with a specimen notch of 20 mm (Allegiance,
Chateaubriand, France) were used. Two or more passes were
performed until macroscopically satisfactory material was
US-ASSISTED BIOPSIES IN SVC SYNDROME C.F.N. KOEGELENBERG ET AL.
1390 VOLUME 33 NUMBER 6 EUROPEAN RESPIRATORY JOURNAL
54
University of Stellenbosch: http://scholar.sun.ac.za
harvested. These specimens were harvested in 4% formalin
and routinely processed for histological evaluation.
Immediate post-procedure care
The TTFNA and CNB site were re-examined by means of US
immediately after the procedures, and a chest radiograph was
obtained if the pre- and post-procedure US findings differed
and at the discretion of the attending physician. All patients
were observed for o2 h prior to discharge, and complications
were noted. The presence or absence of minor or major
haemorrhage, as well as iatrogenic pneumothoraces, was
specifically documented. Major haemorrhage was defined as
any haemorrhage that required additional measures above and
beyond localised pressure and superficial sutures.
Further assessment and statistical analysis
All cytology slides were reviewed in the laboratory by two
other cytopathologists, who were blinded to the on-site
findings. These cytopathologists had an array of special stains
(including immunohistochemistry) at their disposal, and had
to concur prior to issuing a final cytological diagnosis. They
also had access to the results of the flow cytometry in case of
suspected lymphoma. The histological specimens were
reviewed by two independent pathologists. Histology was
classified as either ‘‘diagnostic’’ or ‘‘nondiagnostic’’ (normal
tissue, not representative tissue, or representative but necrotic
tissue). Only histological diagnoses or unequivocal cytology
(where histology was unavailable and as reported by two
laboratory-based cytopathologist) were accepted as diagnostic
and used as the gold standard for statistical analyses. Patients
in whom the initial procedures failed to yield diagnosis
underwent further special investigations in order to obtain a
diagnosis. The choice of further invasive investigations was
guided by the patient’s attending chest physician, and could
potentially have included bronchoscopy with direct forceps or
transbronchial needle aspiration biopsies (TBNA), CT-guided
biopsies, medical thoracoscopy, video-assisted thoracoscopy,
and mediastinoscopy or open surgical procedures.
Descriptive statistics and Chi-squared comparisons of propor-
tional data were performed. Unless otherwise stated, data are
displayed as mean¡SD. Standard methods were used to
calculate the sensitivity [15].
RESULTS
Patients and lesions
Over the 3-yr period of the present study, a total of 59
consecutive patients with clinical and radiological evidence of
SVC obstruction were reviewed by the investigators. Of these,
25 patients (42.4%) were included in the study as they
remained undiagnosed following the initial special investiga-
tions and had an SVC syndrome with an associated mass
lesion that abutted or infiltrated the chest wall with an
interface of o1 cm. These patients had a mean¡SD age of
55.8¡11.6 yrs, and 16 were male. Fifteen patients had a
pulmonary mass lesion, nine patients had a mediastinal mass
and only one patient had a pleural-based mass. Of the
pulmonary lesions that abutted the chest wall, only four were
considered possibly metastatic in nature (all with an associated
primary tumour elsewhere in the lungs). The mean depth of
lesions (as measured on CT scans, and measured from the
point of probable entrance, i.e. measured from the pleural
surface, to the most distal tumour limit) was 78¡17 mm. The
maximum length of the interface between the lesions and the
thoracic wall ranged 10–78 mm, with a mean of 26 mm.
Radiological evidence of chest wall invasion was present in
nine cases.
Each of the 25 patients enrolled were eventually found to have
some form of neoplasm (table 1). Bronchogenic carcinoma was
the most common diagnosis, with 11 NSCLC and 10 SCLC
diagnosed. The remaining four patients had T-cell lympho-
blastic lymphoma, B-cell lymphoma, thymoma and malignant
mesothelioma, respectively.
The diagnoses established in the 34 subjects not included in the
study population are summarised in table 2. These diagnoses
were established by means of supraclavicular lymph node
FNA (diagnostic in four out of six subjects, 67%), pleural fluid
aspirations (diagnostic in one out of 16, 6%), bronchoscopy
with TBNA (diagnostic in 21 out of 25, 84%), mediastinoscopy
(diagnostic in two out of three, 67%) and open surgical biopsy
(diagnostic in one out of one, 100%). Three patients had clear
evidence of SVC thrombosis on contrasted CT scan (all
occurred in the setting of intravascular devices) and two
remained undiagnosed. Three patients (11%) who underwent a
TABLE 1 Final established diagnoses of all study subjects
(n525)
Diagnosis Subjects
Nonsmall cell lung cancer 11 (44)
Adenocarcinoma 5 (20)
Squamous cell carcinoma 1 (4)
Undifferentiated 5 (20)
Small cell lung cancer 10 (40)
Lymphoma 2 (8)
Thymoma 1 (4)
Mesothelioma 1 (4)
Data are presented as n (%).
TABLE 2 Final established diagnoses of subjects not
included in the study (n534)
Diagnosis Subjects
Nonsmall cell lung cancer 16 (47)
Adenocarcinoma 7 (20)
Squamous cell carcinoma 4 (12)
Undifferentiated 5 (15)
Small cell lung cancer 9 (26)
Metastatic breast carcinoma 1 (3)
SVC thrombosis 3 (9)
Fibrosing mediastinitis 2 (6)
Immature teratoma 1 (3)
Undiagnosed 2 (6)
Data are presented as n (%). SVC: superior vena cava.
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bronchoscopy experienced minor haemorrhage, while all other
procedures were uncomplicated.
US-assisted TTFNA
US-assisted TTFNAs were performed on all study subjects.
Diagnostically useful specimens were obtained from 24 of the
25 study subjects. The on-site cytopathologist identified 21
cases of epithelial carcinoma of the lung and three other
malignancies. No ROSE diagnosis was made in one subject. Of
the 21 cases of malignant epithelial neoplasm of the lung, 12
were subtyped on ROSE as NSCLC and three as SCLC,
whereas six cases could only be subtyped on morphological
criteria as unsure type epithelial carcinomas.
After incorporating the results of the immunohistochemistry
and flow cytometry (where applicable), two cytopathologists
were able to reach a definite diagnosis in 24 out of the 25 cases.
It was found that one patient with SCLC was erroneously
diagnosed as adenocarcinoma on-site, as both the final
cytology and histology confirmed SCLC (fig. 1). The formal
laboratory assessment confirmed all other diagnoses, and the
21 cases of epithelial carcinoma of the lung could be subtyped
(fig. 1). Furthermore, three cytological diagnoses other than
lung cancer could be made in the laboratory: T-cell lymphoma,
thymoma and malignant mesothelioma. In all three cases,
these diagnoses were confirmed on histology (CNB). The
overall diagnostic yield of US-assisted TTFNA was 96%.
CNB
CNB were performed in all four patients who did not have an
on-site diagnosis of epithelial carcinoma and in 12 out of the 21
patients with epithelial carcinoma (57.1%). Reasons for not
performing CNB included the close proximity of major blood
vessels or superficial collateral veins (n58) and a poor general
state (n51). Diagnostically useful material was obtained in 14
biopsies and the diagnoses made corresponded to the final
Patients referred with SVC syndrome (n=59)
Initial special investigation diagnostic?
US-assisted TTFNA possible?
Study population (n=25)
US-TTFNA: Diagnostically useful specimen?
Yes
(n=24)
Malignant (n=24)
Epithelial (n=21) Other (n=3)
Uncertain (n=6)SCLC (n=3)
NSCLC 
(n=11)
SCLC 
(n=10)
Mesothelioma 
(n=1)
T-cell lymphoma 
(n=1)
Thymoma 
(n=1)
Nondiagnostic
B-cell lymphoma 
(n=1)
Alternative
diagnosis
procedure
(mediastinotomy)
Adenocarcinoma 
(n=5)
Squamous
carcinoma 
(n=1)
Undifferentiated
(n=5)
NSCLC (n=12)
Nonmalignant (n=0)
CNB
No
(n=1)
No (n=29)
Yes (n=5)
ROSE
Yes
No
Diagnosis
Alternative
diagnostic
procedures
Not included
#
FIGURE 1. The diagnostic pathway followed in the present study. Initial (basic) special investigations included fine needle aspiration (FNA) of supraclavicular lymph
nodes and pleural fluid cytology. Of the initial 25 patients, rapid on-site evaluation (ROSE) showed 24 patients to have diagnostically useful specimens obtained by means of
ultrasound (US)-assisted transthoracic FNA (TTFNA). Cutting needle biopsies (CNB) were performed in all patients who did not have an on-site diagnosis of epithelial
carcinoma of the lung and were deemed safe in 12 out of the 21 patients with epithelial carcinoma. In the case of nonmalignant pathology, further investigations may have
included cultures for mycobacteria or fungi (not shown). The final pathological diagnosis was based on histology and unequivocal cytology (reviewed in the laboratory with
special stains including immunohistochemistry; see text for detail). SVC: superior vena cava; NSCLC: nonsmall cell lung cancer; SCLC: small cell lung cancer. #: one case of
SCLC was erroneously provisionally diagnosed as NSCLC.
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cytological diagnoses in every case. Nondiagnostic specimens
were obtained from two subjects: one patient with undiffer-
entiated NSCLC was convincingly diagnosed on cytology. The
other subject, who also escaped diagnosis by TTFNA, was
eventually diagnosed as having a B-cell lymphoma by means
of an open surgical biopsy (mediastinotomy). The overall
diagnostic yield of CNB was 87.5%.
Complications
The procedures were well tolerated and no pneumothoraces
were noted. Only five cases of haemorrhage were documented.
One of the 25 patients (4%) experienced minor haemorrhage
following TTFNA, and three out of 16 patients (18.8%)
following CNB. One patient required a single superficial
suture in order to achieve haemostasis. No procedure was
complicated by major haemorrhage.
DISCUSSION
The present prospective study is, to the best of the present
authors’ knowledge, the largest single-centre study on US-
assisted TTFNA with ROSE and CNB in the setting of SVC
syndrome ever reported. Utilising these minimally invasive
techniques, it was possible to accurately diagnose 96% of all
patients who presented with an SVC syndrome with an
associated mass lesion that either abutted or infiltrated the
chest wall. US-assisted TTFNA with ROSE by a cytopathologist
yielded specimens that had a diagnostic yield of 96%. CNB
were performed in all cases where a provisional on-site
diagnosis of malignant epithelial neoplasm of the lung could
not be established, and in 57.1% of patients with malignant
epithelial neoplasm of the lung (biopsies limited due to safety
constraints). In this pre-selected group, CNB had a diagnostic
yield of 87.5%. A paucity of complications was observed. No
pneumothoraces or major haemorrhage was caused, and only
mild haemorrhage occurred in 4% of needle aspirations and
18.8% of biopsies. These findings are comparable to case series
not limited to SVC syndrome [13, 14].
Most experts still utilise cervical mediastinoscopy and anterior
mediastinotomy to establish a diagnosis in patients with SVC
syndrome secondary to anterior mediastinal mass lesions [5, 6].
These procedures have a diagnostic yield of almost 100%,
but .15% of patients suffer a major complication [5, 6].
Furthermore, patients need to be able to withstand a general
anaesthetic and lie in a supine position. The present data
suggest that TTFNA and CNB, either US-assisted or CT-
guided, should be the primary investigation, given the speed,
low cost, safety and sensitivity of these minimally invasive
techniques. US-assisted TTFNA has many added potential
benefits: it can be performed in practically any setting (even
outside theatre), on a patient in a variety of positions
(including sitting), and a provisional result can be available
within minutes if ROSE is utilised [7].
US-assisted biopsy performed by clinicians on peripheral
pulmonary and mediastinal mass lesions in the absence of SVC
syndrome is a well-established practice [7, 10, 13, 14, 16–24].
SAITO et al. [16] described US-guided mediastinal biopsies
.20 yrs ago. They were able to diagnose 87% of all malignant
tumours and 67% of benign masses [16]. YANG et al. [17] showed
that US-guided CNB had a diagnostic yield of 94.6% for
subpleural pulmonary tumours, and 88.9% for mediastinal
tumours. The same investigators also pioneered anterior
mediastinal biopsies via the supraclavicular approach [18].
Numerous subsequent studies firmly established transthoracic
mediastinal FNA and CNB as investigations with a diagnostic
sensitivity ranging 80–90% [19–22] and as feasible alternatives to
mediastinoscopy or diagnostic thoracotomy [23, 24]. The
present authors previously reported a combined diagnostic
yield for US-assisted TTFNA and CNB of 89% in 155
consecutive patients with mass lesions that abutted the chest
wall [14]. In that study, TTFNA had a significantly higher
sensitivity than CNB in diagnosing bronchogenic carcinoma (95
versus 81%; p50.006), but CNB was superior in noncarcinoma-
tous tumours and in benign lesions. SCHUBERT et al. [25] reported
similar findings. These observations provide two plausible
explanations for the high diagnostic yield observed in the
present study. First, 84% of the present study population had
bronchogenic carcinoma and, secondly, biopsies (CNB) were
performed in all noncarcinomatous tumours. Decisions con-
cerning the need for biopsies should therefore ideally be guided
by the provisional results on ROSE, particularly when CNB are
deemed to be risky.
There is a paucity of prospective data on the use of broncho-
scopy in the setting of SVC syndrome. SELc¸UK and FIRAT [26]
reported a very high diagnostic yield with TBNA and were able
to diagnose 96% of patients. In fact, only a single case of non-
Hodgkin’s lymphoma escaped diagnosis in their series. Other
smaller studies have reported similar findings [1, 27]. BLACK and
ELOUBEIDI [28] were the first to describe the use of oesophageal
US-guided FNA specifically in the setting of SVC syndrome.
The findings of the present study support earlier recommen-
dations with regard to the early utilisation of contrasted CT
scans in patients who present with suspected SVC obstruction
secondary to malignant disease [1, 4, 29–31]. A CT scan can
confirm SVC obstruction and the presence of an intrathoracic
mass lesion [1, 29–31]. Moreover, in cases where basic
investigations, such as sputum cytology, supraclavicular
lymph node FNA and pleural aspiration, fail to yield a
diagnosis, the findings of a CT scan may guide the choice
between further special investigations, chiefly bronchoscopy
with TBNA (in the case of more central tumours with
mediastinal lymphadenopathy) or US-assisted TTFNA where
tumours abut the chest wall [23, 24]. Mediastinoscopy and
surgical biopsies should be reserved for patients who remain
undiagnosed [23, 24].
Thoracic US has limitations; the most relevant and obvious
limitation to the present study is its technical inability to
visualise mass lesions that do not abut or invade the chest
(fig. 2a). Hence, cases not amenable to US-assisted TTFNA
were not included in the study (fig. 2b). US-assisted TTFNA
was therefore the preferred procedure in only 42.2% of patients
screened, while the majority of the remaining patients were
diagnosed by means of bronchoscopy with TBNA.
The present study has limitations. We specifically evaluated
the diagnostic yield and safety of US-assisted TTFNA and
CNB, and immediately excluded cases that were diagnosed by
means of supraclavicular lymph node FNA. High frequency
ultrasonography of the supraclavicular fossae might have
revealed pathological lymph nodes that escaped palpation [7],
C.F.N. KOEGELENBERG ET AL. US-ASSISTED BIOPSIES IN SVC SYNDROME
c
EUROPEAN RESPIRATORY JOURNAL VOLUME 33 NUMBER 6 1393
57
University of Stellenbosch: http://scholar.sun.ac.za
particularly in patients with severe supraclavicular swelling
from their SVC syndrome, and in those with radiologically
negative nodes on CT scan. This study was not designed to
address this issue. Furthermore, we did not compare the
diagnostic yield and safety of US-assisted TTFNA and CNB to
bronchoscopy in cases amenable to both procedures, nor did
we compare clinicians to radiologists with regard to efficiency
and healthcare cost.
The single case with an erroneous on-site typing of broncho-
genic carcinoma deserved to be highlighted. The diagnosis was
revised on the same cytological specimen after full laboratory
assessment. More errors in typing may have been made by
inexperienced personnel. It should therefore be stressed that
the main purpose of ROSE is to ascertain the presence of
diagnostically useful material and not to make final diagnoses
per se [14, 16]. Vital decisions on patient management should
therefore never be solely based on the ROSE diagnosis.
In conclusion, we were able to show that US-assisted TTFNA
with rapid on-site evaluation and CNB performed by a
clinician had a high diagnostic yield and were safe in the
setting of SVC syndrome with an associated mass lesion that
abutted the chest wall. US-assisted TTFNA (with ROSE) may
be the initial investigation of choice in suspected bronchogenic
carcinoma, whereas both TTFNA and CNB need to be
performed in all other cases.
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was more likely to be diagnostic in epithelial carcinoma and 
tuberculosis (28/30) than all other pathologies (5/15, p  ! 
0.001). CNB yielded a diagnosis in 15/17 (88.2%). Overall, 
42/45 patients were diagnosed by the single-session ap-
proach (93.3%). The final diagnoses included 41 neoplasms, 
with small cell lung cancer (n = 13) the commonest diagnosis. 
We observed no pneumothorax or major haemorrhage. 
 Conclusions: A single-session sequential approach of US-
assisted TTFNA with ROSE followed by CNB, where indicat-
ed, has a high diagnostic yield for anterosuperior mediasti-
nal masses, is safe and offers an alternative to surgical biopsy. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 The differential diagnosis of mediastinal masses is 
broad and computed tomography (CT) scanning fol-
lowed by biopsy is indicated in practically all cases  [1–5] . 
Tissue is most often harvested by means of mediastinos-
copy, mediastinotomy or related surgical procedures
 [2–6] . Although the diagnostic yield of such an approach 
exceeds 90%, surgical biopsies carry a complication rate 
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 Abstract 
 Background: Ultrasound (US)-assisted transthoracic biopsy 
offers a less invasive alternative to surgical biopsy in the set-
ting of mediastinal masses.  Objectives: The aim of this 1-year 
prospective study was to assess the diagnostic yield and 
safety of a novel single-session sequential approach of US-
assisted transthoracic fine-needle aspirations (TTFNA) with 
rapid on-site evaluation (ROSE) followed by cutting needle 
biopsies (CNB) performed by physicians on patients with 
 anterosuperior mediastinal masses.  Methods: US-assisted 
TTFNA with ROSE was performed on 45 consecutive patients 
(49.5  8 27.7 years, 24 males), immediately followed by CNB 
where a provisional diagnosis of epithelial carcinoma or 
 tuberculosis could not be established, provided a safety 
range could be assured.  Results: TTFNA alone was deemed 
adequate by means of ROSE in 27 (60%) patients. CNB could 
be performed in 17 of the remaining 18. The on-site diagno-
sis corresponded to the final diagnosis in 26/45 (57.8%). An 
accurate cytological diagnosis was made in 33 (73.3%), and 
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of up to 5%  [2–5] . Moreover, these procedures usually 
need to be performed in theatre under general anaesthe-
sia and require significant expertise and resources  [3–5] .
 Transthoracic ultrasound (US) has become a valuable 
guide for interventional procedures  [7, 8] , and plays an 
increasing role in biopsies of the chest wall, pleura and 
peripheral lung  [9–13] . US-assisted biopsies of mediasti-
nal masses were first described by Saito et al.  [14] two de-
cades ago, enabling them to diagnose 87% of all malig-
nant tumours and 67% of benign masses. Despite these 
promising findings, US-assisted biopsies have as yet 
failed to gain popularity amongst clinicians, possibly be-
cause subsequent investigators generally utilised only 
cutting needle biopsies (CNB)  [15, 16] and were almost 
exclusively specialist interventional radiologists  [17–21] .
 US-assisted transthoracic fine-needle aspiration
(TTFNA) and CNB in the setting of chest wall, pleural 
and pulmonary malignancies abutting the chest wall 
have a very high diagnostic yield and are safe, even in the 
hands of non-radiologists  [10–12] . The use of TTFNA 
with rapid on-site evaluation (ROSE) and CNB has been 
shown to be complementary  [11, 12, 22] . In our previous 
studies, we found that TTFNA with ROSE of intratho-
racic mass lesions has a significantly higher sensitivity 
than CNB alone in diagnosing bronchogenic carcinoma, 
but that CNB remains superior in noncarcinomatous tu-
mours and in benign lesions  [10–12, 22] . The addition of 
ROSE therefore potentially allows for a single-session ap-
proach, with US-assisted TTFNA followed by CNB lim-
ited to those cases where diagnostically useful material 
could not be confirmed  [11, 12, 22] . 
 The main aim of this prospective study was to assess 
the diagnostic yield and safety of a novel, single-session 
sequential approach of US-assisted TTFNA with ROSE 
followed by CNB performed by physicians in the setting 
of anterosuperior mediastinal masses. 
 Materials and Methods 
 Study Population  
 All adult patients ( 6 18 years) referred to the Division of Pul-
monology of Tygerberg Academic Hospital with an anterosupe-
rior mediastinal mass lesion on contrasted CT scan were potential 
candidates for this 1-year prospective observational study. Our 
institution is a 1,200-bed academic hospital in Cape Town, South 
Africa. It is one of two referral centres and renders a tertiary ser-
vice to a population of approximately 1.5 million people. The 
Health Research Ethics Committee of Stellenbosch University
approved the study (project No. N09/05/136). Written informed 
consent was obtained from all subjects on enrolment and prior to 
any invasive procedures.
 For the purposes of the study we considered the anterosupe-
rior compartment of the mediastinum as the space posterior to 
the sternum and anterior to the heart and brachiocephalic vessels, 
extending from the thoracic inlet to the diaphragm  [23] . Patients 
with a distinct mass lesion that was either confined to the antero-
superior mediastinum ( fig. 1 a) or where the mediastinum was ex-
tensively involved by a mass lesion with the epicentre in the an-
a b
 Fig. 1.  a CT scan of one of the study subjects shows a distinct anterosuperior mediastinal mass, which was prov-
en to be a thymoma.  b An example of an extensive mediastinal mass lesion which in this particular case was 
found to be due to small cell lung cancer. 
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terosuperior mediastinum ( fig. 1 b) were invited to participate in 
the study, provided that the mass lesion abutted the anterior chest 
wall with an interface of at least 1 cm in two dimensions and no 
known coagulopathy was present. 
 Transthoracic US 
 A consultant respiratory physician performed the sonography 
(Toshiba Just Vision 200 SSA-320A; Toshiba Medical Systems 
Corporation, Tochigi-ken, Japan) in a bronchoscopy suite without 
the support of a specialist radiologist. The preferred patient posi-
tion for the procedure was supine, using a standard 3.75-MHz 
sector probe in a parasternal approach. The interface between the 
intrathoracic mass lesion and chest wall was identified. An inter-
face of at least 1 cm in two dimensions visible throughout inspira-
tion and expiration in an area not covered by bony elements was 
considered the minimal requirement for a US-assisted procedure. 
Procedures were performed ‘freehand’ (not under direct US guid-
ance). The intended site was marked, and the direction, the depth 
ROSE
Anterosuperior mediastinal mass
US-TTFNA
Unsure Epithelial carcinomaPossible TBOther Other malignancies
Benign MalignantDiagnostically not useful
NSCLC SCLC Other Flow
cytometry*
AFB and
culture
US-CNB
Cytological diagnosis
Histological diagnosis
Non-diagnostic Diagnostic
Surgical biopsy Final diagnosis
US-CNB
Lab cytology and 
microbiology
Lab cytology and 
immunocytochemistry
Lab cytology and 
immunocytochemistry
 Fig. 2. Scheme of the general diagnostic approach. Solid lines refer 
to on-site activities, and dotted lines to all laboratory and subse-
quent procedures. The cytopathologist first commented on the 
presence or absence of diagnostically useful material obtained 
during each individual pass. Where diagnostically useful mate-
rial was present, the cytopathologist was asked to make a provi-
sional diagnosis of malignant or benign pathology. Where malig-
nant cells were present, the pathologist provisionally typed the 
specimens into one of two main categories: (1) epithelial carcino-
mas or (2) other malignancies. Epithelial carcinomas were sub-
typed into either non-small cell lung cancer, small cell lung can-
cer, other epithelial carcinomas (including thyroid) or epithelial 
carcinoma of unsure origin. In case of malignancies other than 
epithelial carcinoma, the cytopathologist was asked to provide 
provisional diagnosis where possible and to suggest further inves-
tigations including flow cytometry. In the case of benign pathol-
ogy, the specimens were typed into two main categories: (1) sus-
pected tuberculosis and (2) other pathology. Further aspirates for 
cultures for mycobacteria were obtained in case of suspected tu-
berculosis. CNB were performed on all cases except those with an 
on-site diagnosis of either epithelial carcinoma of known origin 
or tuberculosis.  *  Flow cytometry was performed on all cases with 
an on-site diagnosis of possible non-Hodgkin’s lymphoma. US-
TTFNA = ultrasound-assisted transthoracic fine needle aspira-
tion; ROSE = rapid on-site evaluation; US-CNB = ultrasound-as-
sisted cutting needle biopsy; TB = tuberculosis; AFB = acid-fast 
bacilli (stain); NSCLC = non-small cell lung cancer; SCLC = small 
cell lung cancer. 
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of interest and the safety range for the procedure documented. 
Care was taken to avoid the major intrathoracic blood vessels and 
the internal thoracic arteries, as well as any major collateral veins 
that may have formed in cases with superior vena cava obstruc-
tion.
 Transthoracic Fine-Needle Aspirations  
 Aspirations were performed with 22-G spinal needles of 40 or 
90 mm length as needed (Tae-Cang, Kong Ju City, Korea) con-
nected to a 10-ml syringe under sterile conditions with local an-
aesthesia (lignocaine 1%). Aspirates from at least 4 slightly differ-
ent directions and depths were directly expressed onto slides, 
smeared and submitted for ROSE using both Diff-Quik (Rapidiff; 
Clinical Sciences Diagnostics, Southdale, South Africa) and rapid 
Papanicolaou staining methods  [24] . 
 ROSE of Cytology Specimens  
 The cytopathologist present in theatre was asked to comment 
on the presence of diagnostically useful material obtained ( fig. 2 ) 
and to provisionally type the diagnostically useful specimens into 
1 of 4 main categories: (1) epithelial carcinomas of known origin 
(including non-small cell lung carcinoma, thyroid carcinoma and 
small cell carcinoma;  fig. 3 a), (2) other malignancies, (3) probable 
tuberculous disease (necrotising and/or granulomatous inflam-
mation;  fig. 3 b) and (4) other benign pathology. We considered 
specimens with a provisional on-site diagnosis of either epithelial 
carcinomas of known origin or probable tuberculosis as sufficient 
for a potential final cytological diagnosis (that is, no histology was 
obtained). In case of malignancies other than epithelial carcino-
ma, the cytopathologist was asked to provide a provisional diag-
nosis where possible and to suggest further investigations, for ex-
ample flow cytometry for non-Hodgkin’s lymphoma or aspirates 
for mycobacterial cultures in case of suspected tuberculosis. 
 Cutting Needle Biopsies 
 CNB were obtained in the same session immediately following 
TTFNA in all cases where the provisional on-site diagnosis was 
not an epithelial carcinoma of a known origin or tuberculosis, 
provided at least a 1-cm safety range could be assured (that is, no 
mediastinal organs or blood vessels within 1 cm of the intended 
CNB path). Manually operated 14-gauge Tru-cut biopsy needles 
(Allegiance, Chateaubriand, France) were used. Two or more 
passes were performed until macroscopically satisfactory mate-
rial was harvested. These specimens were harvested in 4% forma-
lin and routinely processed for histological evaluation.
 Immediate Post-Procedure Care  
 The TTFNA and CNB site were re-examined by means of US 
immediately after the procedures, and a chest radiograph was ob-
tained if the pre- and post-procedure US findings differed and at 
the discretion of the attending physician. All patients were ob-
served for at least 2 h prior to discharge. Minor or major haemor-
rhage, as well as iatrogenic pneumothoraces, was documented. 
Major haemorrhage was defined as any haemorrhage that re-
quired additional measures above and beyond localised pressure 
and superficial sutures. 
 Further Assessment 
 All cytology slides were reviewed in the laboratory by a second 
cytopathologist, who had an array of special stains (including im-
munocytochemistry and stains for acid-fast bacilli) at his or her 
disposal, and had to concur with the original cytopathologist pri-
or to issuing a final cytological diagnosis. In case of disagreement 
a third cytopathologist was consulted to resolve the case. The his-
tological specimens were reviewed by two independent patholo-
gists. Only histological diagnoses, unequivocal cytology in case 
of epithelial carcinoma or aspirates that were culture positive for 
a b
 Fig. 3.  a An example of an aspirate obtained from a patient with small cell lung cancer showing hyperchromat-
ic nuclei with scanty cytoplasm and nuclear moulding. (Papanicolaou stain,  ! 1,000).  b This aspirate was ob-
tained from a patient with tuberculosis. Note the poorly formed granuloma consisting of epithelioid histiocytes. 
This slide subsequently stained positive for acid-fast bacilli in the laboratory; cultures confirmed these bacilli 
to be  Mycobacterium tuberculosis . (Papanicolaou stain,  ! 400). 
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 Mycobacterium tuberculosis  were accepted as the gold standard 
for statistical analyses. Patients in whom the initial investigations 
(TTFNA and CNB) failed to yield a diagnosis were referred for 
surgical biopsy. All patients were followed up until a tissue diag-
nosis could be confirmed, and in the case of bronchogenic carci-
noma, until they were staged according to the 2009 International 
Association for the Study of Lung Cancer staging system  [25] . 
 Statistical Analysis  
 Descriptive statistics as well as Fisher’s exact test were em-
ployed. A p value of  ^  0.05 in a two-tailed test was considered 
significant. Unless stated otherwise, data are displayed as means 
 8 standard deviation. 
 Results 
 Patients  
 Over the 1-year period (July 2009 to June 2010) we en-
rolled 45 consecutive patients (49.5  8 27.7 years, 24 
males). No patient was excluded or declined to give con-
sent. In total, 20 patients (44%) had clinical evidence of 
SVC syndrome. Bronchogenic carcinoma (n = 25) was re-
sponsible for the majority of anterosuperior mass lesions 
( table 1 ), with small cell lung cancer being the most fre-
quent final established diagnosis (n = 13). Eight of the 
patients with small cell lung cancer were considered to 
have limited disease. Of the patients with non-small cell 
lung cancer, all had either stage IIIB (n = 7) or stage IV 
disease (n = 5). 
 Imaging  
 Distinct lesions confined to the anterosuperior me-
diastinum were present in 26 patients and a further 19 
had more extensive mediastinal involvement on CT
scan (predominantly involving the anterosuperior com-
partment). The maximum anteroposterior dimensions 
ranged from 24 to 119 mm, with a mean of 69 mm ( 8 19 
mm). All lesions were visible at US and TTFNA was pos-
sible in all patients enrolled. 
 Fine-Needle Aspirations  
 Specimens that were considered potentially useful by 
the on-site pathologist were obtained from 37 of the 45 
subjects (82.2%). Of these, the TTFNA were considered 
as being sufficient for a cytological diagnosis (provision-
al diagnosis either epithelial carcinoma or probable tu-
berculosis adenitis) in 27 patients (60.0%). In total, 26 on-
site diagnoses (57.8%) corresponded with the final diag-
noses ( table 2 ), including single cases of breast carcinoma, 
papillary thyroid carcinoma and normal thyroid tissue. 
Two cases of small cell lung cancer were provisionally er-
roneously typed as non-small cell lung cancer. Provision-
al on-site diagnoses made in the remaining patients with 
cellular aspirates (not considered sufficient) included 
possible lymphoma (n = 3), possible thymoma (n = 1) and 
malignant cells of unknown origin (n = 5).
 A final laboratory cytological diagnosis was possible 
in 33 patients (73.3%) after incorporating immunocyto-
chemistry, flow cytometry and stains for acid-fast bacilli 
( table 2 ). US-assisted TTFNA was diagnostic in 26 of 28 
patients with epithelial carcinoma (92.8%), with 23 of 25 
lung cancers, 2 papillary thyroid carcinomas and 1 case 
of metastatic breast cancer having diagnostic morpho-
logical and immunocytochemical features. Included in 
the 2 cases of papillary thyroid carcinoma was 1 case that 
was typed on-site as ‘malignant cells of unknown origin’ 
(laboratory cytology and histology were diagnostic). Both 
patients with tuberculosis had acid-fast bacilli on the 
smears and were culture positive for  M. tuberculosis . US-
assisted TTFNA was therefore diagnostic in 28 of 30 cas-
es of either epithelial carcinoma or tuberculosis. Three 
cases yielding malignant cells of unknown origin could 
not be accurately subtyped on cytology (the final histo-
logical diagnoses were germ cell tumour, leiomyosarco-
Table 1. F inal diagnoses of all study subjects (n = 45)
Diagnoses  n %
Non-small cell lung cancer
Adenocarcinoma
Squamous carcinoma
Undifferentiated 
 6
 5
 1
13.3
11.1
2.2
Small cell lung cancer 13 28.9
Lymphoma
Hodgkin’s lymphoma
B-cell non-Hodgkin’s lymphoma
T-cell non-Hodgkin’s lymphoma
 2
 3
 2
4.4
6.7
4.4
Other malignancies
Papillary thyroid carcinoma 
Breast cancer1
Germ cell tumour (embryonal carcinoma)
Leiomyosarcoma
Pleomorphic sarcoma 
Osteosarcoma1
 2
 1
 1
 1
 1
 1
4.4
2.2
2.2
2.2
2.2
2.2
Thymoma  2 4.4
Tuberculosis (adenitis)  2 4.4
Retrosternal thyroid (normal thyroid tissue)  1 2.2
Complicated hydatid cyst  1 2.2
1  The single cases of breast cancer and osteosarcoma were 
deemed to be metastatic, as both were diagnosed in patients who 
had been treated for primary neoplasms in the preceding 2 years.
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ma and osteosarcoma). Only 5 of the remaining 15 pa-
tients (33.3%) had accurate cytological diagnoses, and
the diagnoses made were diffuse large B-cell lymphoma 
(n = 2), T-cell lymphoblastic lymphoma (n = 1), thymoma 
(n = 1) and normal thyroid tissue (n = 1). US-assisted
TTFNA was therefore more likely to be diagnostic in pa-
tients with either epithelial carcinoma or tuberculosis 
than in patients with all other diagnoses (p  ! 0.001). 
 Cutting Needle Biopsies  
 US-assisted CNB were performed in all but one patient 
with insufficient on-site cytology (in a single case a 1-cm 
safety range could not be assured). Diagnostic histology 
was obtained from 15 of 17 patients who underwent CNB 
(88.2%). Laboratory cytology was also non-diagnostic in 
both patients with negative histology and in the single 
case where CNB was deferred. The combined approach 
of US-assisted TTFNA with ROSE and CNB (where indi-
cated) therefore yielded a diagnosis in 42 patients (93.3%). 
 Complications 
 All procedures were well tolerated and no pneumotho-
races were noted. Only one case of minor haemorrhage 
necessitating a single superficial suture following a CNB 
was observed. 
 Further Investigations  
 Three patients were referred for surgical biopsy. The 
diagnoses made in these three cases were Hodgkin’s lym-
phoma (nodular sclerosing), non-Hodgkin’s lymphoma 
(diffuse large B-cell lymphoma) and complicated hydatid 
cyst  (Echinococcus granulosus) . No further invasive diag-
nostic procedures were deemed necessary in the 24 pa-
tients with lung cancer. 
 Discussion  
 Using a sequential diagnostic approach of US-assisted 
TTFNA which was immediately followed by US-assisted 
CNB where indicated, we were able to diagnose 93.3% of 
all patients with anterosuperior mediastinal masses after 
a single visit to theatre and without the aid of a specialist 
radiologist or thoracic surgeon. TTFNA yielded a final 
cytological diagnosis in 73.3%, and was more likely to be 
diagnostic in the cases of epithelial carcinoma and tuber-
culosis than all other diagnoses (p  ! 0.001). CNB yielded 
diagnostic histology in 88.2%. Furthermore, all proce-
dures were well tolerated and we observed no pneumo-
thoraces or major haemorrhage.
 Saito and co-workers were able to diagnose 31 of 45 
mediastinal masses by means of US-guided needle biop-
sies in their landmark study  [14] . Yang et al. subsequent-
ly found Tru-cut needles to have a diagnostic yield of 
88.9% for mediastinal tumours  [15] . The same investiga-
tors also pioneered the supraclavicular approach for US-
guided biopsies of superior mediastinal tumours  [16] . 
Sawhney et al. reported an even higher sensitivity, as they 
Table 2.  Diagnostic yield in order of procedural sequence
Diagnoses TTFNA: ROSE TTFNA: laboratory CNB Surgical biopsy 
Epithelial carcinoma
Small cell lung cancer (n = 13)
Non-small cell lung cancer (n = 12)
Other (n = 3) 
11/13 (84.6%)1
10/12 (83.3%)
2/3 (66.7%)
13/13 (100%)
10/12 (83.3%)
3/3 (100%)
–
2/2 (100%)
1/1 (100%) 
–
–
–
Lymphoma (n = 7) 0/7 (0%) 3/7 (42.9%) 5/6 (83.3%)2 2/2 (100%) 
Thymoma (n = 2) 0/2 (0%) 1/2 (50%) 2/2 (100%)
Other neoplasms (n = 4) 0/4 (0%) 0/4 (0%) 4/4 (100%) –
Non-neoplastic pathology
Tuberculosis (n = 2)
Other (n = 2) 
2/2 (100%) 
1/2 (50%)
2/2 (100%)
1/2 (50%)
–
1/2 (50%)
–
1/1 (100%) 
All patients (n = 45) 26/45 (57.8%) 33/45 (73.3%)3 15/17 (88.2%) 3/3 (100%) 
1  Two cases of small cell lung cancer were provisionally erroneously typed as non-small cell lung cancer and therefore did not un-
dergo CNB.
2 No CNB was performed in one case due to safety concerns.
3 A cytological diagnosis on TTFNA specimens were more likely to be made in epithelial carcinomas and tuberculosis (28/30) than 
all other diagnoses (5/15, p < 0.001).
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were able to diagnose all 25 patients with mediastinal 
masses by means of a Tru-cut needle  [17] . Samad and co-
workers reported a more modest yield of 80.5%  [18] . 
Comparable findings were subsequently reported by oth-
er investigators  [19–21] . Despite the fact that our sample 
size is on par with these studies, the relatively small num-
bers limit meaningful statistical comparisons between 
the various aetiologies. Studies that included more than 
40 patients reported a 1–6% complication rate from CNB, 
with pneumothoraces, haemothoraces and haemoptysis 
the most common serious complications  [14, 15, 18–20] .
 Although our overall sensitivity is on par with the 
above-mentioned reports, our study design was unique in 
that we utilised ROSE to limit CNB to cases where cytol-
ogy was less likely to provide a definitive diagnosis and 
thereby potentially limiting complications and cost. This 
approach has been validated for epithelial carcinomas 
and tuberculosis, where ROSE has been shown to have a 
high sensitivity for identifying diagnostic material and 
suggesting a provisional diagnosis  [10–12, 26, 27] . Al-
though cytology may be diagnostic in other types of pa-
thology, further investigations are often required and the 
value of ROSE is therefore less well defined  [28] . We de-
cided upfront to acquire tissue samples for histology in all 
other diagnoses. As expected, we found that TTFNA with 
ROSE was superior for epithelial carcinoma and tubercu-
losis compared to all other diagnoses, which arguably 
justifies such an approach. We did not perform ROSE of 
CNB specimens with a touch prep as it would not have 
aided in the identification of candidates for CNB, would 
have lengthened the procedure time and potentially jeop-
ardised the core specimens, which are often fragile (un-
like sentinel lymph nodes). Moreover, we anticipated that 
CNB (irrespective of ROSE) would have a high yield 
based on previous work  [10–12, 14–21] . 
 We encountered a number of unexpected findings 
with regard to the final diagnoses made. We anticipated 
that tuberculous lymphadenitis may be responsible for a 
higher percentage of lesions, given the fact that the local 
incidence of pulmonary tuberculosis is 940 cases per 
100,000 population and more than 50% of all new cases 
of tuberculosis are co-infected with the human immuno-
deficiency virus  [29, 30] . Although thymomas and lym-
phomas are traditionally considered the most frequent 
causes of anterosuperior mediastinal mass lesions  [1, 31] , 
we found that more than half of our patients had lung 
cancer, the commonest diagnosis being small cell lung 
cancer. Approximately 5% of all lung cancers present 
with mediastinal mass lesions  [32, 33] . In fact, 23 of 302 
lung cancer patients treated at our institution in the year 
preceding our study presented with mediastinal mass le-
sions (unpublished data). We actively recruited patients 
with anterosuperior mediastinal mass lesions, irrespec-
tive of their respective clinical presentation, and our in-
clusion criteria did not differ from most published series 
 [14–18, 20] . Historically, however, clinicians have opted 
for bronchoscopy with transbronchial needle aspirations 
in the setting of probable lung cancer with central lesions 
 [34] , which conceivably introduced a selection bias in 
most reported series of surgical or minimally invasive bi-
opsies  [1–6, 31] . There is unfortunately a paucity of local 
data on the prevalence of the various aetiologies of an-
terosuperior mediastinal masses. Although not specifi-
cally designed to address this, our data suggest small cell 
lung cancer to be the commonest cause of anterosuperior 
mediastinal mass lesions in our population.    
 A single-session minimally invasive approach has cer-
tain limitations and risks not addressed in our study. Al-
beit exceedingly rare, some case reports implicated nee-
dle biopsies of early stage thymoma in seeding into the 
chest wall  [35, 36] . It may therefore be advisable to offer 
primary surgical resection to patients with a high suspi-
cion of thymoma in order not to breach the capsule. 
 In conclusion, we found a single-session sequential ap-
proach of US-assisted TTFNA with ROSE followed by 
CNB, where indicated, to have a high diagnostic yield for 
anterosuperior mediastinal masses. On-site evaluation 
provided important guidance for the need for CNB, as 
the yield of US-assisted TTFNA alone was found to be 
significantly higher in patients with epithelial carcino-
mas and tuberculosis than all other diagnoses, justifying 
the routine performance of CNB in the latter group. This 
approach is safe and offers a less invasive alternative to 
surgical biopsy. 
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Direct comparison of the diagnostic yield of
ultrasound-assisted Abrams and Tru-Cut needle
biopsies for pleural tuberculosis
Coenraad Frederik N Koegelenberg,1 Christoph Thomas Bolliger,1 Johan Theron,1
Gerhard Walzl,2 Colleen Anne Wright,3 Mercia Louw,3 Andreas Henri Diacon1,4
ABSTRACT
Background Tuberculous pleuritis remains the
commonest cause of exudative effusions in areas with
a high prevalence of tuberculosis and histological and/or
microbiological confirmation on pleural tissue is the gold
standard for its diagnosis. Uncertainty remains regarding
the choice of closed pleural biopsy needles.
Objectives This prospective study compared
ultrasound-assisted Abrams and Tru-Cut needle biopsies
with regard to their diagnostic yield for pleural
tuberculosis.
Methods 89 patients (54 men) of mean6SD age
38.7616.7 years with pleural effusions and a clinical
suspicion of tuberculosis were enrolled in the study.
Transthoracic ultrasound was performed on all patients,
who were then randomly assigned to undergo $4
Abrams needle biopsies followed by $4 Tru-Cut needle
biopsies or vice versa. Medical thoracoscopy was
performed on cases with non-diagnostic closed biopsies.
Histological and/or microbiological proof of tuberculosis
on any pleural specimen was considered the gold
standard for pleural tuberculosis.
Results Pleural tuberculosis was diagnosed in 66
patients, alternative diagnoses were established in 20
patients and 3 remained undiagnosed. Pleural biopsy
specimens obtained with Abrams needles contained
pleural tissue in 81 patients (91.0%) and were diagnostic
for tuberculosis in 54 patients (sensitivity 81.8%),
whereas Tru-Cut needle biopsy specimens only
contained pleural tissue in 70 patients (78.7%, p¼0.015)
and were diagnostic in 43 patients (sensitivity 65.2%,
p¼0.022).
Conclusions Ultrasound-assisted pleural biopsies
performed with an Abrams needle are more likely to
contain pleura and have a significantly higher diagnostic
sensitivity for pleural tuberculosis.
INTRODUCTION
Approximately one-third of the world’s population
is infected with Mycobacterium tuberculosis1 and,
among communicable diseases, tuberculosis (TB) is
the second leading cause of death.2 Pleural TB
remains a common form of extrapulmonary TB,
particularly among HIV-positive individuals,3 4 and
it is the most common cause of exudative effusions
in areas with a high prevalence of TB.2 5 6
Although a presumptive diagnosis of pleural TB
is often based on raised levels of adenosine deami-
nase (ADA) and interferon g in pleural ﬂuid, actual
histological and/or microbiological conﬁrmation of
TB pleuritis remains the gold standard.5 6 Pleural
tissue can be harvested either by means of closed
biopsies, thoracoscopy or open surgical biopsies.5 6
Access to thoracoscopy and open surgical biopsies is
limited in many parts of the world and closed
biopsies are therefore the preferred initial investi-
gation.6
Closed pleural biopsy needles were introduced in
the mid-1950s and early 1960s and various types
were used, including the Abrams, Cope and Vim-
Silverman needles.7e11 Of these devices, the
Abrams needle was consistently shown to have
a high yield and became the most widely used
device.11e13 In 1989 Macleod et al described blind
cutting needle (Tru-Cut) biopsies as an alternative
to Abrams needles in patients who present with
large pleural effusions.14 Around the same time,
transthoracic ultrasound (US)-assisted biopsy
techniques were pioneered, and the indications
were soon expanded to include cutting needle
pleural biopsies.15e18 Focal pleural abnormalities
(eg, thickening) and ﬂuid collections could be
identiﬁed by means of US, and biopsy may be
aimed at these areas of interest.19 Moreover, esti-
mating the size of an associated effusion decreases
the risk of visceral pleural lacerations, which is
particularly relevant in cases with minimal pleural
effusion and where pointed cutting needle biopsy
devices are employed.19
One small prospective study found a superior
diagnostic yield for pleural TB with US-assisted
Tru-Cut compared with traditional Abrams needle
biopsies.17 In that study, which was performed in
an area with a moderate TB prevalence, only two of
10 Abrams needle biopsies were diagnostic for
pleural TB. As most authors have reported diag-
nostic sensitivities in the order of 50e85% for
Abrams needle biopsies,6 13 uncertainty remains as
to which of these closed pleural biopsy techniques
is superior for pleural TB.
The aim of this prospective study was to
compare US-assisted Abrams needle biopsies with
US-assisted Tru-Cut needle biopsies with regard to
their diagnostic yield for pleural TB.
METHODS
Study population
All adult patients ($18 years) referred to the Divi-
sion of Pulmonology of Tygerberg Academic
Hospital with radiological evidence of a pleural
effusion and clinical suspicion of pleural TB were
potential candidates for this study. Our institution
is a 1200-bed academic hospital in Cape Town,
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South Africa. It is one of two academic referral centres in the
city and renders a tertiary service to a population of approxi-
mately 1.5 million. In 2006 the incidence of pulmonary TB in
this population was 940 cases per 100 000.1
Patients referred to the division’s pleural theatre were screened
for indicators of a high clinical suspicion of TB which, for the
purposes of the study, included (1) known HIV infection, (2)
persistent cough lasting >3 weeks, (3) haemoptysis, (4) weight
loss >4 kg (5) intermittent fever >3 weeks and (6) drenching
night sweats >2 weeks. Patients were included in the study only
if transthoracic US conﬁrmed a pleural effusion of at least
10 mm (as measured from the parietal pleura) and they had at
least two clinical indicators of possible TB.
Transthoracic US
A consultant respiratory physician or a senior registrar under
supervision performed the sonography (Toshiba Just Vision 200
SSA-320A; Toshiba Medical Systems Corporation, Tochigi-ken,
Japan). The preferred patient position for the procedure was the
sitting position, with the subject’s arms folded across the chest
and supported by a bedside table. Surveillance of the dorsolateral
thoracic wall was performed by means of a standard 3.75 MHz
sector probe. The presence of an effusion was conﬁrmed by
standard means.19 The size of the effusion was documented as
follows: minimal (if the echo-free space was conﬁned to the
costophrenic angle); small (if the space was greater than the
costophrenic angle but still within the range of the area covered
with a 3.75 MHz curvilinear probe); moderate (if the space was
greater than a one-probe range but within a two-probe range;
and large (if the space was larger than a two-probe range).19 The
biopsy site was subsequently identiﬁed, with safety being
a main determinant. As a rule, the aspirations and biopsies were
performed in the midscapular line. For minimal to moderate
effusions, the biopsies were taken from the site of maximum
effusion as determined by US. In case of a large effusion, the
puncture site was chosen to be as low as possible, but not
within 25 mm of the diaphragm. All aspirations and biopsies
were performed ‘freehand’ (not under direct US guidance) and
patients were requested to remain motionless during the
procedures.
Diagnostic thoracentesis
Under sterile technique and local anaesthesia with lignocaine
1%, samples were obtained for pH analysis by means of an
on-site blood gas analyser (Bayer Rapidlab 865 Blood Gas
Analyzer, Siemens, Midrand, South Africa), chemical analysis,
microbiology, cell counts and cytology. The chemical analyses
included serum and pleural total protein, albumin, lactate
dehydrogenase and pleural ﬂuid ADA levels. Microbiological
investigations included routine gram stains and cultures, as well
as stains for acid-fast bacilli (Ziehl-Nielsen staining) and TB
cultures (MGIT 960 liquid culture system, Becton Dickinson,
Sparks, Maryland, USA). We deﬁned a lymphocytic predomi-
nant effusion as one with >75% lymphocytes and/or
a lymphocyte to neutrophil ratio >0.75.6
Closed pleural biopsies
Under sterile technique and local anaesthesia, closed pleural
biopsies were subsequently performed on all patients. Patients
were randomly assigned (in blocks of six) to undergo either $4
Abrams needle biopsies followed by $4 Tru-Cut needle biopsies
or $4 Tru-Cut needle biopsies followed by $4 Abrams needle
biopsies. These biopsies were performed from the same incision
site (5 mm in length) and by experienced clinicians. Abrams
needle biopsies were performed according to standardised
guidelines.20 21 Biopsies were taken with the distal tip of the
needle facing up to 458 down in order to avoid laceration of the
intercostal vessels. Cutting needle biopsies were performed by
means of manually operated 14-gauge Tru-Cut biopsy needles
with a specimen notch of 20 mm (Allegiance, Chateaubriand,
France) and technically comparable to the way described by
McLeod and coworkers (ﬁgure 1).16 Abrams and Tru-Cut needle
biopsy specimens were harvested until each technique yielded at
least three macroscopically satisfactory specimens for histolog-
ical evaluation (transported in 4% formalin) and at least one
specimen for microbiological investigations (transported in 0.9%
saline).
Immediate post-procedure care
The incision site was re-examined by means of US immediately
after the procedures for suspected pneumothoraces, and a chest
x-ray was obtained if the pre- and post-procedure US ﬁndings
differed and at the discretion of the attending physician. All
patients were observed for at least 1 h before discharge and
complications were noted. Patient discomfort was documented,
and excessive pain was deﬁned as any pain requiring at least
a single dose of parenteral or opiate analgesics. The presence or
absence of minor or major haemorrhage as well as iatrogenic
pneumothoraces was speciﬁcally documented. Major haemor-
rhage was deﬁned as any haemorrhage that required additional
measures above and beyond localised pressure and a single
superﬁcial suture.
Further assessment and follow-up
All patients with a non-diagnostic closed biopsy or thoracentesis
were referred for medical thoracoscopy. Those who remained
undiagnosed following medical thoracoscopy were followed up
for a total of 6 months, and the choice of further investigations
was guided by the patients’ attending chest physicians. These
could have included observation, video-assisted thoracoscopy or
open surgical procedures. Cases that remained undiagnosed after
Figure 1 Cross section through an intercostal space showing the
position of the open Tru-Cut needle immediately before harvesting
a specimen. The Tru-Cut needle is cautiously introduced through an
incision at 458 to the skin in the direction of the chosen intercostal space
above the lower rib. Adjacent areas of pleura are then sampled. A
distinct ‘give’ indicates entry into the pleural space, which is confirmed
by the ease of advancement of the inner stylet. The whole Tru-Cut
needle is then angled towards the skin (position A to B), allowing the
inner stylet to be advanced along the inner aspect of the thoracic wall
and away from the lung. The outer cutting sheath is subsequently
advanced over the inner stylet, yielding biopsy samples of up to 2 cm of
parietal pleura and intercostal muscle (adapted from McLeod et al14).
858 Thorax 2010;65:857e862. doi:10.1136/thx.2009.125146
Tuberculosis
 group.bmj.com on September 24, 2010 - Published by thorax.bmj.comDownloaded from 
71
University of Stellenbosch: http://scholar.sun.ac.za
6 months were deemed ‘undiagnosed pleural exudates’. As the
negative predicative value of medical thoracoscopy (when
combining histology and microbiology) for TB pleuritis is prac-
tically 100% and its sensitivity for malignancy, in combination
with ﬂuid cytology and closed needle biopsies, is 97%, we
decided upfront to retain these patients in the ‘non-tuberculous’
group for statistical analysis.6 22
Statistical analysis
We expected a diagnostic sensitivity of 80% for both devices
based on our own historical data and data from Chang et al.6 17
Using the McNemar test for equal proportions, it was estimated
that a total sample size of 220 patients was required to prove
non-inferiority (difference of less than 10%). We were, however,
unsure if the diagnostic sensitivity achieved by Chang et al17 in
a relatively small study population would be reproducible, and
given the paucity of data, practical constraints as well as patient
safety aspects, it was decided to calculate the diagnostic yield for
pleural TB of both needles after 36 months or after the inclusion
of 100 patients, whichever came ﬁrst. At 36 months (with 89
patients included), it became apparent that the yield of the
Abrams needle for TB was consistent with the estimate,6 but
that the yield for the Tru-Cut biopsy was clearly lower than
anticipated. We terminated the study as the sensitivities for
pleural TB differed signiﬁcantly between the devises and
subsequently analysed all the data at this point (McNemar test
for equal proportions and c2 tests with p<0.05 accepted as
signiﬁcant). Unless stated otherwise, data are displayed as
mean6SD. We used standard methods to calculate the sensi-
tivity, speciﬁcity, and positive and negative predictive values.23
For the purposes of the study, we accepted either histology
compatible with TB (epithelioid granulomas with central
necrosis, with or without acid-fast bacilli) or microbiological
proof (pleura yielding a positive culture for M tuberculosis) on
any pleural specimen as the gold standard.
RESULTS
Patient characteristics and transthoracic US finding
A total of 89 patients (54 men) of mean6SD age
38.7616.7 years were enrolled over a 3-year period: 8 had
minimal effusions, 19 had small effusions, 36 had moderate
effusions and 26 had large effusions. Pleural TB was diagnosed in
66 cases (74.2%; mean6SD age 35.1615.5 years; 35 men). Of
the remaining 23 patients (mean6SD age 49.1615.9 years; 19
men), 20 (22.5%) had an alternative diagnosis and 3 (3.4%)
remained undiagnosed (table 1). The HIV status of 37 patients
was known at the time of enrolment: 16/26 (61.5%) of patients
who were ultimately diagnosed with pleural TB were HIV
positive compared with 4/11 (36.4%) in the group where TB was
excluded (p¼0.159).
Diagnostic thoracentesis
The pH analysis, biochemistry and microbiological results are
summarised in table 2. In patients ultimately diagnosed with
pleural TB, 90.9% had a lymphocyte predominant effusion and
89.4% had an ADA >50 IU/l. Combining these parameters
yielded a sensitivity of 83.3%, speciﬁcity of 95.7%, positive
predictive value of 98.2% and negative predictive value of 66.7%
for pleural TB (table 3). Seven patients were found to have
complicated parapneumonic effusions (with bacterial cultures)
and malignant cells were present in ﬁve. None of these 12
individuals had histological evidence of pleural TB.
Closed needle biopsies: diagnostic yield
Pleural tissue was present at histology in 91.0% of Abrams
needle biopsies and 78.7% of Tru-Cut biopsies (p¼0.015, table 4).
Abrams needle biopsies had a yield for all diagnoses of 78.7%
compared with 62.9% for Tru-Cut needles (p¼0.014).
In the 66 patients diagnosed with pleural TB, Abrams needle
biopsies provided proof in 81.8%; 77.3% had histological
evidence of TB and biopsies from 63.6% were culture positive for
M tuberculosis. Tru-Cut needles yielded evidence of pleural TB in
65.2% (p¼0.022); 60.6% of patients had histological evidence of
TB (p¼0.029) and biopsies from 39.4% were culture positive
(p<0.001). Two of the 12 cases without a histological diagnosis
of TB with Abrams needles were diagnosed on specimens
harvested with Tru-Cut needles (a total of 56 patients were thus
diagnosed with pleural TB on the basis of closed pleural
biopsies).
Malignant pleural effusions were diagnosed in 12 patients. All
had diagnostic closed pleural biopsies: Abrams needle biopsies
yielded histological conﬁrmation in 10 (83.3%) and Tru-Cut
needle biopsies yielded histological conﬁrmation in 8 (66.7%).
Two cases not diagnosed with Abrams needles were both diag-
nosed on specimens obtained with Tru-Cut needles, and the four
cases with false negative Tru-Cut biopsies (for malignancies) had
positive Abrams needle biopsies. With regard to patients diag-
nosed with parapneumonic effusions (all with positive gram
stains and cultures for bacteria on pleural ﬂuid), acute pleuritis
and/or non-speciﬁc inﬂammation were present in six specimens
obtained by Abrams needles and ﬁve obtained by Tru-Cut
needles.
Closed pleural biopsies: complications
The procedures were generally well tolerated and no pneumo-
thoraces or major haemorrhages were documented. Two
patients required parenteral analgesics; one complained of severe
pain following Abrams needle biopsies and one following
Tru-Cut biopsies (on both occasions the analgesics were
administered following the second procedure). Two women
(aged 20 and 22 years) experienced syncope following Abrams
needle biopsies, both of whom recovered fully within 60 s
(neither required any speciﬁc medical intervention). No proce-
dure was abandoned due to complications.
Further assessment and follow-up
Thoracocentesis and closed pleural biopsy established aetio-
logical diagnoses in 75 of the 89 patients. Diagnostic medical
thoracoscopies were performed in 14. Aetiological diagnoses
were subsequently made in a further 11 patients (10 cases of
pleural TB and 1 of sarcoidosis). Three men aged 18, 51 and
63 years, respectively, remained undiagnosed. All were HIV
negative, had minimal (n¼1) or small (n¼2) effusions, and
Table 1 Final diagnoses established in all patients (n¼89)
Diagnosis n %
Pleural tuberculosis 66 74.2
Bronchogenic carcinoma
Non-small cell lung cancer 4 4.5
Small cell lung cancer 2 2.2
Metastatic adenocarcinoma (other than lung) 3 3.4
Malignant mesothelioma 2 2.2
Sarcoma 1 1.1
Parapneumonic effusion (bacterial) 7 7.9
Sarcoidosis 1 1.1
Undiagnosed pleural exudates 3 3.4
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specimens obtained during thoracoscopy either showed
non-speciﬁc pleuritis (n¼2) or pleural ﬁbrosis (n¼1). A complete
radiological recovery was documented in all three cases and all
were asymptomatic at 6-month follow-up.
DISCUSSION
To the best of our knowledge, this is the largest prospective and
the ﬁrst randomised study performed to compare US-assisted
Abrams needle biopsies with US-assisted Tru-Cut needle biopsies
with regard to their diagnostic yield for pleural TB. We enrolled
a relatively large population with a moderate to high pretest
probability of pleural TB, and randomised patients to undergo
either biopsy technique ﬁrst in order not to disadvantage either
needle. Abrams needle biopsies were more likely to contain
pleural tissue (p¼0.015) and to conﬁrm the diagnosis of TB
(p¼0.022) than pleural biopsies obtained with Tru-Cut needles.
US-assisted Abrams needle biopsies had an overall diagnostic
yield of 81.8% for TB pleuritis in a study population with a high
pretest probability for the disease. We previously found medical
thoracoscopy to have a diagnostic sensitivity of 100% for pleural
TB.6 The present study establishes US-assisted Abrams needle
biopsies as the principal technique for obtaining pleural tissue in
patients with suspected TB pleuritis, with medical thoracoscopy
being reserved for the small number of cases who are not diag-
nosed with closed biopsies.
In general, blind Abrams needle biopsies have a yield of
50e85% for TB pleuritis.6 24e28 Valdés and coworkers reported
a diagnostic sensitivity of 79.8% when they analysed the case
histories of 254 patients with conﬁrmed pleural TB in a Spanish
university hospital.27 Diacon et al found Abrams needle biopsies
to have a diagnostic yield of 79% in patients with undiagnosed
exudative pleural effusions who presented to our institution.6
We speciﬁcally enrolled patients with at least a moderate pretest
probability of TB, which may account for the relatively high
sensitivity. The use of US prior to closed pleural biopsies is
currently advocated,19 29 30 both as a safety measure and to
detect localised pleural thickening and other abnormalities.29 30
Pleural TB is a diffuse disease process,25 and it can therefore be
postulated that the addition of US prior to the Abrams needle
biopsies is unlikely to affect the sensitivity. Although we did not
speciﬁcally employ US to detect localised abnormalities, our
ﬁndings certainly support this.
Tru-Cut biopsies yielded pleural tissue in 78.7% of patients in
the study, with a diagnostic sensitivity of 65.2% for pleural TB
and 66.7% for malignancy. Chang et al conducted the only other
prospective study that speciﬁcally compared the diagnostic yield
of US-guided pleural biopsy with a Tru-Cut needle and (blind)
Table 2 Diagnostic thoracentesis results of tuberculous versus non-tuberculous effusions: continuous and categorical variables
Continuous variables
Variable
Tuberculous effusion (n[66) Non-tuberculous effusion (n[23)
Mean SD Median IQR Mean SD Median IQR
pH 7.33 0.11 7.34 0.16 7.31 0.18 7.32 0.15
Lymphocytes (%) 76 23 84 23 47 35 49 77
Neutrophils (%) 13 19 5 17 30 34 39 59
Protein (g/l) 54.2 13.6 56.0 13.5 49.3 15.9 49.5 21.0
Albumin (g/l) 25.3 9.0 26.0 10.5 26.9 10.1 26.5 12.0
LDH (IU/l) 574 900 385 295 1675 2147 1027 1770
ADA (IU/l) 96.9 41.4 96.9 53 49.2 48.4 37.1 40
Categorical variables
Tuberculous effusion (n[66) Non-tuberculous effusion (n[23)
Variable n % n %
ADA >50 IU/l 59 89.4 6 26.1
Lymphocyte predominant* 60 90.9 9 39.1
ADA >50 IU/l and lymphocyte predominant 55 83.3 1 4.3
Culture positive for bacteria other than M tuberculosis 0 0 7 30.4
AFB positive 0 0 0 0
M tuberculosis culture positive 17 25.8 0 0
Cytology positive for malignant cells 0 0 5 21.7
*Lymphocytic predominant effusion: >75% lymphocytes and/or lymphocyte to neutrophil ratio >0.75.
SD, standard deviation; IQR, interquartile range; ADA, adenosine deaminase; AFB, acid-fast bacilli; LDH, lactate dehydrogenase; M tuberculosis, Mycobacterium tuberculosis.
Table 3 Diagnostic accuracy of pleural fluid analysis
Parameter
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
ADA (IU/l) 89.4 73.9 90.8 70.8
Lymphocyte predominance* 90.9 60.9 87.0 70.0
ADA >50 IU/l and lymphocyte
predominant
83.3 95.7 98.2 66.7
Mycobacterium tuberculosis culture
positive
25.8 100 100 31.9
*Lymphocytic predominant effusion: >75% lymphocytes and/or lymphocyte to neutrophil
ratio >0.75.
ADA, adenosine deaminase; NPV, negative predictive value; PPV, positive predictive value.
Table 4 Diagnostic yield of Abrams and Tru-Cut needle biopsies
(n¼89)
Parameter Abrams Tru-Cut Significance
Pleural tissue present at histology (n¼89) 81 (91.0%) 70 (78.7%) p¼0.015
All diagnoses (n¼89) 70 (78.7%) 56 (62.9%) p¼0.014
Pleural tuberculosis (n=66) 54 (81.8%) 43 (65.2%) p¼0.022
Histological evidence 51 (77.3%) 40 (60.6%) p¼0.029
AFB positive 29 (43.9%) 25 (37.9%) p¼0.423
Culture positive 42 (63.6%) 26 (39.4%) p<0.001
Alternative diagnoses (n=23) 16 (69.6%) 13 (56.5%) p¼0.450
Malignancy (n=12) 10 (83.3%) 8 (66.7%) p¼0.683
Benign pathology (n=8) 6 (75.0%) 5 (62.5%) NA
Undiagnosed exudates (n=3) 0 0 NA
AFB, acid-fast bacilli; NA, not applicable.
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pleural biopsy with an Abrams needle.17 They enrolled 49
patients with unilateral pleural effusions, 24 of whom under-
went pleural biopsy with an Abrams needle and 25 underwent
US-guided pleural biopsy with a Tru-Cut needle. Only 17
patients had pleural TB. Abrams needle biopsies were diagnostic
in 20% (2/10) whereas Tru-Cut needle biopsies were diagnostic
in 86% (6/7). The diagnostic yields for malignancies were 44%
and 77%, respectively. Four major differences in the studies
should be highlighted. We enrolled almost four times as many
patients with pleural TB, performed thoracic US before all
biopsies, used both biopsy needles in all cases and speciﬁcally
reported the presence of pleural tissue at histology. Furthermore,
we used liquid culture media which have a proven superior yield
for the culture of M tuberculosis.31 32
We encountered a number of unexpected results. All pleural
malignancies were diagnosed by means of either the Abrams or
Tru-Cut needles, and the combined diagnostic yield was there-
fore 100%. Although this study was not designed to speciﬁcally
address this issue, this ﬁgure is signiﬁcantly higher than reported
ﬁgures.33 Malignant disease tends to give rise to focal involve-
ment,25 and the lower thoracic and diaphragmatic parietal
pleura are more likely to contain secondary seeding from visceral
pleural metastases.34 35 We aimed to use relatively low (supra-
diaphragmatic) biopsy sites, which may partially explain the
relatively high yield observed in our study. Moreover, we
harvested at least six specimens per patient for histology, and it
is known that the yield of closed biopsies increases with
increasing number of biopsies.25 We did not speciﬁcally evaluate
the role of US in predicting pleural malignancies, as recently
reported by Qureshi and coworkers.36 In their study, US
correctly identiﬁed 73% of malignant effusions on appearance
alone.36 The yield of US-assisted closed pleural biopsies in
experienced hands may be much higher than previously believed
and certainly deserves to be studied prospectively.
We found the Abrams needle to have a signiﬁcantly superior
yield for all diagnoses, and our data even suggested a comparable
yield for pleural malignancy. Tru-Cut pleural biopsies can safely
be performed in the presence of very little pleural ﬂuid and have
a diagnostic yield for pleural malignancy that is generally
reported to be superior to that of Abrams needle biopsies.17 19 26 30
Maskell and co-workers previously found CT-guided Tru-Cut
pleural biopsies to have a superior sensitivity of 87% for pleural
malignancies compared with 47% for unaided Abrams needle
biopsies.33 Local disease prevalence may therefore dictate the
choice of biopsy needle, and the Tru-Cut needle may still be the
needle of choice in patients with suspected pleural malignancy.
Kitinya et al found that the HIV status of a patient impacted
on pleural biopsy results.37 Their data suggested that granu-
lomas were less likely to be observed, whereas pleural tissue
from HIV positive patients was more likely to be culture posi-
tive. However, in our study population the majority of patients
diagnosed with pleural TB by means of closed pleural biopsies
had granulomas on histology, and the addition of TB culture
only marginally increased the overall diagnostic yield.
Our data conﬁrm previous ﬁndings on the very high speci-
ﬁcity of an ADA >50 IU/l in the presence of a lymphocyte
predominant effusion.6 38 We found speciﬁcity of 95.7% and
a positive predictive value of 98.2%. More important was the
observation that, in a population with a high pretest probability
for TB, pleural TB could be diagnosed in the majority of cases
without the need for a pleural biopsy.
After 3 years it became evident that we had to abandon the
original non-inferiority design as the sensitivity of the Tru-Cut
biopsies was signiﬁcantly lower than the original estimation at
this point. While this certainly could be viewed as a weakness in
the original study design, we strongly believe that this had no
impact on the conclusion of the study. We collected robust data
with complete follow-up. The end points used were dichoto-
mous objective laboratory parameters which are not subject to
random variation. Furthermore, the study design was on par
with other studies in the ﬁeld and the achieved sample size was
at the higher end of the spectrum.6 14 17 18 33
In conclusion, US-assisted pleural biopsies performed with an
Abrams needle are more likely to contain pleura and have
a signiﬁcantly higher diagnostic sensitivity for pleural TB. The
Abrams needle should be the needle of choice for closed pleural
biopsies in the setting of probable tuberculous effusions.
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 Chapter 6 
 
DISCUSSION & CONCLUSIONS 
 
 
Discussion  
We investigated the feasibility, diagnostic yield and safety of transthoracic US-
assisted biopsy performed by respiratory physicians in various clinical settings 
relevant to everyday respiratory medicine, and consistently found acceptable to 
very high diagnostic yields with minimal complications, paving the way for greater 
utilisation by clinicians.  
 
Study 1 
“Drowned lung” is a radiological term often used to describe pulmonary collapse 
and postobstructive pneumonitis secondary to central tumours [1,2]. In our 
prospective proof of concept study on the feasibility and utility of US-assisted 
TTFNA of areas of drowned lung we found that passes at a depth greater than 
20 mm from the visceral pleura had a diagnostic sensitivity of 74.2% for 
malignancy [3]. These passes were also more likely to contain malignant cells 
than more superficial passes (74.2% vs. 35.5%, p=0.002). Furthermore, we 
observed no serious complications, thus validating this novel indication for US-
assisted TTFNA. 
 
In the spectrum of benign and malignant lesions that abutted the pleura it was 
previously shown that transthoracic US-assisted FNA with ROSE and CNB had a 
combined sensitivity of 81% [4,5]. More importantly, this technique had a 
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 sensitivity of 95% for bronchogenic carcinoma and a pneumothorax rate of close 
to 1% [1]. Yang et al. found that US-guided cutting needle biopsies had a 
diagnostic yield of 94.6% for subpleural pulmonary tumours [6].  
 
Although the diagnostic yield in our study on US-assisted TTFNA of drowned 
lung was certainly not on par with these figures, our data provided novel 
evidence that this application of US-assisted TTFNA may even be useful in 
cases where the primary tumour does not extend to the chest wall. As the 
parenchyma of normal aerated lungs is not discernable by means of US and 
proximal lung tumours were therefore previously not considered amenable to US-
assisted transthoracic FNA [3]. 
 
Bronchoscopy has an overall sensitivity of 88-95% for malignancy in the setting 
of centrally located lesions with secondary collapse [7,8]. It allows for the 
inspection of central airways, the evaluation for therapeutic airway management 
and the acquisition of histological samples that allow for superior subtyping and 
immunohistochemistry [7]. Furthermore, mediastinal nodal staging by means of 
transbronchial needle aspirations has important implications for staging and the 
management of lung cancer [9,10]. It therefore has to be emphasised that our 
study was purely a proof of concept study, designed to explore the feasibility of 
US-assisted transthoracic FNA in a novel setting, and was not designed to 
compare US-assisted transthoracic FNA with bronchoscopy (or CT-guided FNA), 
nor to define which patient may be best suited for a particular procedure.  
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 Notwithstanding these important considerations, US-assisted TTFNA of drowned 
lung was shown to have an acceptable diagnostic yield, particularly when deep 
passes are performed and our findings suggest that it may be utilised in specific 
circumstances, which may include patients who are considered high risk for 
bronchoscopy, those who refuse to undergo bronchoscopy and in those patients 
where a preceding bronchoscopy was non-diagnostic. Moreover, it may be 
viewed as an acceptable alternative when endoscopic mediastinal staging is not 
relevant or when bronchoscopy is unavailable. Only future randomised studies 
will, however, be able to specifically delineate the subgroup of patients with 
drowned lung in whom a bronchoscopy may be considered superfluous.   
 
Study 2 
We performed the largest single-centre study on US-assisted TTFNA with ROSE 
and CNB in the setting of SVC syndrome ever reported, and were able to 
accurately diagnose 96% of all patients who presented with an SVC syndrome 
with an associated mass lesion that either abutted or infiltrated the chest wall 
[11]. A single-session approach was utilised, with CNB performed in all cases 
where a provisional on-site diagnosis of malignant epithelial neoplasm of the lung 
could not be established, and in 57.1% of patients with malignant epithelial 
neoplasms of the lung. In this pre-selected group, CNB had a diagnostic yield of 
87.5%. No pneumothoraces or major haemorrhage was caused, and mild 
haemorrhage occurred in 4% of needle aspirations and 18.8% of biopsies. These 
findings were comparable to case series not limited to SVC syndrome [4,5]. 
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Most authorities still consider cervical mediastinoscopy and anterior 
mediastinotomy as the gold standard for establishing a diagnosis in patients with 
SVC syndrome secondary to anterior mediastinal mass lesions [12,13]. These 
procedures have a diagnostic yield of almost 100%, but many patients suffer a 
major complication [12,13]. Furthermore, patients need to be able to withstand a 
general anaesthetic and lie in a supine position. Our results suggested that US-
assisted TTFNA and CNB may be viewed as the primary investigation in this 
setting, given the speed, low cost, safety and sensitivity of these minimally 
invasive techniques [11]. In fact, we were able to diagnose 96% percent of 
patients after a single visit, a yield that is comparable to mediastinoscopy [12,13].  
 
US-assisted TTFNA with rapid on-site evaluation and CNB performed by a 
clinician therefore have a high diagnostic yield and are safe in the setting of SVC 
syndrome with an associated mass lesion that abuts the chest wall. Study 2 
validated the single-session approach, and confirmed that US-assisted TTFNA 
(with ROSE) should be the initial investigation of choice in suspected 
bronchogenic carcinoma, whereas both TTFNA and CNB need to be performed 
in all other cases.  
 
Study 3 
Incorporating the knowledge gained in the study 2, we continued to refine and 
validate our novel single-session sequential approach specifically in patients with 
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 anterosuperior mediastinal masses. In our one-year prospective study we 
assessed the yield and safety of US-assisted TTFNA with ROSE followed by 
CNB performed by physicians [14]. US-assisted TTFNA with ROSE was 
performed on 45 consecutive patients, immediately followed by CNB where a 
provisional diagnosis of epithelial carcinoma or probable tuberculosis (necrotising 
and/or granulomatous inflammation) could not be established. TTFNA alone was 
deemed adequate by means of ROSE in 60%. CNB could be performed in 17 of 
the remaining 18 cases. An accurate cytological diagnosis was made in 73.3%, 
and was more likely to be diagnostic in epithelial carcinoma and tuberculosis 
than all other pathology (p<0.001). CNB yielded a diagnosis in 88.2%. Overall 
93.3% of patients were diagnosed by the single-session approach. We observed 
no pneumothorax or major haemorrhage [14].  
 
CT scanning is indicated in practically all cases of mediastinal masses [12,13,15-
17] and tissue is generally harvested by means of mediastinoscopy, 
mediastinotomy or related surgical procedures [12,13,16-18]. Although the 
diagnostic yield of such an approach exceeds 90%, surgical biopsies carry a 
complication rate of up to 5% [12,13,16-18]. Moreover, these procedures usually 
need to be performed in theatre under general anaesthesia and require 
significant expertise and resources [12,13,16]. 
 
US-assisted biopsy of mediastinal masses is admittedly not a novel technique. 
Saito and co-workers described it two decades ago when they reported a 
80University of Stellenbosch: http://scholar.sun.ac.za
 diagnostic yield of 87% for malignant tumours and 67% for benign masses [19]. 
Despite these promising findings, US-assisted biopsies have as yet failed to gain 
popularity amongst clinicians, possibly because subsequent investigators 
generally utilised only CNB [6,20] and were almost exclusively specialist 
interventional radiologists [21-25]. Studies that included more than 40 patients 
reported a 1-6% complication rate from CNB, with pneumothoraces, 
haemothoraces and haemoptysis the most common serious complications 
[19,20,22-24].  
 
Although our overall sensitivity was on par with previous reports [6,19-25], our 
study design was unique in that ROSE was utilised to limit CNB to cases where 
cytology was less likely to provide a definitive diagnosis and thereby potentially 
limiting complications and cost. This approach has been validated for epithelial 
carcinomas and tuberculosis, where ROSE has been shown to have a high 
sensitivity for identifying diagnostic material and suggesting a provisional 
diagnosis [3,4,26,27]. Although cytology may be diagnostic in other types of 
pathology, further investigations are often required and the value of ROSE is 
therefore less well defined [28]. We decided upfront to acquire tissue samples for 
histology in all other diagnoses. As expected, we found that TTFNA with ROSE 
was superior for epithelial carcinoma and tuberculosis compared to all other 
diagnoses, which justified this approach. Albeit exceedingly rare, some case 
reports implicated needle biopsies of early stage thymoma in seeding into the 
chest wall [29,30]. It may therefore be advisable to offer primary surgical 
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 resection to patients with a high suspicion of thymoma in order not to breach the 
capsule.  
 
A single-session sequential approach of US-assisted TTFNA with ROSE followed 
by CNB, where indicated, therefore has a high diagnostic yield for anterosuperior 
mediastinal masses. On-site evaluation provided important guidance for the need 
for CNB, as the yield of US-assisted TTFNA alone was found to be significantly 
higher in patients with epithelial carcinomas and tuberculosis than all other 
diagnoses, justifying the routine performance of CNB in the latter group. This 
approach is safe and offers a less invasive alternative to surgical biopsy. 
 
Study 4 
In the largest prospective and the first randomised study performed to compare 
US-assisted Abrams needle biopsies with US-assisted Tru-Cut needle biopsies 
with regard to their diagnostic yield for pleural TB, we enrolled 89 patients with a 
moderate to high pre-test probability of pleural TB, and randomised patients to 
undergo either biopsy technique first. Pleural biopsy specimens obtained with 
Abrams needles contained pleural tissue in 91.0% of patients and were 
diagnostic for tuberculosis in 81.8%, whereas Tru-Cut needle biopsy specimens 
only contained pleural tissue in 78.7% (p=0.015) and were diagnostic in 65.2% 
(p=0.022) [31].  
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 We found US-assisted Abrams needle biopsies to have an overall diagnostic 
yield of 81.8% for TB pleuritis in a study population with a high pre-test 
probability for the disease. Medical thoracoscopy has a diagnostic sensitivity of 
100% for pleural TB, but is not widely available [32]. Study 4 established US-
assisted Abrams needle biopsies as the principle technique to obtain pleural 
tissue in patients with suspected TB pleuritis, with medical thoracoscopy being 
reserved for the minority of cases that escape diagnosis by means of closed 
biopsies. 
 
An interesting and unexpected finding in this study was the fact that we were 
able to diagnose all malignant effusions by means of either the Abrams or Tru-
cut needles. Although this study was not designed to specifically address this 
issue, this figure is significantly higher than reported figures [33,34]. Malignant 
disease tends to give rise to focal involvement [34], and the lower thoracic and 
diaphragmatic parietal pleura are more likely to contain secondary seeding from 
visceral pleural metastases [33,34]. We aimed to utilise relatively low (supra-
diaphragmatic) biopsy sites, which may partially explain the relatively high yield 
observed in our study. Moreover, we harvested at total of at least six specimens 
for histology per patient, and it is known that the yield of closed biopsies 
increases with increasing number of biopsies [35]. We did not specifically 
evaluate the role of US in predicting pleural malignancies, as reported by Qureshi 
and co-workers [36]. In their study, US correctly identified 73% of malignant 
effusions on appearance alone [36]. The yield of US-assisted closed pleural 
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 biopsies for pleural malignancy may be much higher than previously believed 
and certainly deserves to be studied prospectively. 
 
US-assisted pleural biopsies performed with an Abrams needle are therefore 
more likely to contain pleura and have a significantly higher diagnostic sensitivity 
for pleural TB. Abrams needle should be the needle of choice for closed pleural 
biopsies in the setting of probable tuberculous effusions. 
 
General Comments  
As a central theme, US-assisted biopsy performed by clinicians was shown to be 
feasible in the settings described, very safe and to have diagnostic yields 
comparable to more conventional techniques (ranging from bronchoscopy to 
surgical biopsies, as discussed above). The four studies expanded the evidence 
base for the greater utilisation of US-assisted biopsy by chest physicians, not 
only a novel setting (drowned lung), but also in combination with ROSE in a 
structured single-session approach in the settings of SVC syndrome with an 
associated mass lesion that abutted the chest wall and anterosuperior 
mediastinal masses. Furthermore, with regards to US-assisted pleural biopsy, 
the Abrams needle was shown to have a superior yield for pleural tuberculosis, 
although a combination of Abrams and Trucut needle biopsies was found to have 
an overall diagnostic yield for pleural malignancy never before recorded in the 
literature.     
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 Modern US units are mobile, cheap and available in practically all secondary and 
tertiary, as well as many primary healthcare facilities, even in the developing 
world [37-42]. All the US-assisted biopsy techniques described in this dissertation 
can be performed by a single operator with no sedation and minimal monitoring, 
potentially outside of theatre [37,38]. Furthermore, the consumables 
(transmission gel, local anaesthetic, needles and syringes) are relatively cheap 
[37-40]. These practical consideration need to be emphasised when comparing 
the yield of US-assisted with marginally superior conventional techniques that are 
invariably performed in theatre under general anaesthesia or conscious sedation 
and that require significant expertise and resources [38]. 
 
Transthoracic US is still not utilised to its full potential by chest physicians, both 
in the developed and developing world [37-40]. We validated the use of US-
assisted biopsy by clinicians in various settings, all of which are common in 
resource poor settings. We showed that specialised services including radiology 
and cardiothoracic surgery were only required in a minority of patients studied in 
all four sub-studies. In fact, in studies 2 and 3 we found US-assisted procedures 
to have comparable yields to conventional invasive investigations. At our 
institution the current average waiting period for CT-guided biopsy and 
mediastinoscopy is 6 weeks. The implementation of the protocols described has 
already expedited the definitive treatment of many patients, as practically all 
procedures are performed within 5 days. Additionally, and as discussed above, 
the direct cost-lowering implications are potentially considerable. Moreover, less 
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 utilisation of overburdened specialist radiology and thoracic surgery services may 
lead to an increased efficiency in our institution as well as other facilities that 
operate under the same constraints.  
 
The diagnostic algorithms and techniques developed in this thesis were 
developed with the resource limited health care system in mind. We validated the 
use of US-assisted FNA of drowned lung, potentially negating the need for 
bronchoscopy in up to two thirds of patients. Using a novel single-session 
approach of US-assisted FNA with ROSE followed where indicated by CNB, we 
were able to reduce the need for surgical biopsy to less than 10% of patients with 
SVC syndrome (with masses amenable to US-assisted FNA) and anterosuperior 
mediastinal masses. Furthermore, we showed that US-assisted Abrams needle 
biopsy is not only superior to Tru-cut needle biopsy in the setting of probable TB 
pleuritis, but could potentially lessen the need for thoracoscopy to less than 20% 
of cases not diagnosed on pleural fluid analysis.  
 
Although our research should be of particular interest to physicians practicing in 
resource poor health care settings, our findings could potentially also impact on 
the way respiratory medicine is practiced in the first world. Given the diagnostic 
yield, safety profile and rapidity of the techniques described, as well as the fact 
that no radiological or surgical input is initially required, it seems logical to offer 
these minimally invasive techniques to patient as first line investigations, and to 
reserve surgical biopsies for non-diagnostic cases [11,14].  
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Recently there have been renewed calls for formal instruction of basic 
transthoracic ultrasound skills to all respiratory physicians in training, and for 
some form of certification in basic competence in ultrasonography [43-46]. The 
studies contained in this dissertation add to an ever growing evidence base, and 
certainly echo these sentiments.  
 
We concentrated on US in the hands of the clinician, but it seems plausible that 
the US-assisted diagnostic techniques in the hands of interventional radiologist 
may have an equal or even higher yield. Although CT-guided biopsy has a 
marginally superior diagnostic yield in general [47], interventional radiologists 
should be encouraged to utilise this modality, particularly where a biopsy needs 
to be performed outside of a radiology unit or when CT services are 
compromised in any way.  
 
The boundaries of the applications of transthoracic US have yet to be defined 
and several unanswered questions remain. Our study on US-assisted TTFNA of 
drowned lung was, for example, purely a proof of concept study designed to 
explore the feasibility of US-assisted TFNA in a novel setting, and not designed 
to compare US-assisted TFNA with bronchoscopy (or CT-guided FNA), nor to 
define which patient may be best suited for a particular procedure. Only future 
randomised studies will specifically be able to delineate the subgroup of patients 
with drowned lung in whom a bronchoscopy may be considered superfluous. The 
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 single session approach used to investigate patients with SVC syndrome and 
anterior mediastinal masses needs validation in other settings.  
 
Although we were able to show that Abrams needles were more likely to contain 
pleura and be diagnostic for pleural TB, it remains to be elucidated if these 
findings could be extrapolated to malignant diseases. Clearly there is a need for 
further studies in the field.  
 
US-assisted biopsy is conceivably a cheaper alterative to traditional surgical 
biopsy. Yet, very little data exist on the actual cost-effectiveness of US-assisted 
biopsy as a modality and on where this modality should be strategically 
positioned in the greater field of imaging. Future studies are certainly indicated to 
address this question and how US-assisted biopsy can be optimally incorporated 
into the field of medical imaging and specifically interventional radiology.  
 
The author of this dissertation is currently involved in numerous studies (in 
various phases of development) in the field of transthoracic US, including a study 
on the diagnostic yield of US-assisted closed pleural biopsy for pleural 
malignancy, the sensitivity of transthoracic ultrasound to detect pulmonary 
collapse in an intensive care setting, a study on the role of on-site US findings in 
the decision to drain parapneumonic effusions, and a study on liquid based 
cytological evaluation of TTFNA specimens.   
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 Conclusions and Reflective Assessment of Contribution 
Several theoretical contributions to current literature were made. A novel 
indication for US-assisted biopsy, TTFNA of drowned lung was described; this 
technique was shown to be safe and to have an acceptable diagnostic yield, 
particularly when deep passes are performed. US-assisted TTFNA with ROSE 
and CNB performed by a clinician was found to have a high diagnostic yield 
comparable to surgical biopsies and were safe in the settings of SVC syndrome 
with an associated mass lesion that abutted the chest wall and anterosuperior 
mediastinal masses. On-site evaluation provided important guidance for the need 
for CNB, as the yield of US-assisted TTFNA alone was found to be significantly 
higher in patients with epithelial carcinomas and tuberculosis than all other 
diagnoses, justifying the routine performance of CNB in the latter group. Finally, 
we were able to show that the US-assisted pleural biopsy performed with an 
Abrams needle is more likely to contain pleura and have a significantly higher 
diagnostic sensitivity for pleural tuberculosis than biopsy performed by means of 
Tru-cut needles. 
 
The major methodological contribution of this thesis was validation of US-
assisted biopsy in a novel setting (drowned lung), as well as the prospective 
validation of a single session approach in two challenging clinical settings, that of 
SVC syndrome and anterosuperior mediastinal masses. Furthermore, we found 
that the Abrams needle should be the needle of choice for closed pleural 
biopsies in the setting of probable tuberculous effusions.  
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The empirical contribution of this thesis is significant. The diagnostic algorithms 
and concepts described in this thesis have been developed specifically for health 
care systems with limited resources. Moreover, we consistently found that US-
assisted biopsy performed by clinicians in the various settings had diagnostic 
yields comparable to surgical or CT-guided biopsy, therefore limiting the need for 
these special investigations that require significant expertise and cost. This body 
of work should pave the way for greater use of US-assisted biopsy as a first line 
investigation, reserving surgical biopsy for the undiagnosed cases, even in non-
resourced constrained settings.   
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Transthoracic ultrasonography can be
performed with the most basic ultrasound
(US) equipment. It is used for the
investigation of chest wall abnormalities,
pleural thickening and pleural tumours, and
the qualitative and quantitative description of
pleural effusions. Lung tumours, pulmonary
consolidations and other parenchymal
pulmonary processes abutting the pleura can
also be visualised. Furthermore, US is ideal to
guide thoracentesis, drainage of effusions and
other thoracic interventions. US is particularly
useful in intensive care units where
radiographic equipment is unavailable.
Advantages of thoracic US include its
mobility, dynamic properties, lack of radiation
and low cost.
The ultrasonographic appearance of the
normal thorax and the most common
pathologies are reviewed in this chapter.
General technical aspects and
appearance of the normal thorax
A low-frequency probe (e.g. 3.5 MHz) is
routinely used for screening purposes, while
detailed assessment of an abnormal chest
wall or pleura can be performed with a high-
frequency probe (e.g. 8 MHz).
Superficial muscles and fascia planes appear
as a series of echogenic layers during the
initial surveillance of a normal chest.
Curvilinear structures on transverse scans,
associated with posterior acoustic shadowing
represent the ribs.
The visceral and parietal pleura normally
appear as one highly echogenic line.
Movement of the lung with the respiratory
cycle in relation to the chest wall on real-time
US is called the ‘‘lung sliding’’ sign. Its
presence is strong evidence against a
pneumothorax.
US cannot visualise normal aerated lung
tissue. The large change in acoustic
impedance at the pleura–lung interface,
however, causes horizontal artefacts that are
seen as a series of echogenic parallel lines
equidistant from one another below the
pleura. These bright but formless lines are
known as reverberation artefacts (fig. 1).
Chest wall pathology
Soft-tissue masses, such as abscesses, lipomas
and a variety of other lesions, can be detected
by US. These lesions are mostly benign, but
variable echogenicity and nonspecific US
findings make differentiation between various
aetiologies difficult. Supraclavicular and
axillary lymph nodes are usually accessible,
and US may even help to distinguish benign
from malignant lymph nodes. Hypoechoic
masses disrupting the normal structure of a
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rib may represent bony metastases and can be
seen on US.
Pleural pathology
Transthoracic US is most commonly used to
investigate pleural effusions, and is more
sensitive than decubitus radiographs at
demonstrating minimal or loculated effusions.
The US appearance of a pleural effusion
depends on its nature and chronicity. Four
appearances based on the internal
echogenicity are recognised: anechoic;
complex but nonseptated; complex and
septated; and homogenously echogenic.
Transudates are invariably anechoic,
unseptated and free flowing, whereas
complex, septated or echogenic effusions are
usually exudates. Malignant effusions are
frequently anechoic. The atelectatic lung
inside a large effusion may appear as a
tongue-like structure within the effusion.
Inflammatory effusions are often associated
with strands of echogenic material and
septations that show more or less mobility
with respiration and the cardiac cycle (fig. 2).
The volume of a pleural effusion can be
estimated using the following classification:
minimal, if the echo-free space is confined to
the costophrenic angle; small, if the space is
greater than the costophrenic angle but still
within the range of the area covered with a
3.5 MHz curvilinear probe; moderate, if the
space is greater than a one-probe range but
within a two-probe range; and large, if the
space is bigger than a two-probe range.
Both small effusions and pleural thickening
may appear as hypoechoic on US, so
differentiation might be difficult. An
important sign in favour of an effusion is
mobility on real-time US.
Metastatic pleural tumours and malignant
mesothelioma can be visualised as polypoid
pleural nodules or irregular sheet like pleural
thickening. They are often associated with
large pleural effusions. Benign pleural
tumours are rare.
QURESHI et al. found that pleural thickening
.1 cm, pleural nodularity and diaphragmatic
thickening .7 mm were highly suggestive of
malignant disease. In their study, US correctly
identified 73% of malignant effusions.
The absence of normal lung sliding, the loss of
comet-tail artefacts and exaggerated
horizontal reverberation artefacts are reliable
signs for the presence of a pneumothorax.
Pulmonary pathology
A lung tumour abutting the pleura will be
detectable by US (fig. 3). In most cases these
tumours present as a hypoechoic mass with
posterior acoustic enhancement (fig. 4).
Visceral pleura or chest wall involvement is
important for staging of malignant lung
tumours. Loss of movement of a visualised
ERS Handbook ERH-0236-2009.3d 21/6/10 13:31:11
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Figure 1. The typical appearance of a normal chest
on ultrasound (US). A transverse view through the
intercostal space is shown. The chest wall is
visualised as multiple layers of echogenicity
representing muscles and fascia. The visceral and
parietal pleura appear as an echogenic bright line
(two distinct lines sliding during respiration are
visible on real-time US). Reverberation artefacts
beneath the pleural lines imply an underlying air-
filled lung. P: pleura; L: lung; R: reverberation
artefact.
2 ERS Handbook: Respiratory Medicine
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tumour with respiration suggests infiltration
beyond the parietal pleura.
US can detect pneumonic consolidations
provided they have contact with the pleura.
Non-infective causes of consolidations with
similar appearance on US include pulmonary
infarction, haemorrhage and bronchoalveolar
carcinoma.
A hypoechoic lesion with a well-defined or
irregular wall abutting the pleura might
represent a lung abscess. The centre of the
abscess is most often anechoic, but may
reveal septations and internal echoes.
Conclusion
The value of US for chest physicians is firmly
established. Basic thoracic ultrasonography is
an elegant and inexpensive investigation that
extends the physicians’ diagnostic and
interventional potential at the bedside in
peripheral lung, pleural, and chest wall
disease.
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permission from the publisher.
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Figure 4. A sonographic image showing a solid lung
lesion with posterior echo enhancement. Note that
the tumour is abutting the pleura and is therefore
visible on ultrasound. P: pleura; L: lung; T: tumour.
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Although diagnostic
ultrasonography was pioneered as
early as the 1940s, many modern-
day respiratory physicians still
underestimate its usefulness and
growing number of applications.
Interest in ultrasound (US) as an aid
to the clinician has been revived in
recent years; this article will review
transthoracic and endobronchial
US. 
TRANSTHORACIC
ULTRASOUND
Transthoracic US can be performed
by means of the most basic US
equipment and its mobility allows
use in the endoscopy theatre,
intensive care unit (ICU) and
emergency room. Other important
advantages of transthoracic US are
the ability to produce dynamic
images in a noninvasive manner,
the lack of radiation and its
relatively low cost [1–6]. 
General technical aspects and
principles 
Although US images are not as
reproducible as computed
tomography (CT), magnetic
resonance imaging (MRI) or
positron emission tomography
(PET)/CT images, a major
advantage of US is the ability to
create dynamic real-time images.
The quality of the images is
dependent on the skills of the
operator, on the positioning of the
probe and respiratory movement.
The dynamic properties are not
only highly valuable in
characterising pathologies but also
in guiding interventions with real-
time images.
Most US devices come equipped
with a low frequency curvilinear
transducer probe (2–5 MHz) and a
high-frequency linear transducer
probe (7.5–10 MHz). Doppler and
colour-flow echo are not required for
routine pleural or pulmonary
examination. Higher frequency gives
better resolution closer to the probe,
but at the cost of lower penetration.
The lower frequency probe is
therefore suitable for initial screening
of superficial and deeper structures,
while the high frequency probe is
used for refined assessment of an
abnormal chest wall or pleural area. 
The three most important controls
on a standard US are “depth”,
“gain” and “freeze”. The depth
function is a zoom that defines
what portion of the scanned image
is displayed. Obese subjects or
patients with a large effusion
require a depth setting of up to 
12 cm. The gain is a measure that
determines the brightness of the
image. The freeze function allows
for the capturing of still images for
documentation and measurements.   
The optimal patient position for
scanning is of great importance.
Access to the chest can be achieved
via the abdomen, intercostal spaces
or the supraclavicular fossae. It is
imperative to review relevant chest
radiographs and CT scans prior to
performing an US. The posterior
chest is best scanned with the
patient in the sitting position. The
lateral and anterior chest wall can
be scanned in either the lateral
decubitus or supine position.
Maximum visualisation is achieved
by examining along the intercostal
spaces. Elevating the arm above the
head increases the intercostal space
distance and facilitates scanning. A
patient can fold the arms across the
chest in order to displace the
scapulae when surveying the upper
posterior thorax. An apical
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approach is used with superior
sulcus pathology. 
Applications
Chest wall pathology
A variety of chest wall lesions,
mostly soft tissue masses, such as
abscesses and lipomas, can be
detected by US. Most of these
lesions are benign but nonspecific
US findings make differentiation
between various aetiologies difficult
[1, 4]. Bony metastases may present
as hypoechoic masses disrupting
the normal rib structure [7].
Pleural pathology
The most common application of
transthoracic US is the investigation
of pleural effusions, as it is more
sensitive than decubitus chest
radiographs, especially in small and
loculated effusions [8]. The
appearance of a pleural effusion on
US depends on its nature and
chronicity. Four appearances based
on the internal echogenicity have
been described and are recognised:
anechoic; complex but nonseptated;
complex and septated; and
homogenously echogenic.
Transudates are invariably
anechoic, unseptated and free
flowing, whereas complex, septated
or echogenic effusions are usually
exudates [9, 10]. Malignant
effusions are frequently anechoic,
while inflammatory effusions are
often associated with strands of
echogenic material and septations
which show more or less mobility
with respiration and the cardiac
cycle (fig. 1).
Differentiation between small
effusions and pleural thickening
might be challenging, as both may
appear hypoechoic on US. An
important feature in favour of an
effusion is mobility on real-time US.
Metastatic pleural tumours and
malignant mesothelioma can be
visualised as polypoid pleural
nodules or irregular sheet-like
pleural thickening [11], often
associated with large pleural
effusions. In a recent study, QURESHI
et al. [12] were able to identify 73%
of malignant effusions on
appearance alone. They found that
pleural thickening >10 mm, pleural
nodularity and diaphragmatic
thickening >7 mm were highly
suggestive of malignant disease. 
The loss of comet-tail artefacts,
exaggerated horizontal
reverberation artefacts and the
absence of normal lung sliding are
reliable signs for the presence of a
pneumothorax [13].
Pulmonary pathology
Lung tumours are detectable by US
provided they abut the pleura or
the chest wall (fig. 2). In most cases,
these tumours present as a
hypoechoic mass with posterior
acoustic enhancement (fig. 3) [3].
Chest wall infiltration has obvious
implications for the staging of lung
cancer and is suspected when the
movement of a visualised tumour
with respiration is lost.
Pneumonic consolidations with
contact to the pleura can be
detected by US. Noninfective causes
of consolidations with similar
appearance on US include
pulmonary infarction, haemorrhage
and bronchoalveolar carcinoma. A
hypoechoic lesion with a well-
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Figure 1. Example of an anechoic pleural
effusion is shown on the left. It presents as
an echo-free space between the visceral and
parietal pleura. Compressive atelectasis of
the lung may be seen as a tongue-like
structure. Note the difference to the effusion
on the right which is classified as complex
septated. Multiple septa form many
compartments in the same effusion. PE:
pleural effusion; L: lung; S: septum.
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defined or irregular wall abutting
the pleura may represent a lung
abscess [14]. The centre of the
abscess is most often anechoic but
may reveal septations and internal
echoes.
Interventions
Compared with blind procedures,
US-guided procedures have an
increased success rate and are safer
[1]. Specific probes for real-time
guidance of fine needle aspirations
(FNA) or biopsies are available but
many experienced physicians prefer
the ‘freehand’ technique. Following
adequate patient positioning, the
intended site of needle insertion is
identified under US and marked,
while the direction, the depth of
interest and the safety range for the
procedure are memorised.
Movement should be avoided at all
cost; it may even be necessary to
ask the patient to hold their breath
for the duration of the aspiration or
biopsy.
Pleural fluid aspiration under US
guidance can have a success rate as
high as 97% [15] and even small
fluid accumulations can be
identified, the most accessible site
chosen and the aspiration
performed using the ‘freehand’
technique.
Intercostal drains can be inserted
more safely after determination of
the insertion site by means of US. In
an ICU setting and with
complicated parapneumonic
effusions this becomes particularly
relevant. US may also guide further
decisions regarding the need for
interventions in addition to
drainage and antibiotics [16]. A
recent survey carried out in the UK
highlighted the dangers of blind
pleural procedures: 67 out of 101
trusts reported at least one serious
complication from intercostal
drainage. In all, 47 cases of serious
lung or chest wall injuries with
eight deaths and six cases of
intercostal chest drain placement on
the wrong side were described [17]
Closed pleural biopsies can only be
performed unaided in sizeable
effusions. Recent studies have re-
emphasised the importance of
transthoracic US as a guide to
pleural procedures, both with
regards to safety and diagnostic
yield [1]. In a recent prospective
randomised study, we found that
US-assisted Abrams needle biopsy
specimens were more likely to
contain pleural tissue than
specimens obtained by means of
US-assisted Tru-cut biopsies (91.0
versus 78.7%) [18].
Peripheral lung tumours can safely
be assessed by US-guided FNA or
ULTRASOUND IN PULMONARY MEDICINE
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Figure 2. A peripheral pulmonary lesion is
shown schematically without (top) and with
(bottom) pleural contact. Only the lesion
with pleural contact is visible on ultrasound
(from [3] with kind permission).
Figure 3. A sonographic image showing a
solid lung lesion with posterior echo
enhancement. Note that the tumour is
abutting the pleura and is therefore visible
on ultrasound. The distance to the distal
tumour end is measured. P: pleura; L: lung;
T: tumour.
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cutting biopsy provided they either
abut or invade the pleura or the
chest wall. Those procedures can be
performed by nonradiologists
under local anaesthesia and have a
high diagnostic yield [19]. The risk
of pneumothorax is low as no
aerated lung tissue needs to be
transversed. A study by DIACON et
al. [19] showed that transthoracic
FNA and closed needle biopsies
corresponded well in the diagnosis
of epithelial lung carcinoma. US-
assisted ‘free-hand’ closed needle
biopsies of tumours abutting the
chest wall had a sensitivity of
85.5%. US can even be used to
guide biopsies of the mediastinum
and peripheral lung in the setting of
superior vena cava syndrome [20]. 
US-assisted FNA can also be helpful
in defining the aetiology of
pulmonary consolidation. YANG et
al. [21] found that US-assisted
biopsies of pulmonary
consolidations were diagnostic in
93% of cases. Lung abscesses could
be demonstrated by means of US in
94% of patients with radiologically
confirmed lung abscesses. More
than 90% of aspirates yielded a
positive culture, whereas less than
10% of patients had positive blood
cultures [22].
Ultrasound of the neck  
The most common indication for US
evaluation of the neck is staging of
lung cancer including US-assisted
biopsy of suspicious lymph nodes.
US has been shown to be superior
to CT in the detection of metastases
of lung cancer in the neck and
should be included early in the
diagnostic work up [23]. US was
able to avoid bronchoscopy in
about 15% of patients with lung
cancer where neck metastases were
detected by US. Nonmalignant
conditions, such as sarcoidosis and
tuberculosis, can also be diagnosed.
ENDOBRONCHIAL US
Endobronchial US (EBUS) has
revolutionised bronchoscopy. It
allows the endoscopist to evaluate
the mediastinum and lungs beyond
the endoluminal surface.
Peribronchial structures and
peripheral lung lesions become
visible. The gastroenterologists
HAGENMÜLLER and CLASSEN [24]
were the first to report on the use of
endoscopic (oesophageal) US
endoscopic ultrasound scan (EUS)
in 1980. The endobronchial use of
this technology lagged by 10 yrs;
the first report by Hürther and
Hanrath [25] on the endobronchial
use of US was only published in
1990. Most research has been
conducted in Germany and Japan,
from where landmark publications
by BECKER [26] and KURIMOTO et al.
[27] came. Two forms of EBUS
systems with specific transducers
and different applications are
currently commercially available,
namely the “linear” and “radial”
EBUS transducers. 
The development of a dedicated
EBUS- transbronchial needle
aspiration (TBNA) bronchoscope
with a convex US probe in 2005
made needle aspirations under real-
time US possible [28].
Radial EBUS
Radial EBUS probes generally have
a 20 MHz rotating transducer that
can be inserted through the working
channels of flexible bronchoscopes.
Radial miniature probes are
available in different sizes and can
be used with balloon sheaths to
assess central peribronchial
structures in the proximal airways
or without balloon sheaths to
identify peripheral lung lesions.
Two different types of miniprobes
are mostly used: a 20 MHz probe
(UM-BS20-26R; Olympus, Tokyo,
Japan) is used with an inflatable
balloon for the assessment of the
central airways (fig. 4). By inflating
the balloon and filling it with sterile
water, coupling of the transducer
with the bronchial mucosa is made
easier. The probe is inserted through
the working channel of a standard
therapeutic bronchoscope (2.8 mm)
and produces a 360º image
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perpendicular to the insertion access
of the probe (fig. 5). Another
miniature radial probe (UM-S20-17S;
Olympus) has a maximum insertion
tube diameter of 1.8 mm and can be
inserted through the 2.0 mm
working channel of a standard
flexible bronchoscope. For sampling
of peripheral lesions, the radial
probe is covered by a guide sheath
also called ‘extended working
channel’ (fig. 6) and brought to the
area of interest. As the lesion is
identified the probe is pulled back,
leaving the guide sheath in place
and a biopsy tool is advanced to
obtain specimens. 
In a large-scale prospective study,
EBUS-guided transbronchial biopsy
has been shown to significantly
increase the diagnostic yield in
lesions <3 cm and <2 cm [29]. In
patients with fluoroscopy-invisible
solitary pulmonary nodules, 89% of
lesions were identified by EBUS
[30]. EBUS can also distinguish
between benign and malignant
lesions. A classification system has
been reported, dividing lesions into
three categories according to their
US appearance. 92% of type I
lesions were benign, whereas 99%
of type II and III lesions were
malignant [31]. Although radial
EBUS provides detailed information
about the location and the nature of
a peripheral lesion, biopsies are not
real-time.
Complications of EBUS guided
transbronchial biopsies are rare and
do not differ significantly from
those of regular transbronchial
biopsies [30, 32]. Complications,
such as minor bleeding and
pneumothorax, are therefore rather
attributed to the biopsy itself and
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not to the EBUS procedure. Even
without fluoroscopic guidance,
EBUS-guided transbronchial
biopsies appear to be safe and
effective [33, 34].
Linear EBUS
Linear EBUS technology is used
with a dedicated EBUS
bronchoscope and enables real-time
TBNA (fig. 7). The latest addition to
the range of instruments (BF-
UC180F, Olympus) has an insertion
tube outer diameter of 6.3 mm,
making oral intubation preferable.
It contains an electronic curved
linear array transducer (5–12 MHz)
with a penetration depth of 50 mm,
which also supports Power Doppler
functions. The angle of view is 80º
in a 35º forward oblique direction
and the US view is parallel to the
long axis of the bronchoscope. A
balloon filled with sterile water can
be inflated to improve coupling
with the bronchial wall if needed.
US image and bronchoscopic image
can be viewed side by side and the
US image can be frozen for
measurement of the target lesion.
For a full inspection of the airways,
a standard flexible bronchoscope
might be required due to the size of
the EBUS bronchoscope.
Real-time TBNA using a 22G needle
through the 2.2 mm working
channel can be performed, once the
target lesion is identified (fig. 8).
With exception of American
Thoracic Society lymph node
stations 5, 6, 8 and 9, all mediastinal
stations are reachable by EBUS-
TBNA. Real-time EBUS-TBNA has a
higher diagnostic yield in
mediastinal lymph node staging
than blind TBNA and may be
comparable in sensitivity to cervical
mediastinoscopy [35, 36]. Even in
the absence of rapid on-site
cytology evaluation, high diagnostic
yields up to 100% have been
reported for real-time EBUS-TBNA.
The fairly high false-negative rate
makes further investigations such
as mediastinoscopy necessary for
negative results.
Accurate staging of non-small cell
lung cancer is of utmost importance,
as it not only determines the
patient’s prognosis but has
important implication with regards
to the therapy. In the absence of
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Figure 4. A radial endobronchial ultrasound
miniprobe (UM-BS20-26R, Olympus,
Japan) is shown inside the working channel
of a standard bronchoscope. For improved
coupling with the bronchial mucosa in the
central airways the balloon can be inflated.
Figure 5. Endosonographic image of a
peripheral lung lesion. Note the 360° view of
the radial probe.
Figure 6. Radial miniprobe (UM-S20-17S,
Olympus, Japan) inside the guide sheath.
Once a peripheral lesion is located by
endobronchial ultrasound the probe is
retracted and the guide sheath left in place.
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distant metastasis, mediastinal
involvement often determines
operability. Noninvasive techniques
(i.e. CT, PET-CT, and MRI) have
been improved over time, but most
abnormal findings on imagery still
require confirmation with histology
or cytology. EBUS-TBNA has proven
to be a minimally invasive, safe and
accurate procedure. In the largest
study, HERTH and co-workers [37]
showed a sensitivity of 94% and a
specificity of 100% in 502 patients
[37]. The same authors reported
unexpected mediastinal metastases
in 17% of 119 lymph nodes in
patients with a radiologically
normal mediastinum [38]. Even in
the radiologically normal and PET-
normal mediastinum, a 9%
prevalence of mediastinal
metastases was detected by EBUS-
TBNA [39]. Combination of
endoscopic US (EUS) with EBUS
represents a sampling method that
may replace mediastinoscopy, since
all mediastinal lymph node stations
become accessible [35, 40].
CONCLUSIONS
The value of both transthoracic and
EBUS for clinicians is firmly
established. Basic thoracic US is an
inexpensive investigation that
extends the physicians’ diagnostic
and interventional potential in
peripheral lung, pleural and chest
wall disease. It can potentially
replace CT-guided fine-needle
biopsies of all lesions involving the
pleura and chest wall, as well as
lung masses or consolidations
abutting the pleura.
EBUS provides an accurate and safe
means of evaluating a variety of
pulmonary conditions. It has a high
diagnostic rate in mediastinal
lymph node staging, and radial
EBUS can facilitate identification of
more peripheral lung lesions.
All academic institutions should
have a basic training program in
transthoracic and endobronchial US
in place in order to ensure that all
aspiring chest physicians are
familiar with the basic aspects. 
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Figure 7. The tip of a dedicated
endobronchial ultrasound transbronchial
needle asperation bronchoscope (BF-
UC180F, Olympus, Japan) is shown in this
image. A needle is advanced through the
working channel of the endoscope for real-
time TBNA.
Figure 8. Endosonographic image of real-
time lymph node transbronchial needle
asperation. Note the needle (N) as it is
advanced into the lymph node (LN).
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tween tube thoracostomy (with or without fibrinolytics) and 
thoracoscopy. Open surgical intervention is sometimes re-
quired to control pleural sepsis or to restore chest mechan-
ics. This review gives an overview of parapneumonic effu-
sion and empyema, focusing on recent developments and 
controversies.  Copyright © 2008 S. Karger AG, Basel 
 Introduction and Definitions 
 At least 40% of all patients diagnosed with pneumonia 
will have an associated pleural effusion, although the mi-
nority of these will require active intervention  [1, 2] . A 
parapneumonic pleural effusion refers to any effusion 
secondary to pneumonia or lung abscess  [1] . It becomes 
‘complicated’ when an invasive procedure is necessary 
for its resolution, or if bacteria can be cultured from the 
effusion  [1] . Empyema is a term derived from the Greek 
verb  empyein (‘to suppurate’) and literally refers to frank 
pus in the pleural space. Parapneumonic effusion and 
empyema remain important medical conditions associ-
ated with significant morbidity and mortality  [2] . It is 
estimated that in the United States alone, pleural infec-
tions have an incidence of 60,000 per year and a mortal-
ity of approximately 15%  [3, 4] . Yet, controversy remains 
regarding the management and specifically the role of 
fibrinolytic therapy. 
 Key Words 
 Parapneumonic pleural effusion   Empyema   Fibrinolytics   
Thoracoscopy   Thoracotomy   Thoracostomy 
 Abstract 
 At least 40% of all patients with pneumonia will have an as-
sociated pleural effusion, although a minority will require an 
intervention for a complicated parapneumonic effusion or 
empyema. All patients require medical management with 
antibiotics. Empyema and large or loculated effusions need 
to be formally drained, as well as parapneumonic effusions 
with a pH  ! 7.20, glucose  ! 3.4 mmol/l (60 mg/dl) or positive 
microbial stain and/or culture. Drainage is most frequently 
achieved with tube thoracostomy. The use of fibrinolytics 
remains controversial, although evidence suggests a role for 
the early use in complicated, loculated parapneumonic effu-
sions and empyema, particularly in poor surgical candidates 
and in centres with inadequate surgical facilities. Early tho-
racoscopy is an alternative to thrombolytics, although its 
role is even less well defined than fibrinolytics. Local exper-
tise and availability are likely to dictate the initial choice be-
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 Epidemiology and Risk Factors 
 Complicated parapneumonic effusions and empyema 
are more common at both extremes of age  [2, 3] . At least 
two thirds of patients will have an identifiable risk factor 
at presentation  [2] , which may include immunosuppres-
sive states (most frequently HIV infection, diabetes mel-
litus and malnutrition), alcohol or intravenous drug 
abuse, bronchial aspiration, poor dental hygiene, gastro-
oesophageal reflux, and chronic parenchymal lung dis-
ease  [3, 4] . Microbial virulence and idiosyncrasies of the 
immune system are often also implicated, principally in 
individuals with no apparent predisposition.
 Pathogenesis 
 Although pleural infection may occur as a primary 
event, most cases of pleural sepsis are secondary to pneu-
monias, lung abscesses or infective exacerbations of bron-
chiectasis. It should be noted that the associated pulmo-
nary consolidation may be minimal  [2] . Other identifi-
able causes include thoracic surgery, diagnostic proce-
dures involving the pleural space, trauma, oesophageal 
rupture, transdiaphragmatic spread and rarely bronchial 
obstruction  [5] . Primary pleural infections are presum-
ably most often due to the haematogenous spread of or-
ganisms from gingival and upper respiratory tract infec-
tions (with cultures yielding oropharyngeal flora and an-
aerobes)  [2, 6] or due to  Mycobacterium tuberculosis  [7] .
 The development of a parapneumonic effusion occurs 
in three clinically relevant stages that represent a con-
tinuous spectrum  [1, 8] . A rapid influx of exudative fluid 
into the pleural space is observed in up to 40% of patients 
with pneumonia and heralds the first or exudative stage 
 [1, 2] . The accumulation of fluid is thought to be a direct 
result of increased pulmonary interstitial fluid traversing 
the pleura to enter the pleural space  [1] and an increase 
in vascular permeability secondary to pro-inflammatory 
cytokines  [2, 9] , e.g. interleukin-8 and tumour necrosis 
factor-  . During this stage pleural fluid culture is nega-
tive for bacteria, fluid pH is  1 7.20, the glucose level is 
within the normal range and lactate dehydrogenase re-
mains  ! 3 times the upper limit of normal  [1, 2] . Most 
patents with uncomplicated parapneumonic effusions 
will respond to antibiotics alone and drainage is gener-
ally not required  [1, 2, 10] . 
 Untreated exudative effusions may develop into fibri-
nopurulent effusions. This second stage is characterized 
by positive microbial cultures. Ongoing phagocytosis 
and cell lysis result in fluid that most frequently has a
pH of  ! 7.20, a lactate dehydrogenase  1 3 times the upper 
limit and a low glucose  [1, 2, 10] . Rarely, fibrinopurulent 
effusions can have a pH in the normal or even in the al-
kaline range. This phenomenon is limited to a few patho-
gens (e.g.  Proteus spp.) with enzymatic activity that can 
elevate fluid pH, for instance by cleaving urea into am-
monia  [11] . During the fibrinopurulent stage the pleural 
space becomes increasingly infected. Loculations may 
develop and closed or open drainage becomes neces-
sary – the point in time where an effusion is referred to 
as ‘complicated’. A critical characteristic of the fibrino-
purulent stage of pleural sepsis is the disturbance of the 
physiological equilibrium between clotting and fibrino-
lysis within the pleural space  [2, 12] . Several mediators for 
the activation of the coagulation cascade and inhibition 
of fibrinolysis have been suggested: TNF-  , for example, 
has been shown to stimulate the release of plasminogen 
activator inhibitors from pleural mesothelial cells. Ale-
man et al.  [13]  were able to show increased levels of plas-
minogen activator inhibitor-2 and depressed levels of 
 tissue plasminogen activator (tPA) during complicated 
pleural sepsis. Although the exact mechanisms behind 
the procoagulate state still need to be elucidated, its ef-
fects are well-known: pleural surfaces coated with fibrin 
and fibrin strands with secondary adhesions and locula-
tions, all complicating pleural fluid drainage.
 The third and final stage of pleural infection is the or-
ganizing phase  [1, 2] . Fibroblasts grow into the pleural 
space from both the visceral and parietal pleura. This 
eventually results in a thick pleural peel, which restricts 
chest mechanics and often necessitates a surgical decor-
tication to address restrictive impairment. Recent re-
search on animal models has suggested a cardinal role for 
transforming growth factor-  1 as a fibrogenic cytokine 
in the development of pleural fibrosis  [14] .
 Bacteriology 
 The reported bacteriology of pleural sepsis varies sig-
nificantly between community-acquired and nosocomi-
al infections  [2] . Maskell et al.  [15]  reported the large pro-
spective MIST 1 trial (Multicenter Intrapleural Sepsis 
Trial 1) in 2005. Their study included 430 subjects across 
52 centres in the United Kingdom. Of these, 232 (54%) 
had positive pleural cultures. The  Streptococcus milleri 
group was the most common pathogen (29%), followed 
by staphylococci (21%) and  Streptococcus pneumoniae 
(16%). Anaerobes were isolated in 15%. Other isolates in-
111
University of Stellenbosch: http://scholar.sun.ac.za
 Parapneumonic Effusion and Empyema Respiration 2008;75:241–250 243
cluded other streptococci,  Haemophilus influenzae , en-
terobacteria,  M.  tuberculosis , and  Nocardia . The same in-
vestigators previously reported that nosocomial pleural 
infections were most commonly caused by methicillin-
resistant  Staphylococcus aureus (27%), other staphylococ-
ci (22%) and enterobacteria (20%)  [16] .
 Clinical Presentation 
 The presenting symptoms of complicated parapneu-
monic effusions and empyema can vary significantly and 
can be dominated by the preceding infective process. Im-
munocompetent patients with aerobic infections tend to 
be more acutely ill, and the clinical presentation is similar 
to pneumonia. This is followed by a ‘non-resolving pneu-
monia’ picture with pleuritic chest pain, fever spikes and 
a failure to improve on apparently adequate antibiotic 
therapy. Elderly individuals, immunocompromised pa-
tients and those with anaerobic infections can have a 
more indolent course, and may present with weight loss, 
cough, unexplained fever and anaemia  [1] .
 Diagnosis 
 Imaging 
 The chest radiograph usually shows a small to moder-
ate pleural effusion with or without parenchymal infil-
trates ( fig. 1 a). There may be evidence of loculations and 
air-fluid levels. Longstanding empyema may sometimes 
cause isolated rounded pleural opacities, which may be 
 Fig. 1. A series of images obtained from the same patient who pre-
sented with a complicated parapneumonic effusion.  a The chest 
radiograph: note the inhomogeneous nature of the left-sided 
opacity, the absence of the associated costophrenic angle, and the 
apparent air lucencies within the opacity.  b A thoracic US re-
vealed a classic septated complicated parapneumonic effusion. 
Note the strands of echogenic material within the loculations.
L = Loculations; S = septae.  c A chest CT scan did not show any 
loculations within the pleural fluid collection. Note the underly-
ing pulmonary consolidation that was not apparent on the chest 
radiograph. C = Consolidation; E = effusion. 
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confused with malignant pathology. It was once consid-
ered standard practice to request a lateral decubitus ra-
diograph on all patients with suspected pleural sepsis and 
to use the lateral thickness of the effusions on these films 
to guide the decision on the need for a thoracentesis  [1, 2] . 
Light et al. [17] showed that pleural effusions less than
1 cm thick on these radiographs resolved with antibiotic 
therapy alone and did not require pleural aspiration tho-
racentesis. Thoracic ultrasound (US), however, is an at-
tractive alternative to a lateral decubitus film, as it can 
very accurately measure the extent of pleural effusions 
and yields significantly more information regarding the 
state of the pleural space  [18, 19] .
 The routine use of thoracic US in patients with sus-
pected pleural sepsis should be encouraged. US is par-
ticularly helpful in determining the nature of localized or 
diffuse pleural opacities, and is more sensitive than decu-
bitus expiratory films in identifying small or loculated 
effusions  [18, 19] . Complicated parapneumonic effusions 
are associated with floating strands of echogenic mate-
rial which shows mobility with the respiration cycle and 
denotes advancing stage and chronicity. Complicated ef-
fusions may be subdivided into either septated or non-
septated effusions ( fig. 1 b). The presence of septae is clin-
ically relevant: Chen et al.  [20] demonstrated that patients 
with septated effusions needed longer chest tube drain-
age, longer hospital care, and were more likely to require 
fibrinolytic therapy or surgery compared with those with 
unseptated effusions. Tu et al.  [21]  confirmed these find-
ings in medical intensive care unit patients. Empyema 
with high viscosity may cause a strongly echogenic effu-
sion that can be mistaken for a solid pleural lesion. A 
change in shape during respiratory excursion and the 
presence of movable strands or echo densities are signs in 
favour of empyema  [22] . Furthermore, thoracic US is in-
valuable in guiding pleural aspirations and drainage and 
is superior to chest radiographs at identifying the optimal 
site for diagnostic thoracentesis  [23] . The success rate of 
US-guided thoracentesis can be as high as 97%. US guid-
ance also decreases the risk of complications following 
pleural procedures  [24] . 
 A thoracic computed tomography (CT) scan may be 
indicated to better delineate pulmonary and pleural anat-
omy, particularly if there is a suspicion of an alternative 
diagnosis (e.g. bronchogenic carcinoma) or prior to sur-
gical intervention  [25] . It should be appreciated that locu-
lations within a collection are best appreciated on US, 
and often not seen on a chest CT scan ( fig. 1 c). However, 
collections in interlobar spaces and those adherent to the 
paramediastinal pleura may escape detection by US and 
may only be visible on a CT scan (fig. 2: the small para-
vertebral collection will not be detected on ultrasound). 
Thickening of the parietal pleura ( fig. 2 ) on a contrasted 
CT scan is suggestive of empyema  [26] and thus an indi-
cation for thoracentesis, even in the presence of relatively 
small pleural collections. 
 Diagnostic Thoracentesis 
 All but small ( ! 10 mm on US or lateral decubitus radio-
graph), free-flowing parapneumonic effusions should be 
aspirated for diagnostic purposes  [27] . Apart from the rou-
tine chemistry, cytology and cell count analysis fluid 
should be sent off for a Gram stain and culture, and pleural 
fluid pH should be measured by means of a blood gas ma-
chine (not a pH meter or an indicator strip)  [1] . A positive 
result from either the Gram stain or culture, or a pH of 
 ! 7.20 is associated with a worse outcome and indicates the 
need for drainage  [27, 28] . If the pleural fluid pH is unavail-
able, the pleural fluid glucose may serve as a surrogate. A 
glucose level  1 3.4 mmol/l (60 mg/dl) is associated with a 
better prognosis  [1] . Pleural fluid adenosine deaminase is 
usually elevated in bacterial parapneumonic effusions and 
empyema, which are neutrophilic in nature. In the setting 
of a lymphocytic effusion, however, an elevated pleural ad-
enosine deaminase is highly suggestive of a tuberculous 
effusion, even in low prevalence areas  [25, 29, 30] .
L
S
 Fig. 2. A CT scan of a patient with empyema showing marked 
pleural thickening with enhancement, as well as volume loss of 
the left hemithorax (L, large collection). Also note the second, 
much smaller, left paravertebral pleural collection (S).  
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 Management 
 Principles 
 The treatment options for parapneumonic effusions 
range from non-invasive antibiotic therapy and observa-
tion, to semi-invasive techniques such as therapeutic 
 aspiration, tube thoracostomy and intrapleural fibrino-
lytics, to invasive interventions such as thoracoscopy, 
thoracotomy or open drainage  [1] . In practical terms, 
however, the initial evaluation should focus on three crit-
ical questions, namely: (1) Should the pleural space be 
drained? (2) How should the pleural space be drained? (3) 
Should fibrinolytics be instilled?  Table 1 is adapted from 
the American College of Chest Physicians’ (ACCP) con-
sensus statement that categorizes parapneumonic effu-
sions according to the need for drainage  [25] . It is impor-
tant to realize that the pleural space anatomy (best visu-
alized by means of US), pleural fluid appearance and 
smell, as well as pleural pH are often the only useful cri-
teria for initial decision making, as all other laboratory 
tests need time for processing. Frank pus on aspiration, 
large effusions greater than half of one hemithorax, effu-
sions with loculations (see  fig. 2 ), or fluid with a pH  ! 7.20 
all herald the need for immediate drainage. Further indi-
cations include a positive Gram stain, a positive micro-
bial culture and pleural fluid glucose of  ! 3.4 mmol/l (60 
mg/dl).
 Antibiotics 
 The initial antibiotic cover of patients with parapneu-
monic effusions is generally dictated by treatment guide-
lines for pneumonia, and is altered according to blood 
and pleural fluid microbial cultures and antibiotic sensi-
tivities. Empirical anaerobic antibiotic cover is generally 
advised  [2] , as there may be an anaerobic co-infection 
which is generally not as amenable to culture as aerobes. 
Choices in community-acquired empyema include intra-
venous amoxycillin with clavulanic acid or a combina-
tion of a second generation cephalosporin (e.g. cefurox-
ime) and metronidazole  [31] . Clindamycin monotherapy 
is an effective alternative for patients with a   -lactam al-
lergy. Patients with nosocomial empyema need adequate 
Gram-negative cover. Possible choices include carbapen-
ems, antipseudomonal penicillins (e.g. piperacillin/tazo-
bactam), or third or fourth generation cephalosporins 
(e.g. ceftazidime, cefepime) with metronidazole  [31] . Van-
comycin, linezolid or alternatives may have to be added 
for suspected or proven methicillin-resistant  S. aureus 
infections. Aminoglycosides demonstrate poor pleural 
penetration and reduced efficacy in acidic environments 
and should thus be avoided  [32] .
 Observation  
 ACCP category 1 ( table 1 ) effusions may be observed 
without a diagnostic aspiration, as the risk of a compli-
cated course is remote  [11] . All other cases require at least 
a diagnostic pleural aspiration before this decision can be 
made: only category 2 effusions may be observed without 
formal drainage. There should be no delay in draining 
category 3 and 4 effusions, as a free-flowing effusion may 
become loculated in a matter of 1 day. 
Table 1. Risk of poor outcome in patients with parapneumonic effusions and empyema
Cate-
gory 
Pleural space anatomy Pleural fluid 
chemistry
Pleural fluid bacteriology Risk of poor 
outcome
Drainage
1 Minimal, free-flowing effusion (<10 mm) and pH unknown and Gram stain and culture 
results unknown
very low no
2 Small to moderate free-flowing effusion 
(≥10 mm and <½ hemithorax)
and pH ≥7.20 and negative Gram stain and 
culture 
low no
3 Large, free-flowing effusion (≥½ hemithorax), 
loculated effusion, or effusion with thickened 
parietal pleura
or pH <7.20 or positive Gram stain and/
or culture
moderate yes
4 Empyema pus high yes 
Adapted from the American College of Chest Physicians’ consensus statement on the Medical and Surgical Treatment of Para-
pneumonic Effusions [27]. Note that the presence of frank pus indicates need for drainage irrespective of pH.
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 Therapeutic Thoracentesis 
 A once-off US-guided therapeutic thoracentesis is
an initial treatment option for moderately sized effu-
sions involving less than one hemithorax, in the absence 
of empyema or a pH  ! 7.20. It may serve as both diag-
nostic and, if no re-accumulation occurs, definitive 
management. Recurrent therapeutic pleural aspirations 
for empyema or complicated parapneumonic effusions 
have been largely abandoned, although Simmers et al. 
 [23]  showed that they were able to successfully treat 24 
of 29 patients with parapneumonic effusions by means 
of alternate day US-guided pleural aspirations. Major 
disadvantages of this technique seem to be the high 
number of necessary aspirations and the long hospital 
stay, as a mean of 7.7 aspirations in 31 days was needed 
in their study.
 Tube Thoracostomy 
 Indications for chest tube drainage include empyema, 
complicated parapneumonic effusions (pH  ! 7.20, locula-
tions or positive bacteriological investigations) and large 
effusions (more than half of a hemithorax involved)  [27] . 
This is most commonly achieved by a standard (24–28 
french) intercostal chest drain that is positioned in the 
dependent part of a free-flowing pleural effusion (most 
often the posterior costophrenic recess). Insertions are 
best guided by US, as thickened parietal pleura, adhe-
sions or loculations often complicate insertion. Common 
sense suggests that smaller bore drains are likely to fail in 
the presence of pus with a high viscosity. However, some 
prospective studies have found that 8- to 12-french pig-
tail catheters or 10- to 14-french catheters inserted with 
the Seldinger technique under US or CT guidance were 
at least as effective as larger catheters inserted without 
imaging  [33–35] . However, the positioning of the catheter 
tips with guidance is likely to be superior compared to 
blind insertion, irrespective of drain size. Most of these 
studies also employed a strict rinsing schedule (often sev-
eral times a day), which might be difficult to sustain in 
everyday clinical practice. Moreover, a very recent study 
found a failure rate of 19% with small-bore catheters and 
concluded that the threshold for using fibrinolytics and 
large-bore catheters should be low in empyema  [36] .
 Thrombolytics 
 Complicated parapneumonic effusions and empy-
emas are characterized by a procoagulant state within the 
pleural space which results in the progressive develop-
ment of dense layers of fibrin and loculations. It therefore 
seems highly plausible that intrapleural fibrinolytics giv-
en early in the fibronopurulent phase should prevent loc-
ulations and promote pleural drainage. In fact, Tillett 
and Sherry  [37]  described the use of streptokinase and 
streptodornase for this very indication as early as 1949. 
Unjustified fears of systemic side effects and a paucity of 
controlled clinical trials have unfortunately delayed the 
compilation of an evidence base for the use of this modal-
ity for many years.
 Numerous case series and controlled trials have shown 
that intrapleural fibrinolysis is safe, increases drainage 
and improves radiological appearance. A randomized 
controlled study by Davies et al.  [38] established that sys-
temic fibrinolysis or bleeding complications did not oc-
cur with streptokinase, and that patients who were given 
intrapleural streptokinase drained significantly more 
pleural fluid both during the days of treatment (n = 24; 
mean 391 vs. 124 ml, p  ! 0.001) and overall. Patients who 
received fibrinolytics also showed greater improvement 
on the chest radiograph at discharge.
 Bouros et al.  [39]  demonstrated that urokinase was a 
safe intrapleural fibrinolytic. The same group showed 
that streptokinase and urokinase were clinically and ra-
diologically equally effective as intrapleural fibrinolytics 
 [40] , and that intrapleural urokinase decreased the dura-
tion of hospitalization, duration of pleural drainage and 
time to defervescence. Furthermore, Bouros et al.  [41] 
 were able to show that urokinase’s effect in empyema was 
through the lysis of pleural adhesions, rather than the 
volume effect of instilled urokinase and saline. 
 Lim and Chin  [42]  evaluated the efficacy of three dif-
ferent treatment protocols, namely simple chest tube 
drainage, adjunctive intrapleural streptokinase, and an 
aggressive empirical approach incorporating streptoki-
nase and early surgical drainage in patients with pleural 
empyema and high-risk parapneumonic effusions. In 
this non-randomized, prospective, controlled series they 
found that the average duration of hospital stay and mor-
tality in both the streptokinase and early surgical drain-
age group was significantly shorter than with tube drain-
age alone. The authors concluded that an empirical treat-
ment strategy which combines adjunctive intrapleural 
fibrinolysis with early surgical intervention resulted in 
shorter hospital stays and possible reduced mortality in 
patients with pleural sepsis.
 The most meaningful clinical endpoint, that of the 
necessity for surgical intervention, was only recently ad-
dressed in randomized controlled studies. Tuncozgur et 
al.  [43]  found a significantly lower decortication rate (60 
vs. 29.1%, p  ! 0.01) and shorter duration of hospitaliza-
tion (14 vs. 21 days, p  ! 0.01) with urokinase than with 
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placebo. A single-centre, randomized, placebo-con-
trolled study by Diacon et al.  [44] used structured clini-
cal protocols for inclusion and evaluation and demon-
strated that intrapleural streptokinase resulted in faster 
resolution of infection, reduced need for surgery (13.6 
vs. 45.5%, p = 0.018) and improved clinical outcome in 
patients with loculated parapneumonic effusions and 
empyema.
 The largest prospective double-blind controlled study 
on the role of intrapleural streptokinase for pleural in-
fection was published in 2005 (MIST 1)  [15] . In this study 
454 patients with pleural pus, pleural sepsis with a pH 
 ! 7.2 or bacterial invasion of the pleural space were ran-
domly assigned to receive streptokinase or placebo. The 
patients included were older than in most other studies 
(average age 60 years) and had a high prevalence of co-
morbidities. The MIST 1 study could not substantiate the 
role of streptokinase in pleural infections: There was no 
difference in mortality, need for surgery, radiographic 
outcome or length of hospitalization. The design and ex-
ecution of this study, however, were criticized  [45–47] . 
The lack of image-based selection criteria meant that pa-
tients with pleural sepsis were included irrespective of 
presence, quantity and quality of loculations. Questions 
were raised about the reproducibility of clinical manage-
ment decisions taken across 52 study centres, many of 
which lacked on-site surgical expertise and contributed 
only small numbers of patients. The study permitted 
small-bore chest tubes, but did not report on pleural 
drainage volumes, which casts doubt on the efficacy of 
the drainage techniques used. Furthermore, owing to 
the decentralized and blinded design streptokinase/pla-
cebo was shipped to the study centres after randomiza-
tion causing delays in the initiation of treatment. The 
value of mortality as an endpoint was also questioned, as 
patients with serious concomitant illnesses that made 
survival beyond 3 months unlikely were excluded from 
the study. The 3-month mortality after hospitalization 
for pneumonia among middle-aged and older patients is 
more closely associated with the fact that an episode of 
pneumonia often identifies a fragile underlying health 
status than with the severity of the acute episode of pneu-
monia itself  [45] . Intrapleural streptokinase may there-
fore not have been given a fair chance to improve the 
short-term mortality  [45] . These deficiencies do not in-
validate this large randomized trial, but concerns remain 
about the validity of its results with regards to younger, 
more severely ill patients and in different health care set-
tings. 
 The most recent and second largest prospective study 
was conducted by Misthos et al.  [48] . In their study pa-
tients were randomized to a group managed solely with 
tube thoracostomy or a group treated with a combina-
tion of tube thoracostomy and streptokinase instillation 
(no placebo control). They found that tube thoracostomy 
was successful in 67.1% of cases, whereas the installation 
of streptokinase led to a favourable outcome in 87.7%
(p  ! 0.05) and significantly shortened hospital stay. The 
mortality rate was also significantly lower in the fibrino-
lytic group, and streptokinase was found to decrease the 
rate of surgical interventions and the length of hospital 
stay.
 Tokuda et al.  [49]  published a meta-analysis of all the 
major placebo-controlled studies on intrapleural fibrino-
lysis  prior to publication of the study by Misthos et al. 
Albeit they were able to demonstrate a trend towards im-
proved survival and a decreased need for surgical inter-
ventions, the differences failed to become statistically sig-
nificant.
 Clinical trials on the efficacy of recombinant tPA and 
DNase are currently being performed. An interesting ex 
vivo observation by Light et al.  [50]  was that DNase com-
bined with streptokinase (known as Varidase) was supe-
rior to either streptokinase or urokinase at liquefying em-
pyemic pleural material obtained from rabbits. It was 
postulated that the streptodornase (DNase) was neces-
sary for the liquefaction of the deoxyribose nucleopro-
teins, which make up a sizable proportion of the solid 
sediment of purulent exudates .
 In conclusion, current evidence suggests that intra-
pleural fibrinolytics cannot be recommended as the stan-
dard treatment of parapneumonic effusion and empy-
ema. There seems to be a place for fibrinolytics in the 
early management of loculated (complicated) parapneu-
monic effusions and empyema, particularly in young, 
acutely ill patients, poor surgical candidates and in cen-
tres where surgical facilities are limited. Streptokinase 
and urokinase are presumably equally effective and safe. 
The efficacy of tPA and DNase still needs to be estab-
lished. The suggested dosages of the current fibrinolytics 
in use are summarized in  table 2 .
 Thoracoscopy 
 Thoracoscopy remains a treatment option for the pa-
tient with an incompletely drained loculated parapneu-
monic effusion, provided that it is performed early in the 
disease and that the pleural anatomy is defined by means 
of either US or CT scan  [51, 52] . Loculations can be bro-
ken down, the visible pleural space completely drained, 
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and an intercostal chest tube can be optimally placed  [1] . 
Furthermore, visual inspection of the pleura may guide 
decisions regarding the need for an open surgical proce-
dure  [1] .
 The exact point where thoracoscopy becomes useful 
in the management of pleural sepsis remains unclear and 
is even less well defined than the role of fibrinolytics. Sev-
eral small retrospective and unblinded prospective stud-
ies suggest that thoracoscopy is superior to fibrinolysis 
 [51–54] , with the need for thoracotomy or thoracostomy 
almost halved  [53] . At least one study performed on a pae-
diatric population, however, found urokinase to be more 
cost-effective than routine thoracoscopy  [55] . Practically 
all prospective studies on the role of thoracoscopy  [51, 
53–55] utilized video-assisted thoracoscopy (VATS), as 
opposed to medical thoracoscopy. Current evidence does 
not allow a clear choice between the modalities, and local 
expertise is likely to dictate the preferred method.
 Surgical Management 
 Open surgery may be required at various stages of the 
evolution of complicated parapneumonic effusions or 
empyema. The aim of a procedure in the subacute phase 
is usually to control sepsis, whereas a procedure in the 
chronic phase aims to restore chest mechanics by remov-
ing a restrictive fibrotic peel encasing the lung ( fig. 3 ).
 The main indications for open surgical drainage are 
failure of medical management to control sepsis in the 
acute stages of pleural sepsis and failure of tube thora-
costomy or thoracoscopy to yield reexpansion of the 
lung  [1, 56] . Thoracotomy with drainage and subsequent 
closure of the chest with one or more drains left in situ 
is the standard procedure. Thoracostomy involves inci-
sion through the chest wall with rib resection, which 
produces a stoma with continuous drainage of the chest 
cavity. In addition, one or more chest tubes can be in-
serted through the opening, and irrigated daily. The 
chest tubes can gradually be retracted until complete re-
moval, a process that takes 2–3 months to complete. 
Drainage from the thoracostomy or from the tubes (cut 
off close to the skin) can be collected in a colostomy bag. 
A different approach involves packing the empyema cav-
ity with gauze. A more complex procedure may be per-
formed when the tract between the pleural cavity and the 
surface of the chest is lined with a skin and muscle flap 
following rib resection  [1] . Drainage is thus achieved 
without chest tubes with gradual obliteration of the em-
pyema cavity  [57] .
 Decortication is a major surgical intervention that en-
tails the excision of all fibrous tissue from the pleura, with 
or without the evacuation of associated pus and debris 
Table 2. Intrapleural fibrinolytics – practical use
Fibrinolytic Dose Instillation1 Duration 
Streptokinase 250,000 IU 100–200 ml saline daily for up to 7 days (until drainage <100 ml/day) 
Urokinase2 100,000 IU 100 ml saline daily for up to 3 days 
tPA   10–25 mg 100 ml saline twice daily for up to 3 days 
1 Drain should be clamped for approximately 2 h following installation of fibrino lytics.
2 Urokinase is no longer universally available.
Fig. 3. A chest radiograph showing the long-term sequelae of em-
pyema. Note the formation of a thick pleural peel with volume loss 
and incarceration of the left lung causing restrictive impair-
ment.
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from the pleural cavity, in order to permit lung reexpan-
sion  [58] . It remains a procedure with significant morbid-
ity and a reported mortality of up to 10%  [59] . As pleural 
thickening may resolve over time, decortication is best 
deferred for up to 6 months  [60] . 
 Conclusions: Suggested Management of 
Parapneumonic Effusions and Empyema 
 All patients with parapneumonic pleural effusions 
and empyema require early and adequate antibiotic treat-
ment. Thoracic US should be performed on patients with 
suspected parapneumonic effusion that is not clearly vi-
sualized on a routine postero-anterior chest radiograph. 
Small, unseptated and free-flowing effusions may be ob-
served, but all other effusions warrant an urgent diagnos-
tic thoracentesis. Sterile effusions with a pH  6 7.20 may 
be observed on antibiotic cover. Empyema and large or 
loculated effusions need to be drained, as well as para-
pneumonic effusions with a pH  ! 7.20, glucose  ! 3.4 
mmol/l or positive microbial stain and/or culture. 
 An US-guided therapeutic thoracentesis is an elegant 
initial treatment option for uncomplicated effusions of 
moderate size, in the absence of empyema or a pH  ! 7.20, 
loculations or positive bacteriological investigations. It 
may serve both as a diagnostic and, if no reaccumulation 
occurs, definitive procedure. The US evaluation of the 
pleural cavity will also guide further management. Large 
bore tube thoracostomy is the treatment option of choice 
for patients with empyema. Parapneumonic effusions 
that recur following a single aspiration or cases at high 
risk should be drained by means of either standard or 
small-bore intercostal drains.
 The use of fibrinolytics remains controversial, al-
though evidence suggests a role for the early use in com-
plicated, loculated parapneumonic effusions and empy-
ema, particularly in young, acutely ill patients, poor sur-
gical candidates and in centres with inadequate surgical 
facilities. Early thoracoscopy is an alternative to throm-
bolytics. Local expertise and availability will to a certain 
extent dictate the initial choice between tube thoracos-
tomy with fibrinolytics or thoracoscopy, although thora-
coscopy may also be performed following fibrinolytics if 
complete drainage is not achieved.
 An open surgical drainage procedure will be required 
for complete drainage where tube thoracostomy or tho-
racoscopy with associated medical management fails to 
control pleural sepsis. A surgical decortication may be 
needed to remove a thick pleural peal and to restore chest 
mechanics, but this procedure is best deferred for at least 
6 months. 
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The most common cause of unilateral pleural 
effusions in the UK and USA is malignancy, with an 
estimated 250,000 new cases of malignant pleural 
effusions diagnosed annually1. The gold standard 
imaging modality for patients with suspected 
malignant effusion is thoracic contrast-enhanced 
computed tomography (CECT) scanning. CECT is 
both a specific and a sensitive test for differentiating 
benign and malignant pleural disease2. 
Recently, an emerging role for thoracic ultrasound 
(TUS) in the investigation of malignant pleural 
effusion has been demonstrated. TUS is a quick, 
relatively inexpensive investigation, which is 
increasingly being performed by chest physicians. 
TUS is recognized as an accurate and reliable 
technique for pleural fluid detection, assessment of 
fluid characteristics and for guiding pleural 
intervention3.  
More recently, TUS has been shown to be a 
valuable clinical tool in the diagnosis of malignant 
pleural effusion. Studies have evaluated high 
frequency real-time sonography in determining the 
nature of pleural effusions: appearances consistent 
with a high suspicion of malignancy include pleural 
thickening of more than 1 cm and the detection of 
pleural nodules4, but the sonographic fluid 
characteristics themselves are non-specific5. 
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The accuracy of TUS in the diagnosis of suspected 
malignant pleural effusion has been shown to be 
comparable to that of CECT6. In the study by Qureshi 
et al. TUS correctly diagnosed malignant pleural 
effusion with an overall sensitivity of 79%, 
specificity of 100%, positive predictive value (PPV) 
of 100% and negative predictive value of 73%. Good 
inter-observer agreement between TUS operators was 
also demonstrated6. This study used previously 
reported CECT morphological criteria for the 
diagnosis of malignant pleural disease2 and applied 
them to TUS. These included: 1) diaphragmatic and 
parietal pleural nodule or nodules; 2) pleural 
thickening >1 cm (below); and 3) hepatic metastasis. 
By employing a threshold value for parietal pleural 
thickening of >1 cm as suggestive of malignancy, 
TUS had a specificity of 95% and a PPV of 93% for 
distinguishing 
malignant from 
benign disease6. 
The appearance of 
nodular pleural 
thickening on 
TUS was also 
associated with 
malignant pleural 
effusions and 
demonstrated a specificity of 100% and a PPV of 
100%6. The TUS echotexture of malignant pleural 
thickening appeared to be non-specific, and was 
hypoechoic, hyperechoic or isoechoic relative to the 
intercostal muscles. In contrast, TUS echotexture of 
benign pleural thickening was most often hypoechoic. 
As well as the recognized CECT criteria, additional 
TUS morphological features were also shown to be 
associated with malignant pleural effusions, namely, 
visceral pleural thickening, diaphragmatic nodularity 
and thickness >7 mm (Table). In contrast, 
diaphragmatic thickening <5 mm and readily 
resolved normal diaphragmatic appearances, with all 
five layers clearly seen, were suggestive of benign 
disease6.  
In summary, there are now defined TUS 
morphological features enabling the differentiation 
between benign and malignant pleural effusions. 
With its low cost and ready availability, TUS should 
be performed initially in the investigation of patients 
with pleural effusion of unknown etiology, with 
CECT being reserved for patients requiring further 
investigation. 
  
TUS morphological 
feature 
Malignant pleural 
effusion 
Benign pleural 
effusion 
Parietal pleural thickening >1 cm 
Non-specific 
echotexture 
<1 cm 
Hypoechoic 
echotexture 
Pleural 
nodularity/irregularity 
Present Absent 
Visceral pleural 
thickening 
Present Absent 
Diaphragmatic thickening >7 mm <7 mm 
Diaphragmatic nodularity Present Absent 
Hepatic metastasis Present Absent 
 
1. American Thoracic Society. AJRCCM 2000; 162:1987-
2001. 
2. Leung AN, et al. AJR Am J Roentgenol 1990; 154:487-492. 
3. Qureshi NR, et al. Clin Chest Med 2006; 27:193-213. 
4. Yang PC, et al. AJR Am J Roentgenol 1992; 159:29-33. 
5. Gorg C, et al. Eur Radiol 1997; 7:1195-1198. 
6. Qureshi NR, et al. Thorax 2009; 64:139-143. 
 
 
Ultrasound Guided Thoracentesis 
 
David Feller-Kopman MD FCCP 
John Hopkins University, Baltimore, USA 
dfellerk@jhmi.edu 
  
Approximately 1.5 million persons are found to have 
pleural effusions each year in the USA. Over the last 
several years, the use of portable, point of care 
ultrasound has greatly enhanced the evaluation and 
management of patients with pleural disease.  
Ultrasonography has been found to be more sensitive 
than chest X-ray for the detection of pleural fluid, can 
predict the need for more invasive pleural 
intervention and has been associated with a 
significant reduction in pneumothorax rates, when 
used to guide thoracentesis. Though there is a 
learning curve associated with the use of thoracic 
ultrasound (TUS), it is relatively short and should 
consist of both didactics as well as hands-on 
training1,2.   
Examination of the pleural space with ultrasound is 
best performed with a convex array 3.5 – 5MHz 
probe. This frequency range provides both excellent 
resolution and penetration. In the absence of pleural 
fluid, identification of the hyperechoic visceral and 
parietal pleurae can be difficult. However, when it is 
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present, evaluation of the pleural space, visceral and 
parietal pleura and even the lung becomes possible. 
Movement of the lung with respiration produces a 
‘sliding’ or ‘gliding’ sign, and this dynamic 
movement identifies the visceral pleura and lung 
parenchyma. Diaphragmatic movement can also be 
visualized in real-time, and is a key reference point 
when starting to perform TUS examination of the 
pleural space. 
Several studies have found that ultrasound can be 
helpful in identifying exudative pleural fluid. 
Complex effusions (either septated or non-septated) 
or homogenously echoic effusions are always 
exudates. The converse, however, may not be true. 
Though transudates are almost always anechoic, 
anechoic fluid can be transudative or exudative.  
Thoracentesis is typically thought to be a relatively 
safe procedure with few complications. The incidence 
of pneumothorax, however, has been reported to be 
as high as 20-39%. Though there are no blinded 
randomized trials comparing ultrasound vs physical 
exam guided thoracentesis, several studies have 
associated ultrasound use with lower complications. 
Procedural factors that have been shown to reduce the 
rate of pneumothorax include performance by 
experienced personnel3 as well as the use of 
ultrasound4,5. Diacon’s group found that, even in the 
hands of trained pulmonologists, the use of 
ultrasound increased the accuracy in site selection by 
26%, and decreased the number of near misses (i.e. 
the number of potentially dangerous needle insertion 
sites) by 15% when compared to fluid localization by 
physical exam and chest radiography6. In a recent 
meta-analysis of 6,605 thoracenteses, Gordon et al. 
found that the use of ultrasound was associated with a 
50% reduction in the risk of pneumothorax, using 
historical controls for comparative analysis3. In 
Mayo’s study of critically ill patients receiving 
mechanical ventilation, the rate of pneumothorax 
using ultrasound-guided thoracentesis was 1.3%. 
TUS has also been shown to be an excellent tool to 
both rule-out and in pneumothorax and is 
increasingly being used to evaluate lung parenchyma 
as well. Its use is quickly becoming the standard of 
care for procedural guidance in the pleural space. 
  
1. Mayo PH, et al. Chest 2004; 125:1059-1062. 
2. Mayo PH, et al. Chest 2009; 135:1050-1060. 
3. Gordon CE, et al. Arch Intern Med 2010; 170:332-339. 
4. Grogan DR, et al. Arch Intern Med 1990; 150:873-877. 
5. Jones PW, et al. Chest 2003; 123:418-423. 
6. Diacon AH, et al. Chest 2003; 123:436-441. 
 
 
Ultrasound-Assisted Pleural Biopsies 
 
Coenraad FN Koegelenberg MBChB FCP MRCP 
Andreas H Diacon MD PhD 
University of Stellenbosch, Cape Town, South Africa 
coeniefn@sun.ac.za 
 
Recent studies have reemphasised the importance of 
transthoracic ultrasound (TUS) as a guide to pleural 
procedures, both with regards to safety and diagnostic 
yield. TUS is an ideal aid to the clinician, given its 
mobility, low cost, lack of irradiation, and short 
examination time. TUS is superior to chest 
radiography for the visualisation of pleural effusions. 
Moreover, the volume of fluid, the presence of 
septations, pleural thickening and pleural-based 
tumours can be accurately assessed.  
Closed pleural biopsies were introduced in the late 
1950s, and the Abrams, Cope or Vim-Silverman 
needles were used blindly for many decades. Unaided 
closed biopsies have a modest yield for malignancy, 
on the order of 60%. Tru-cut needle pleural biopsies 
were first performed in the 1980s, initially without 
TUS assistance. Maskell et al. showed that CT-
guided Tru-cut pleural biopsies were superior for 
pleural malignancies compared to unaided Abrams 
needle biopsies (diagnostic yields 87% and 47% 
respectively)1. Chang et al. previously found the 
diagnostic yield of TUS-guided Tru-cut pleural 
biopsy to be as high as 87% for all pleural 
pathologies (77% for malignancies)2. For malignant 
mesothelioma our research has shown that this figure 
may be as high as 100%3.  
In a recent prospective randomized study it was 
found that TUS-assisted Abrams needle biopsy 
specimens were more likely to contain pleural tissue 
than specimens obtained by means of TUS-assisted 
Tru-cut biopsies (91% vs 78.7%, p=0.015)4. 
Furthermore, Abrams needle biopsies had a 
significantly superior yield for pleural tuberculosis 
compared to Tru-cut needle biopsies (81.8% vs. 
65.2%, p=0.022), but not compared to previously 
reported figures for blind Abrams needle biopsies. 
The distribution of granulomatous inflammation in 
pleural tuberculosis is uniform over the pleura and 
visual aids, therefore, seem to offer little advantage 
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beyond increased safety. Interestingly, and contrary 
to previous reports, the respective yield for both 
needle types for pleural malignancies was 
comparable and relatively high, with TUS-assisted 
Abrams needle being diagnostic in 83.3%4. One 
possible explanation for this may have been the 
selection of low biopsy sites utilised, as the lower 
thoracic parietal pleura is more likely to contain 
secondary spread from visceral pleural metastases. 
Such an approach is possible with TUS assistance, 
but not with digital percussion as a guide. Moreover, 
malignant disease tends to give rise to more focal 
pleural involvement which may be visible on high 
frequency TUS (see article by Matin and Gleeson in 
this issue).  
Apart from increasing diagnostic sensitivity, TUS 
very likely lowers the procedure-related risk. A 
recent survey carried out in the UK highlighted the 
dangers of blind pleural procedures: 67 of 101 trusts 
reported at least one serious complication from 
intercostal drainage (ICD)5. In all, 47 cases of serious 
lung or chest wall injuries with 8 deaths and 6 cases 
of ICD placement on the wrong side were described. 
Although similar multicenter data for unaided closed 
pleural biopsies does not exist, it seems plausible that 
similar complications can occur. Such incidents could 
be avoided by means of TUS assistance6.   
In conclusion, we believe that closed pleural 
biopsies should routinely be performed under TUS 
guidance, as it is likely to increase the yield for 
malignancies and to decrease the risk of 
complications.   
 
1. Maskell NA, et al. Lancet 2003; 361:1326-1330. 
2. Chang BD, et al. Chest 1991; 100:1328-1333. 
3. Diacon AH, et al. Respiration 2004; 71:519–522. 
4. Koegelenberg CF, et al. Thorax 2010 (in press). 
5. Harris A, et al. Postgrad Med J 2010; 86:68-72. 
6. Diacon AH, et al. Chest 2003; 123:436-441.  
 
 
 Competence in Pleural 
Ultrasonography 
 
J Terrill Huggins MD 
Steven A Sahn MD 
Peter Doelken MD 
Medical University of South Carolina, USA 
 doelkenp@musc.edu 
 
Ultrasonography has emerged as an important 
modality in the management of pleural diseases over 
the past decade. Routine use of ultrasonography for 
thoracentesis, pleural biopsy, placement of chest 
tubes and chronic indwelling pleural catheters lower 
the procedure risk and improves diagnostic accuracy. 
Reducing complications and improving diagnostic 
accuracy of pleura-related procedures have been the 
impetus’ to mandate the routine use of ultrasound as 
the standard of care. However, formal training in the 
use of ultrasound has been adopted in a limited 
number of pulmonary/critical care programs in the 
United States.   
The Critical Care Network of the American 
College of Chest Physicians and La Société de 
Réanimation de Langue Francaise collaborated in the 
development of a consensus statement on competence 
in critical care ultrasonography1. Pleural 
ultrasonography was identified as one of the core 
areas in this statement. The proposed standard 
establishes the training goals needed for the non-
radiologist to acquire competencies in pleural 
ultrasonography and is applicable outside the ICU 
environment.   
The clinician must demonstrate competences in 
five areas according to the consensus document by: 
1) having an understanding of basic ultrasound 
physics and how images are created through the 
interaction of sound waves and tissue; 2) 
demonstrating knowledge of the machine controls 
and transducer manipulation since they are personally 
conducting the exam; 3) being able to distinguish 
normal from abnormal ultrasound anatomy; 4) being 
able to interpret acquired images and know the 
limitations of ultrasonography pertinent to the 
examination conducted; and 5) being able to 
recognize when an examination is beyond the 
technical capabilities of either the device or 
themselves.     
The elements required for mastery of pleural 
ultrasonography include: 1) identifying safe puncture 
sites and knowing how far to insert needles to avoid 
inadvertent penetration into lungs or other organs and 
vasculature; 2) identifying and characterizing pleural 
effusion echogenicity patterns such as anechoic, 
complex non-septate, complex septate, and 
homogenously complex; 3) identifying pleural 
effusion boundaries; 4) identifying the dynamic 
findings of pleural fluid, such as lung flaps, swirling 
123
University of Stellenbosch: http://scholar.sun.ac.za
 10 
debris, and respirophasic shape changes; 5) 
identifying the liver, spleen, ascites, kidneys, heart, 
pericardium, aorta, and inferior vena cava; 6) 
providing a semi-quantitative assessment of pleural 
fluid volume; 7) identifying pleural-based masses and 
thickening; and 8) recognizing the technical 
limitations to image acquisition in the presence of 
subcutaneous emphysema, hemothorax, and echo-
dense empyemas1. 
In our institution, new-trainees to our fellowship 
program spend the first week reviewing the basic 
ultrasound operations, understanding ultrasound 
probe manipulation, identifying landmarks above and 
below the diaphragm, and watching a 45-minute real-
time video showing normal and abnormal pleural 
pathology. Image acquisition, transducer 
manipulation, and image interpretation is taught at 
bedside. In summary, competence can be easily 
obtained by those who are non-radiologically trained 
if a systematic approach is adopted.  
  
1. Mayo PH, et al. Chest 2009; 135:1050-1060. 
 
 
  
Pleural Metastases 
 
José M Porcel MD FCCP FACP 
Marina Pardina MD 
Carlos Galindo MD 
Paula Hernández MD 
Arnau de Vilanova University Hospital, Lleida, Spain 
jporcelp@yahoo.es 
 
  
Case 1. An 80-year-old-man was hospitalized after a 
lung mass with an associated left pleural effusion was 
detected on a chest radiograph that was done to 
evaluate new-onset dyspnea on exertion. He had a 60-
pack-year history of cigarette smoking. Thoracentesis 
yielded bloody fluid and analysis showed: 
erythrocyte count 250,000/µL, leukocytes 800/µL 
with 79% lymphocytes, total protein 3.9 g/dL, lactate 
dehydrogenase (LDH) 461 U/L, glucose 135 mg/dL, 
pH 7.44, adenosine deaminase (ADA) 18.4 U/L and 
positive cytology for an undifferentiated carcinoma. 
Immunoreactivity for thyroid transcription factor 1 
(TTF-1) was negative in a cell block preparation of 
pleural fluid.  
Both chest ultrasound and CT scanning revealed a 
moderate effusion along with multiple parietal pleural 
nodules (below) consistent with metastases. The CT 
images also indicated mediastinal lymph node and 
liver involvement from a primary lung tumor. 
Additional diagnostic maneuvers were considered 
unnecessary. The patient died two weeks later.  
 
 
 
Case 2. An 89-year-old man was evaluated for a 3-
month history of left scrotal swelling, growing lump 
in the upper back chest wall and progressive dyspnea. 
Chest ultrasound and CT exhibited parietal pleural 
thickening and effusion (below). Pleural fluid 
analyses showed: erythrocyte count 1010/µL, 
leukocytes 280/µL (99% lymphocytes), total protein 
4 g/dL, LDH 636 U/L, glucose 117 mg/dL, pH 7.6, 
ADA 40.2 U/L, and negative cytological 
examination.   
 
 
 
Biopsies of the parietal pleura (Tru-cut CT-guided), 
testicular mass and bone marrow were diagnostic of a 
diffuse large B-cell lymphoma. Staging also 
demonstrated chest wall, myocardial and abdominal 
lymph node involvement. The patient is currently 
receiving treatment with cyclophosphamide, 
doxorubicin, vincristine and prednisone (CHOP).       
PLEURAL IMAGES 
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Malignant Pleural Diseases
Guest editor: Dr Ioannis Kalomenidis
­ ­ ­ ­
Pleuro-peritoneal Shunt for Malignant
Pleural Effusions
Simon Jordan FRCS
Peter Goldstraw FRCS
Royal Brompton Hospital, London, UK
p.goldstraw@rbht.nhs.uk
The prognosis of patients who have a malignant
pleural effusion (MPE) is poor, with a median
survival of 4 months1. The presence of a malignant
effusion significantly impairs quality of life due to
dyspnea (96%), pain (57%) and cough (44%)2. The
management remains controversial for recurrent MPE
in the presence of a trapped lung that fails to
completely re-expand after drainage of the effusion.
The pleuro-peritoneal shunt allows continuous
drainage of pleural fluid into the peritoneal cavity.
This allows the lung to expand to its maximal
possible extent and the mediastinum to shift back
towards the affected side, thus improving dyspnea.
Pleuro-peritoneal shunts are more commonly used for
intractable aseptic MPE, when a trapped lung is
present. The shunt has also been used for the
treatment of chylothorax in both adults and children.
The pleuro-peritoneal shunt
(see figure, courtesy of Cardinal
Health, Inc.) is made of silicone
and consists of a double-valved
pumping chamber with a catheter
at either end. These peritoneal and pleural catheters
are both fenestrated to facilitate drainage.
Operative technique. The shunt is normally
inserted under general anesthesia with the patient in a
supine position or with the operative side slightly
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7elevated. We perform bronchoscopy to exclude
endobronchial obstruction. Thoracoscopic assessment
is then performed. If the lung is trapped, we proceed
with shunt insertion. The VATS port site is extended
to 4-5 cm in length and a subcutaneous pocket is
created in a position to allow fixation of the pumping
chamber over a rib for ease of palpation and
compression. The shorter of the two catheters is
inserted into the pleural space. Fluid should be left in
the pleural space or normal saline instilled to allow
flushing of the shunt in the early post-operative
period. A separate 3-4cm transverse, sub-costal
incision is made and purse-string sutures are placed
in either the posterior rectus sheath or transversalis
fascia and the peritoneum.
We then verify, visually and digitally, that the
peritoneal space is free of adhesions. The peritoneal
catheter is passed through the pocket and tunneled to
the sub-costal incision using long Robert’s forceps.
The catheter is then passed through the purse-strings
into the peritoneal cavity. The pumping chamber is
secured within the pocket using non-absorbable
sutures. It is then primed by pressing until fluid flows
though from the pleural cavity.
In the next 24 hours the pumping chamber is
pressed 25-30 times every 3 to 4 hours. After the first
day the patient is encouraged to press the chamber for
5 to 10 minutes, three to four times a day. Regular
pumping of the shunt reduces the likelihood of
occlusion. Port-site radiotherapy is considered after
recovery from surgery3. The intra-operative use of a
single VATS port limits the radiation field.
Results. Over a 15 year period, 360 patients with
a MPE were treated in our unit, 160 (44%) of which
had a trapped lung at operation and underwent
pleuro-peritoneal shunt insertion. Good palliation was
achieved in 95% of patients4. There were no
operative deaths, although three patients died in
hospital from progressive respiratory failure. Twelve
patients (8.5%) developed shunt occlusion requiring
revision or replacement (we prefer the latter). 4% of
the shunts had to be removed because of infection
and one patient developed tumor seeding along the
tract. Peritoneal seeding was not a problem, even in
longer term survivors (>6 years in one case). The
patients’ relatively short life expectancy means that
any peritoneal seeding that develops is unlikely to
impact significantly on their quality of life.
Pleuro-peritoneal shunts have been used in many
cancers, including breast carcinoma (36%), malignant
mesothelioma (23%) and lung carcinomas (22%).
Discussion. The majority of patients with MPEs
suffer from dyspnea. In most cases, dyspnea can be
relieved or improved by talc pleurodesis if the lung
re-expands, or by pleuro-peritoneal shunt insertion if
it remains trapped. Other treatment modalities include
the use of a permanent indwelling catheter,
decortication or pleurectomy. The former has been
associated with infection and empyema, and also has
the drawback of external tubing and requiring
training of the patient or carer. Decortication and
pleurectomy are more major surgical procedures
unsuitable for palliative purposes.
1. Heffner JE, et al. Chest 2000;117:79-86.
2. Moragon EM, et al. Respiration 1998; 65:108-113.
3. Boutin C, et al. Chest 1995; 108:754-58.
4. Genc O, et al. Eur J Cardiothorac Surg 2000; 18:143-6.
Prophylactic Drain Site Radiotherapy for
Mesothelioma: Does it Make Sense?
Noelle O’Rourke MA MD MRCP FRCR
Gartnavel General Hospital, Glasgow, UK
Noelle.orourke@btinternet.com
Diagnosis of pleural mesothelioma can be made by
cytology of pleural effusion, closed pleural biopsy or
video-assisted thoracoscopy. Many patients require
repeated drainage of effusions and both the original
and subsequent drain sites are at risk of subcutaneous
tumor growth from direct seeding outwards from the
pleural surface. Estimates of the incidence of tumor
seeding ranged from 5 to 48%1-4. Prophylactic
radiotherapy to drain sites has been offered by an
increasing number of centers over recent years2 to
reduce the incidence of tumor seeding based on the
premise that such tumor deposits are common,
painful and resistant to treatment.
The table at the end of the article lists seven
published series addressing this topic of which only
three are randomised controlled trials. The Boutin
trial, based on which prophylactic radiotherapy was
first promoted, was published in 19951. None of the
20 patients treated with prophylactic radiotherapy
developed drain site metastasis whereas 8/20 (40%)
who did not receive radiotherapy had tumor seeding.
The radiotherapy delivered was 21 Gy in three
fractions on consecutive days. In those patients who
did develop subcutaneous tumour deposits, the mean
interval between intervention and appearance of
nodule was 6 months (range 1-13). This study
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8stimulated other investigators to publish retrospective
case series. A Dutch Belgian survey in 2002 found
that prophylactic irradiation of intervention sites was
offered in 32 of 38 responding centers (84%)2.
In Glasgow, having adopted the Boutin regimen,
we observed that in spite of prophylactic radiotherapy
some patients still developed subcutaneous tumor.
We also noted that for many patients these nodules
were not symptomatic and in those who did have
discomfort, further radiotherapy appeared to be
effective in reducing the size and tenderness of the
mass. We designed a study to assess the efficacy of
radiotherapy in preventing tumor seeding and to
determine if tumor nodules were painful or
troublesome to patients3. Patients (n=61) were
randomised to immediate drain site radiotherapy 21
Gy in three fractions given within 21 days of
intervention, or to best supportive care, and followed
up for 12 months. Subcutaneous tumor deposits
developed in 10 patients: 7/31 (23%) in the treated
arm and 3/30 (10%) in the best supportive care arm
p<0.05). Median time to development of
subcutaneous tumor was six months. The one other
published RCT by Bydder4 randomised 43 patients
with 58 drain sites between single fraction (10 Gy)
prophylactic radiotherapy and no treatment. The rate
of subcutaneous tumor development was 7% in the
radiotherapy arm compared to 10% in the control
arm. Given the short survival of patients with
mesothelioma and that subcutaneous tumor deposits
may take months to develop and may not cause
symptoms, prophylactic radiotherapy is not justified.
Puu bb lll iiiss hh ee dd ss ee rr iii ee ss oo nn rr aa dd iiioo ttthh ee rr aa pp yy tttoo mee ss oo ttthh ee lll iiioo maa dd rr aa iiinn ss iii tttee ss
Year First
author
design Patients
(nr)
RT
Mets
no RT
Mets
1995 Boutin RCT 40 0% 40%
1995 Low RS 20 0% NA
2004 Bydder RCT 43 7% 10%
2004 Cellerin RS 33 22% 48%
2005 Pinto RS 85 NA* 0%
2006 West RS 37 5% NA
2007 O’Rourke RCT 61 23% 10%
RCT= randomized controlled trial; RS=retrospective
series; mets = metastasis*. All patients in this trial
received chemotherapy but no drain site radiotherapy
1. Boutin C, et al. Chest 1995; 108:754-8.
2. De Ruysscher D, et al Radiother Oncol 2003; 68:299-302.
3. O’Rourke N, et al. Radiother Oncol 2007; 84:18-22.
4. Bydder S, et al. Br J Cancer 2004; 91:9-10.
Pleural Biopsy for Patients with Suspected
Malignant Effusions
Coenraad FN Koegelenberg MBChB FCP MRCP
Andreas H Diacon MD PhD
University of Stellenbosch, Cape Town, South Africa
ahd@sun.ac.za
Malignant pleural effusions (MPE) result from
infiltration of the pleura by malignant cells1.
Cytological examination of pleural fluid is diagnostic
in 60-90%, depending on the volume and frequency
of aspirations. Pleural biopsy offers excellent
specificity, but sensitivity varies among different
methods and whether or not an image-guided
procedure is performed.
Closed pleural biopsy needles with either Abrams
(guillotine) or Cope (hook) devices were developed
over 50 years ago. Yields of >90% have been
reported in pleural tuberculosis (TB). Malignant
pleural disease is less homogeneously distributed
over the pleura than TB, which predisposes blind
biopsies to sampling errors. Furthermore, only 70-
90% of all pleural biopsy specimens contain pleural
tissue. It is therefore no surprise that unguided pleural
biopsies are only diagnostic in approximately half of
all MPEs2. Among patient with negative cytology for
malignant disease only an additional 7% will have
diagnostic unguided biopsies1.
Utilizing imaging to assist pleural biopsy
increases the diagnostic yield, particularly if a pleural
based tumor or focal nodular pleural thickening can
be identified. Ultrasound (US)-assisted Tru-cut
needle biopsies have higher sensitivity and specificity
in the diagnosis of pleural malignancy than unaided
biopsies. Diacon et al3 found that US-assisted cutting
needle biopsy (CNB) had 85% sensitivity for
malignant neoplasms in general and 100% for
mesothelioma in tumors over 2cm in diameter3. The
same authors showed that the less traumatic US-
assisted transthoracic fine needle aspiration (TTFNA)
with rapid on-site evaluation was diagnostic in 87%
of cases while avoiding the increased risk of bleeding
with CNB in the vicinity of intercostals arteries4.
Compared to CNB, US-guided TTFNA had a
superior yield for bronchial carcinoma whereas CNB
was superior in the minority of cases with non-
carcinomatous tumors and non-malignant lesions.
CT-guided pleural biopsies with CNB have the
highest diagnostic yield and can be performed in
lesions as small as 5mm. Maskell et al reported a
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9sensitivity of 87% in patients with suspected MPEs
but negative pleural fluid cytology5.
A suspected MPE that remains undiagnosed on
cytology and transthoracic biopsy is an indication for
either medical thoracoscopy or video-assisted
thoracoscopic surgery (VATS). Local expertise and
availability often dictate the choice between the
procedures. Both allow for wide inspection of the
pleura and harvesting large biopsy specimens which
results in sensitivities of >90% in MPE1. Medical
thoracoscopy is usually performed under local
anesthesia and conscious sedation, whereas VATS
requires general anesthesia, which can put patients
with impaired pulmonary reserve at increased risk.
Semi-rigid pleuroscopy was recently introduced6. The
technique is similar to medical thoracoscopy, but uses
devices derived from bronchoscopes, which should
make medical thoracoscopy more affordable and
technically accessible to practicing interventional
pulmonologists. Recent studies have reported
sensitivities of 62-90% for MPE.
In conclusion, patients with a suspected MPE and
negative cytology should undergo transthoracic
pleural biopsy, preferably using US or CT guidance.
Patients who remain undiagnosed should be referred
for medical thoracoscopy, and if non-diagnostic or
unavailable, VATS. Very rarely open surgical biopsy
may be required.
1. Heffner JE. Respirology 2008;13:5-20.
2. Chakrabarti B, et al. Chest 2006;129:1549-1555.
3. Diacon AH, et al. Respiration 2004; 71:519-522.
4. Diacon AH, et al. Eur Respir J 2007; 29:357-62.
5. Maskell NA, et al. Lancet 2003; 361:1326-1330.
6. Lee P, Colt HG. Respirology 2005; 10:418-425.
Mesothelin for Diagnosis of Mesothelioma:
Enough evidence for clinical use?
Arnaud Scherpereel MD PhD
CHRU of Lille, France
a-scherpereel@chru-lille.fr
Malignant mesothelioma (MM) is a cancer with poor
survival, mainly induced by past asbestos exposure.
MM incidence is rising in many countries worldwide.
The possible use of serum or pleural fluid proteins to
establish an early diagnosis or assess response to
treatment and disease progression has been recently
evaluated. Finding a biomarker for these purposes is
extremely challenging, given the biologic features of
MM, and the need to differentiate MM from benign
pleural diseases and metastatic pleural malignancies1.
Mesothelin is a glycoprotein expressed on the cell
surface of normal mesothelial cells and highly
overexpressed in mesothelioma and various
carcinomas. Soluble mesothelin (SM) or soluble
mesothelin-related peptides, have emerged as a
promising biomarker for MM. SM levels were
significantly increased in serum and in pleural
effusion of patients with MM compared to healthy
asbestos-exposed subjects or patients with benign
pleural lesions or pleural metastasis. Serum and
pleural fluid SM showed excellent sensitivity (70-
80%) and specificity (80-100%) as diagnostic
markers for MM1-3. However, SM does not capture
sarcomatoid (and some of the biphasic)
mesotheliomas which hampers its use as a sole
diagnostic (or screening) marker. Combining
osteopontin or CA125 with SM was not helpful
towards this goal4, 5.
It has been suggested that elevated serum SM in
asbestos-exposed subjects may predict the
development of MM long before it becomes clinically
apparent, reflecting the presence of yet undetectable
small foci of MM. It could be thus suggested that
invasive diagnostic methods should be used in
subjects with pleural abnormalities and high SMRP
levels to exclude mesothelioma or metastatic
malignancies though such a strategy requires
validation by prospective trials. Presently
mesothelioma cannot meet the essential criteria for
cancer screening programs: there is no validated
screening tool or effective cure for MM, and no
evidence that early detection alters outcome.
However, detecting mesothelioma years before its
clinical presentation may allow the investigation of
new treatment modalities in early-stage patients.
Studies assessing SM alone or combined with other
potential biomarkers for MM diagnosis or screening
are underway.
Serum SM levels were higher in patients with
larger tumor load2. Preliminary data suggested that
serum SMRP may be helpful in monitoring patient
response to therapy. In those who underwent tumor
debulking surgery for peritoneal MM (or ovarian
carcinomas), serum SMRP levels decrease
dramatically within days. Our (unpublished) data
from patients subjected to chemotherapy or gene
therapy support this hypothesis. Reports on SM value
as a prognostic marker in patients with MM are
discordant2, 4.
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In conclusion, there is not enough evidence yet to
justify clinical applications of serum or pleural fluid
SM determination in all MM patients. SM alone has
probably insufficient specificity and sensitivity for
MM screening, but may help clinicians in the
diagnosis of epithelioid MM. In the meantime,
histopathologic diagnosis should remain the “gold
standard” given the important therapeutic and
medical-legal implications of mesothelioma. SM may
be also used to assess MM patients’ outcome and
response to treatment, but this needs to be tested in
prospective studies.
1. Scherpereel A, Lee YCG. Curr Opin Pulm Med 2007; 13:
339-443.
2. Robinson BW, et al. Lancet 2003; 362:1612-6.
3. Scherpereel A, et al. Am J Respir Crit Care Med 2006;
173:1155-60.
4. Grigoriu B, et al. Clin Can Res 2007; 13: 2928-35.
5. Creaney J, et al. Chest 2007;1 32:1239-46.
CASE REPORT
Epithelioid Hemangioendothelioma/
Angiosarcoma of the Pleura
Epitheliod hemangioendothelioma (EHE)-
angiosarcoma, first described in 19751, is a rare
malignant tumor of vascular origin usually arising in
bone, liver, soft tissue, or lung but rarely the pleura2.
We describe a case of EHE with bilateral pleural,
lung and bone manifestations.
A 71 years old asbestos-exposed ex-smoker was
evaluated for persistent low back pain and a left-sided
pleural effusion. The pleural fluid was a
serosanguinous, lymphocytic (lymphocytes 75% of
total leukocytes) exudate with a low ADA level (22
IU/L). Blood tests showed anemia (Hct 31%), raised
serum CA125 (2135 U/ml) and ESR (105). Bone
scintigraphy revealed increased osteoblastic activity
of the vertebral body of T12.
Medical thoracoscopy on the
left pleural cavity revealed
diffuse irregular thickening
of visceral and parietal pleura
and scarce white nodules on
the parietal pleura (figure 1).
Histologic studies failed to establish a specific
diagnosis. Cytology revealed clusters of atypical cells
with hyperchromatic nuclei and well visible
nucleolus. Immunostaining was negative for keratin
5/6, 7, 20, TTF1, calretinin, thrombomodulin,
PAS/AB and Perls. No staining for vascular markers
were performed.
Two months later the patient developed bilateral
pleural effusions together with
multiple pulmonary nodules.
Thoracoscopy was performed
again, this time on the right side,
and revealed diffuse white-gray
nodules and plaques on the
parietal pleura (figure 2).
The pleural biopsies
showed thickening with large
epithelial-like malignant cells
with abundant eosinophilic
cytoplasm and large nuclei
with discrete nucleolus,
moderate cellular atypia and
rare mitotic figures (figure 3).
The tumor cells were surrounded by cellular
fibrous stroma. Intense mesothelial hyperplasia was
observed. Tumor cells were positive for CD31, factor
VIII, CEA and vimentin confirming the diagnosis of
EHE/pleural angiosarcoma. The patient received four
courses of carboplatin/etoposide, and had an initial
partial response before he deteriorated and died 12
months after diagnosis.
Pleural angiosarcoma is a multi-organ, aggressive
malignancy that is difficult to characterize. Prognosis
is poor, though sensitivity to cisplatin/etoposide has
been reported3,4. High suspicion and thorough
pathologic investigation are needed for its diagnosis.
Malignant cells are cytokeratin negative but vimentin
positive. Immunoreactivity to CD31, CD34 and
factor VIII is further diagnostic.
1. Dail DH, Liebow AA. Am J Pathol 1975; 78:6a-7a.
2. Lin BT-Y, et al. Am J Surg Pathol 1996; 20:1431-1439.
3. Kitaichi M, et al. Eur Respir J 1998; 12:89-96.
4. Pinet C, et al. Eur Respir J 1999; 14:237-8.
Grigoris Stratakos MD
Vassilis Papas MD
Dimitra Rontogianni MD
Evaggelismos Hospital, Athens, Greece,
grstrat@hotmail.com
Figure 1
Figure 2
Figure 3
The 2008 Congress of the International Mesothelioma
Interest Group will be held in Amsterdam from Sept 25th
to 27th. For details, see www.imig.org.
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Diagnosis of TB Pleural Effusions 
 
Coenraad FN Koegelenberg   MBChB FCP MRCP  
                 Andreas H Diacon  MD 
University of Stellenbosch, Cape Town, South Africa 
ahd@sun.ac.za 
 
Tuberculous (TB) pleural effusions may occur at any 
age, reach any size and be uni- or bilateral. Patients 
present with fever, night sweats, weight loss, cough, 
chest pain and dyspnea varying in severity with the 
size of the effusion. The diagnosis is straightforward 
when typical radiographic changes hint at 
parenchymal TB or when expectorated sputum is 
found positive for acid fast bacilli. A recent study 
from Brazil1 demonstrated that the yield of induced 
sputum in patients with pleural TB but without 
spontaneous sputum production was as high as 52%.  
Although some cases might be self-limiting, 
pleural TB should be diagnosed and treated 
expeditiously as a high proportion of untreated 
patients will eventually develop more serious 
manifestations of TB. An array of special 
investigations exists, the diagnostic value and cost-
effectiveness of which are greatly dependent on the 
local prevalence of TB and hence the pre-test 
probability. The pleural aspirate is frequently a non-
malodorous, clear, straw-colored exudate with a pH 
of 7.2-7.4. It is rarely turbid or hemorrhagic. The 
fluid is rich in proteins and tends to clot if not 
injected into a heparinized container. Microscopy 
reveals inflammatory cells with lymphocytic 
predominance. Polymorphonuclear cells may 
predominate in very early exudates. The presence of 
>5% mesothelial cells is unusual in TB pleuritis. 
Microscopy and culture are often negative due to the 
paucibacillary nature of the disease. 
Pleural fluid surrogate markers are in widespread 
use in countries with a high prevalence of TB. Pleural 
adenosine deaminase activity (ADA) is a simple, 
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cheap and robust colorimetric test. A range of cut-off 
values has been suggested depending on the 
prevalence of the disease. ADA levels of >40 IU 
have a sensitivity of 96-100% and specificity of 89-
97% for TB in effusions with a lymphocytic 
predominance2,3. ADA levels in non-tuberculous 
lymphocytic effusions seldom exceed this cutoff, 
which makes ADA a valuable screening tool in 
regions with a low TB incidence3,4. Although the 
determination of ADA isoenzymes may increase the 
specificity, this is infrequently performed.  
Pleural interferon-gamma (IFN-γ) is technically 
more demanding and more expensive than ADA. In a 
study from India using a cutoff of 138pg/ml, IFN-γ 
had a sensitivity of 90% and specificity of 97% for 
pleural TB5. In contrast to ADA, IFN-γ does not yield 
false positive results in empyema or parapneumonic 
effusions. Combining ADA with the equally cheap 
cell count and restricting its application to 
lymphocytic effusions nullifies this apparent 
advantage. PCR and nucleic acid based techniques 
have disappointingly low sensitivities. This might be 
due to the presence of inhibitors in the pleural fluid 
or to intracellular sequestration of mycobacteria, 
which makes the target proteins less accessible for 
amplification.  
The gold standard for the diagnosis of pleural TB 
remains histological evidence of granulomatous 
pleural inflammation combined with the finding of 
mycobacteria on microscopy or culture. Material for 
histology can be obtained with closed pleural biopsy. 
Published results vary greatly, but if at least six 
specimens are harvested a yield of up to 87% can be 
expected in experienced hands6. The problem of 
sampling errors can be overcome by taking biopsies 
under vision during thoracoscopy, which has a 
sensitivity and specificity of close to 100% but is not 
universally available2.  
 
References 
1. Conde MB, et al. Am J Respir Crit Care Med 2003; 167:723-5 
2. Diacon AH, et al. Eur Respir J 2003; 22:589-91 
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4. Lee YC, et al.  Chest 2001; 120:356-61 
5. Sharma SK, et al. J Interferon Cytokine Res 2004; 24:213-7 
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Pleural TB:  
Epidemiology & Drug Resistance 
 
Michael H Baumann   MD FCCP 
Univ of Mississippi Med Ctr, Jackson, MS, USA 
mbaumann@medicine.umsmed.edu 
 
Pleural TB should be considered in any patient with a 
lymphocyte predominant exudative pleural effusion1-
3
. The diagnostic approach is debated1,2, particularly 
with the advent of new pleural fluid measurements 
including ADA, IFN-γ, nucleic acid amplification, 
tuberculous proteins and antibodies, and lysozyme 
levels3. Such measurements may obviate the need for 
a pleural biopsy (closed biopsy or by video-assisted 
thoracoscopic surgery) to identify pleural 
granulomas, culture the TB organism, and obtain 
antimicrobial sensitivity studies. A central weakness 
of the use of pleural fluid measurements alone to 
diagnose pleural TB is their failure to provide 
antimicrobial sensitivity data. Culture confirmation 
and drug-susceptibility testing remains a mainstay of 
the United States Centers for Disease Control and 
Prevention (CDC)4.  
Knowledge of the epidemiology and 
antimicrobial resistance pattern of pleural TB can aid 
its diagnosis and treatment. The most comprehensive 
epidemiological analysis of pleural TB in U.S.A. 
utilized the CDC TB database5 (full report6). From 
1993 to 2003, 7,549 pleural and 156,779 pulmonary 
TB cases were analyzed. The annual proportion of 
pleural TB was relatively stable (median 3.6%) 
compared to pulmonary TB which steadily decreased 
(mean decrease 0.9% / year), p=0.001. Pleural TB 
occurred significantly more often proportionally than 
pulmonary TB (30.4% vs 23.3%, p=0.001) among 
persons >65 years old and significantly less often 
among children <15 years (pleural 1.8%, pulmonary 
6.1%, p<0.001). Pleural TB patients (63.4%) were 
slightly more often born in the US than pulmonary 
TB patients (61.0%). Among foreign-born persons 
with TB, more than twice as many patients with 
pleural TB (9.4%) than pulmonary TB (4.4%) 
reported being born in India. Among 25-44 year olds, 
persons with pleural TB (11.7%) were significantly 
less likely to report positive HIV test results than 
those with pulmonary TB (20.0%), p=0.0009.5  
Drug resistance patterns of pleural TB generally 
reflected those of pulmonary TB. However, isolates 
from pleural TB patients were less often resistant to 
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at least isoniazid (6.0% vs 7.8%, p<0.01) and to at 
least one first-line TB drug (9.9% vs 11.9%, p<0.01) 
compared with pulmonary cases. Not surprisingly, 
rates of drug resistance were higher among foreign-
born than among US-born persons. Approximately 
twice as many foreign-born pleural patients as US-
born pleural patients had isolates resistant to at least 
isoniazid (8.7% vs 4.6%, p<0.01) and at least one 
first-line drug (14.2% vs 7.6%, p<0.01)5,6. 
Such information for patients in U.S.A. may alter 
physician diagnostic and treatment habits for 
suspected pleural TB. For example, clinicians should 
pursue a tissue diagnosis by pleural biopsy with 
accompanying culture and sensitivity data in foreign-
born patients suspected of pleural TB given concerns 
for drug resistance. Conversely, given the similarity 
of drug resistance patterns of pleural and pulmonary 
TB, for US-born patients from areas with low drug-
resistance rates for pulmonary TB, diagnosis and 
treatment of pleural TB based solely upon pleural 
fluid measurements seems reasonable. Similar 
epidemiological information from other countries 
could assist in the management of pleural TB.   
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Management of TB Pleural Effusions 
 
Wing Wai Yew   MB 
Grantham Hospital, Hong Kong 
yewww@ha.org.hk 
 
TB pleural effusion generally arises from the rupture 
of a sub-visceral pleural focus of disease within the 
lung parenchyma into the pleural space, followed by 
the development of a delayed-type hypersensitivity 
(immunological) reaction to the mycobacterial 
antigens1. The involvement of elaborated cytokines 
leads to clinical symptoms like malaise, fever, and 
pleuritic pain, as well as the pathological appearance 
of an exudative pleural effusion due to increased 
vascular permeability. 
The chemotherapy of TB pleural effusion does 
not differ basically from that used for pulmonary 
tuberculosis1. Standard short-course treatment is 
usually successful. The Cochrane review analyzed 
randomized and quasi-randomized clinical trials 
evaluating the role of systemic corticosteroids as 
adjunctive therapy in patients diagnosed with TB 
pleural effusion2. However, it has only furnished the 
conclusion of insufficient evidence to know whether 
corticosteroids are effective in TB pleural effusion, 
the alluded immunological mechanism in its 
pathogenesis notwithstanding. 
Lately, there has been some preliminary 
suggestion on the possible utility of percentage 
changes in pleural cytokine level3, and perhaps even 
radiographic area of effusion4 after two weeks of 
therapy in predicting the extent of residual pleural 
adhesion. From these two studies, the rate of 
resolution of pleural inflammation appears to be more 
important than the intensity of inflammation initially 
in determining the residual pleural scarring. Thus, 
some patients with pleural TB may be intrinsically 
more prone to develop subsequent scarring than 
others. If such findings can be further confirmed, 
they might usefully enable selecting a more 
“homogeneous” population of subjects with 
tuberculous pleural effusion for evaluation of the 
therapeutic benefit of anti-inflammatory 
interventions. Hopefully, a more informative answer 
regarding the efficacy of such treatment strategies 
would be obtained eventually.  At present, given the 
potential side effects of corticosteroids, I would 
contemplate the selective use of such adjunctive 
therapy in patients with TB pleuritis on a case-by-
case basis, in the absence of a contraindicating co-
morbidity. Perhaps, steroids can help in some patients 
with significant symptoms (like fever) and very 
sizeable radiographic effusion after 1-2 weeks of 
anti-TB chemotherapy. 
Aside from very early reports of the equivocal 
efficacy of intrapleural steroid therapy in managing 
TB pleuritis which were not further pursued, there 
has been a recently reported study regarding the 
possible efficacy of intrapleural urokinase in 
reducing subsequent pleural adhesion among subjects 
with loculated TB effusion5. 
Finally, TB empyema representing an extreme 
form of tuberculous pleural effusion with pus 
recovered from the pleural cavity generally 
necessitates surgical drainage (thoracostomy or 
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decortication) as an adjunctive therapy to improve 
patient outcome6. In this setting, the accumulated 
thick pus and its encapsulation by chronic 
inflammatory tissue might pose a significant barrier 
to the penetration of anti-TB drugs, thus increasing 
the risk of treatment failure and even emergence of 
drug resistance. In the rare occasions of functionally 
incapacitating fibrin-trapped lung or overt fibrothorax 
that results from tuberculous pleural effusion, 
recourse to decortication as an adjunct to 
chemotherapy may also be required. 
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IMAGES OF THE PLEURA 
 
Blind needle biopsy of pleura is the most commonly 
used method in the diagnosis of TB pleurisy. 
Demonstration of granuloma in the biopsy specimen 
from parietal pleura suggests TB pleuritis. It should 
be kept in mind that other disorders such as fungal 
diseases, sarcoidosis, tularemia and rheumatoid 
pleuritis may also produce granulomatous pleuritis. 
However, >95% of patients with granulomatous 
pleuritis have TB.  
Histologically, coalescent granulomas are 
present, composed of 
epithelioid cells 
surrounded by a zone 
of fibroblasts and 
lymphocytes that 
usually contains 
Langhans giant cells 
(fig). Some necrosis 
(caseation) may be 
present in the centers 
of these tubercles, the amount of which depend on 
the sensitization of the patient and the virulence of 
the organism.  
Oner Dikensoy MD        
Gaziantep University, Gaziantep, Turkey 
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Genetic Predisposition to Pleural Infection 
 
Stephen J Chapman   MRCP 
Oxford Ctr for Respir Med & University of Oxford, U.K. 
schapman@well.ox.ac.uk 
 
The importance of an individual’s genetic 
background in determining their susceptibility to 
many infectious diseases is now well established1. 
Studies have highlighted the genetic basis of 
susceptibility to respiratory infections, such as 
tuberculosis and invasive pneumococcal disease1,2,3. 
Research into the role of host genetics in 
susceptibility to pleural infection has been neglected 
until recently, however, reflecting the considerable 
difficulty in assembling large collections of DNA 
samples from individuals with this phenotype. The 
UK Multicenter Intrapleural Streptokinase Trial-1 
(MIST-1) study generated samples from patients with 
well-documented pleural infection4, and work in 
Oxford utilizing this sample collection has recently 
identified the first susceptibility locus for Gram-
positive pleural infection, a gene called PTPN225.   
PTPN22 is of considerable interest because it has 
emerged as the leading genetic risk factor for 
autoimmunity outside the major histocompatibility 
complex region. The gene encodes the lymphoid 
protein tyrosine phosphatase LYP, which inhibits T-
cell signaling by dephosphorylating and inactivating 
T-cell-receptor-associated kinases and their 
substrates6. A naturally occurring variant 
(polymorphism) within the PTPN22 gene results in a 
substitution of arginine to tryptophan at codon 620 of 
the protein and exerts an effect on LYP function, 
with the tryptophan variant associated with an 
increase in phosphatase activity in T cells. In keeping 
with such a functional effect leading to down-
regulation of immune responses, the tryptophan 
variant appears to confer increased susceptibility to 
both Gram-positive pleural infection and invasive 
pneumococcal disease (primarily pneumococcal 
bacteremia and meningitis): odds ratios for the 
development of invasive bacterial disease were just 
over 1.5 in heterozygote individuals carrying a single 
copy of the tryptophan variant, and over 5 in 
homozygote individuals with two copies of the 
tryptophan mutant5. As samples from non-invasive 
pneumonia were not available for study, it was not 
possible to further define the action of PTPN22 
within the overall pathogenesis of pleural infection.  
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As with other infectious diseases, the 
development of pleural infection in a particular 
individual is likely to reflect a combination of 
multiple acquired and genetic risk factors. Many 
additional genes besides PTPN22 are likely to 
influence the development of pleural infection, and 
indeed other recent work suggests that common 
polymorphisms within genes encoding the innate 
immune signaling ‘Toll-like receptors’ may also 
affect susceptibility to both pneumococcal empyema 
as well as other manifestations of invasive 
pneumococcal disease (Chapman SJ, unpublished). 
An increased knowledge of the genes involved in 
empyema development may eventually lead to novel 
therapeutic targets for pleural infection. Furthermore, 
the identification of any genetic predictors of 
outcome may perhaps be combined with clinical 
predictors, leading to a more complete prognostic 
model and ultimately more effective, individually-
targeted treatment. 
 
References 
1. Cooke GC, et al. Nat Rev Gen 2001; 2: 967-77 
2. Roy S, et al. Lancet 2002; 359: 1569-73 
3. Roy S, et al. BMJ 2002; 324: 1369 
4. Maskell NA, et al. N Engl J Med 2005; 352: 865-74 
5. Chapman SJ, et al. Nat Gen 2006; 38: 499-500 
6. Bottini N, et al. Sem Immunol 2006; 18 : 207-213 
 
 
CASE REPORT 
 
Primary Spontaneous Hemopneumothorax  
 
EK Tan & TK Lim 
National University Hospital, Singapore 
mdclimtk@nus.edu.sg 
 
A 28 year-old Chinese smoker presented at the 
Emergency Department for left-sided chest pain of 4 
hours. There was no history of trauma. His younger 
brother has had a spontaneous pneumothorax. He was 
afebrile, hemodynamically stable and has no 
marfanoid features. A chest radiograph showed a 
small apical left pneumothorax. He was kept under 
observation and given supplemental oxygen. A repeat 
x-ray (below) taken 6hrs later showed no change.  
He was admitted to hospital and treated 
conservatively. Two days later, his hemoglobin level 
fell from 16.5 to 13.5g/dL, and a repeat chest film 
showed a large effusion in addition to the known left 
pneumothorax. A 20-F chest tube was inserted and 
drained 1.1L of frank blood. Urgent video-assisted 
thoracoscopic surgical evacuation of blood clots, 
hemostasis, pleurectomy, bullectomy and pleurodesis 
was performed. 
Discussion: This case highlights the insidious 
development of a primary spontaneous 
hemopneumothorax (PSH-P) over 2 days in a patient 
who initially presented with a small innocuous 
pneumothorax. The Ohmori Criteria1: draining 
≥400ml of blood on initial chest tube insertion in the 
presence of a pneumothorax is used to facilitate 
diagnosing a PSH-P.  
 
                    
CXR at 6 hr (left) and the 2nd day after admission 
 
Hwong et al2 found that 10% of their PSH-P cases 
had admission chest radiographs showing only a 
pneumothorax with no apparent pleural fluid, as was 
in our patient. Up to 12%3 of admission for 
spontaneous pneumothorax may potentially develop 
into PSH-P. Eight out of 16 patients (50%) who were 
referred for surgical management of PSH-P from 
2002 to 2006 at our hospital had an occult 
presentation. So far, only the male gender has been 
found to confer higher associations with PSH-P4 over 
PSP.  
PSH-P is potentially life-threatening due to 
unopposed bleeding into the thoracic cavity and, as 
this case has illustrated, can be occult in nature and 
develop after hospitalization. While surgical 
treatment is well established, this warrants vigilance 
in considering the possibility of PSH-P in all cases of 
PSP. For patients bearing clinical indices of 
suspicion, adequate venous access, cross-matching of 
blood and close monitoring should be performed. 
 
1. Ohmori K, et al.  J Jpn Assoc Thorac Surg 1988; 36:1059-64 
2. Hwong TMT, et al. Eur J Cardiothorac Surg 2004; 26: 893-6 
3. Tatebe S, et al. Ann Thorac Surg 1996; 62:1011-5 
4. Fry W, et al. Am Rev Tuberc 1955; 71: 30-48 
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